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Abstract
The tendency for breast cancer cells in the primary tumour to spread to other parts of the
body and form new tumours in vital organs, termed metastasis, is the main cause of breast
cancer-related mortality. Therapies that target highly metastatic cells have proved
successful in the clinic, but the development of therapeutic resistance to these targeted
therapies significantly limits clinical efficacy. Therefore, new anticancer therapies that
target invasive tumour cells while minimising systemic toxicity are required. The
urokinase plasminogen activator receptor (uPAR) is recognised as a biomarker for
metastasis in breast cancer. Targeting uPAR in breast cancer can be achieved by attaching
plasminogen activator inhibitor-2 (PAI-2) to the surface of drug-loaded liposomes in
order to facilitate liposome uptake into uPAR-positive cells. This thesis aimed to develop
and evaluate novel uPAR-targeted liposomes containing a potent anti-mitotic cytotoxin,
N-alkylisatin (N-AI), for the treatment of metastatic breast cancer.

Novel N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were prepared and
characterised for the first time using optimisations to previously reported methods. N-AI
PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, were monodisperse (polydispersity
index of 0.086 ± 0.030), had a zeta potential of –4.66 ± 0.52 mV and contained N-AI at a
concentration of 2.2 mM, equating to 43.1% drug loading (% w/w). PAI-2 conjugation to
the surface of N-AI-loaded liposomes was confirmed using size-exclusion
chromatography and Western blotting. A PAI-2 inhibitory activity assay confirmed that
PAI-2 attached to the surface of liposomes remained active against urokinase
plasminogen activator after conjugation, making N-AI PAI-2 liposomes suitable for
further in vitro and in vivo evaluation against breast cancer cells.

In vitro, cellular uptake of fluorescently labelled PAI-2 liposomes into MDA-MB-231
breast cancer cells (uPAR-positive) was increased (P < 0.01) relative to MCF-7 breast
cancer cells (uPAR-negative) as measured by flow cytometry. Confocal microscopy
confirmed uptake of PAI-2 liposomes and localisation within lysosomes. N-AI PAI-2
liposomes showed a potent cytotoxic effect against MCF-7 and MDA-MB-231 cells
grown in 2D after 72 h (IC50 values of 31.84 ± 8.20 µM and 5.40 ± 1.14 µM, respectively)
and in 3D as multicellular tumour spheroids after 96 h (IC50 values of 40.2 ± 4.0 µM and
ii

60.4 ± 7.1 µM, respectively). In vivo, N-AI PAI-2 liposomes had a plasma half-life of
5.82 h and showed an increased accumulation at the primary tumour site in an orthotopic
MDA-MB-231 BALB/c-Fox1nu/Ausb xenograft mouse model relative to nonfunctionalised liposomes at the 10 min, 3 h and 6 h post-injection time points (P < 0.001).
However, N-AI PAI-2 liposomes did not have a significant effect on primary tumour
growth or metastatic burden in the lungs and liver relative to non-functionalised N-AIloaded liposomes or empty control liposomes in the two breast tumour mouse models
used.

Finally, quantification of PAI-2 attached to the surface of liposomes was achieved using
single-molecule fluorescence microscopy. Liposome and protein signals showed a high
degree of colocalisation, indicating that proteins were bound to intact liposomes. The
average number of attached PAI-2 molecules per liposome was determined to be 11 ± 4.
Imaging of dual-functionalised liposomes revealed stoichiometries of the two attached
proteins in accordance with the molar ratios of protein added during preparation. For dualligand liposomes, the post-insertion method generated liposomes with a more equal ratio
of the two ligands than the conventional method (2.1 ± 2.5 and 17 ± 18, respectively).
This work demonstrated, for the first time, the practical utility of single-molecule
fluorescence microscopy to quantify the density and stoichiometry of ligands attached to
the surface of liposomes.

Together, the findings in this thesis support the rationale for targeting uPAR-positive
breast cancer cells using N-AI-loaded PAI-2-functionalised liposomes. The results
provide a basis for the further development of dual-ligand liposomes that can target
heterogeneous tumour cells within the HER2-positive and triple-negative breast cancer
subtypes in which uPAR has been shown to play a key role in driving metastasis. The
development of novel liposomal drug carriers that can target uPAR to deliver cytotoxic
drugs to heterogeneous populations of breast cancer cells is a promising therapeutic
strategy to improve the treatment of metastatic breast cancer. This thesis will guide future
work exploring targeting of the urokinase plasminogen activator system as a strategy to
overcome breast cancer metastasis.
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1.1 Introduction
The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem in the treatment of breast cancer, with intratumoural
heterogeneity playing a key role. In this context, improving the therapeutic outcome
through simultaneous targeting of multiple tumour cell subtypes within a heterogeneous
breast tumour is a promising approach. Liposomes have emerged as useful drug carriers
that can reduce systemic toxicity and increase drug delivery to the tumour site. While
clinically used liposomal drug formulations show marked therapeutic advantages over
free drug formulations, ligand-functionalised liposomes that can target multiple tumour
cell subtypes may further improve therapeutic efficacy by facilitating drug delivery to a
broader population of tumour cells making up the heterogeneous tumour tissue. Liganddirected liposomes enable the active targeting of cell receptors via surface-attached
ligands that direct drug uptake into tumour cells or tumour-associated stromal cells and
therefore can increase the selectivity of drug delivery. This literature review will discuss
the utility of recent ligand-directed liposome approaches, with a focus on dual-ligand
liposomes for targeting intratumoural heterogeneity, for the treatment of solid tumours.

1.2 Breast cancer growth and metastasis
Breast cancer is the most common invasive cancer in women worldwide, accounting for
approximately one quarter of all cancer cases in women, and remains a leading cause of
cancer-related morbidity and mortality (Jemal et al. 2011). While overall survival rates
have improved steadily over the last several decades, breast cancer still accounts for
almost half a million deaths each year (Ward et al. 2015). Breast cancer is a particularly
deadly disease due to the tendency for cancer cells of the primary tumour to spread to
other parts of the body and form new tumours in vital organs – most commonly the bones,
liver, lungs and brain (Lee 1983). This process, termed metastasis, is the leading cause of
breast cancer-related mortality, with more than 90% of patient deaths resulting from
metastatic disease (Dolznig et al. 2011). Despite a growing understanding of the
molecular biology of breast cancer metastasis and several key advancements in treatment
options, there is currently no cure for metastatic breast cancer (Sledge 2016).
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Metastasis occurs when tumour cells break away from the primary tumour and form new
tumours at distant sites (Fig. 1.1). The primary tumour microenvironment is a complex
heterogeneous structure, consisting of an extracellular matrix (ECM), blood vasculature
and a collection of cell types that support tumour cell growth, including endothelial cells,
fibroblasts and immune cells (Thoma et al. 2014). Through the activation or inactivation
of particular genes, tumour cells acquire the ability to proliferate indefinitely and utilise
key cellular systems to facilitate their tumourigenic properties (Hanahan & Weinberg
2011; Klein 2008). One of the key processes facilitating metastasis is the degradation of
the ECM, the physical barrier separating distinct tissue types in the body. Proteolytic
enzymes expressed by tumour cells and tumour-associated cells (Section 1.5) degrade
structural proteins of the ECM and create a passageway that allows the movement of
tumour cells out of the area (Krueger et al. 2005). Angiogenesis, the process by which the
tumour creates its own vasculature to obtain vital nutrients and remove waste products,
facilitates the escape of tumour cells into the bloodstream and lymphatic system (Weidner
et al. 1991). This process, termed intravasation, enables tumour cells to travel to distant
sites in the body and form new secondary metastatic tumours.

Figure 1.1: Tumour cell invasion and metastasis in breast cancer. Cells of the primary tumour
produce proteolytic enzymes that degrade components of the extracellular matrix (ECM), allowing
tumour cells to escape from the area and enter the bloodstream or lymphatic system. Tumour cells can
then travel to other sites in the body and form secondary tumours. Figure adapted from Liu et al.
(2005).
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1.3 Molecular classification of breast cancer
The identification of tumour biomarkers and the associated molecular classification of
breast cancer is highly useful for determining the most appropriate treatment course and
evaluating prognosis. Many important biomarkers and cellular pathways involved in
tumour progression and metastasis have been identified and assist in the prediction of
patient responses to hormone-, chemo-, immuno- and molecular-targeted therapies, the
determination of mechanisms of therapeutic resistance, and the prediction of disease
progression and likelihood of relapse (Bailey et al. 2016; Schnitt 2010). Overexpression
of specific cell surface receptors by tumour cells may be exploited to directly target
tumour cells using antibodies or smaller molecules, or to enable targeted delivery of
cytotoxic compounds to tumour cells. Such targeted approaches enable more specific
anti-tumour effects, potentially resulting in enhanced tumour cell kill and/or a reduction
in off-target effects.

Several important biomarkers involved in breast cancer progression and metastasis have
been identified, including the estrogen receptor (ER), progesterone receptor (PR) and
human epidermal growth factor receptor 2 (HER2) (Schnitt 2010). These biomarkers can
be used to classify breast cancer into broad molecular subtypes (Table 1.1) (Howlader et
al. 2014), which assist in the prediction of patient responses to chemotherapy treatments,
the determination of mechanisms of resistance to treatments, the prediction of disease
course and likelihood of relapse, and provide a possible target for anticancer therapies
(Dos Anjos Pultz et al. 2014). The following sections will focus on the HER2-enriched
subtype and the triple-negative breast cancer (TNBC) subtype. For further information
regarding the hormone receptor-positive breast cancer subtypes, see previously published
reviews on these topics (Abraham & Staffurth 2016; Basile et al. 2017; De Marchi et al.
2016).
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Table 1.1: Breast cancer molecular subtypes. Breast cancer can be broadly divided into four main
subtypes: Luminal A, Luminal B, HER2-enriched and triple-negative. ER, estrogen receptor; PR,
progesterone receptor; HER2, human epidermal growth factor receptor 2.
Clinical Features

Luminal A

Luminal B

HER2-enriched

Triple-negative

ER expression

+

+

–

–

PR expression

+

+

–

–

HER2 expression

–

+ or –

+

–

Incidence (%)

~30-70

~10-20

~5-15

~15-20

Targeted therapies

Endocrine

Endocrine

Anti-HER2

None

Rate of metastasis

Low

Low

High

High

Prognosis

Good

Good

Poor

Poor

1.3.1 Triple-negative breast cancer
The TNBC subtype is characterised by a lack of expression of ER and PR, and a lack of
overexpression and/or amplification of HER2 (Gluz et al. 2009). As this subtype lacks
these three main breast cancer molecular biomarkers, there are no targeted therapy options
for TNBC, and the use of conventional chemotherapies remains the standard of care
(Waks & Winer 2019). In addition, TNBC is a markedly heterogeneous subtype at both
the clinical and molecular scale, which can make treatment difficult. The prognosis of
TNBC is generally poor, with high rates of disease recurrence and relapse (Liedtke &
Kiesel 2012). The progression-free survival and overall survival rates of TNBC patients
are significantly shorter than those of non-TNBC patients (Keam et al. 2007) (Fig. 1.2).

Figure 1.2: Probability of survival in triple-negative breast cancer. Kaplan-Meier analyses of (A)
relapse-free survival and (B) overall survival according to triple-negative and non-triple-negative
breast cancer. Figure from Keam et al. (2007).
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In order to develop novel and effective targeted treatment options for TNBC, the
discovery and validation of genetic targets relevant to the TNBC subtype remains an
active area of research (Denkert et al. 2017). Research has focused on identifying
prognostic and predictive markers for this subtype, such as overexpression of the TP53
gene, mutations in BRCA1/2 and dysregulation of the PI3K/AKT/mTOR pathway
(Sporikova et al. 2018), and several clinical trials are in progress for novel molecular
therapies and immunotherapies (Vikas et al. 2018). Therefore, the continued validation
of further novel molecular targets for TNBC, and breast cancer more broadly, is an
important area of research (Dos Anjos Pultz et al. 2014).

1.3.2 HER2-positive breast cancer
HER2 (also known as Erb-B2 receptor tyrosine kinase 2 (ERBB2)) belongs to the
transmembrane epidermal growth factor receptor subfamily of tyrosine kinases involved
in the initiation of signal transduction pathways that regulate cell growth and
differentiation (Yarden 2001). Amplification and overexpression of HER2 (chromosome
position 17q12) occurs in 15–25% of breast cancers and results in uncontrolled tumour
cell proliferation (Slamon et al. 1987). The HER2-positive breast cancer subtype is
associated with an aggressive disease course, increased resistance to chemotherapy,
increased likelihood of metastasis and recurrence, and is indicative of an overall poor
patient prognosis (Schnitt 2010). For this reason, HER2 has been identified as an
important biomarker for breast cancer, as well as for several other cancer types where
HER2 may be overexpressed, including ovarian, uterine and pancreatic cancers (Asuthkar
et al. 2013).

Several HER2-targeted therapies have been developed to treat HER2-positive breast
cancer. Trastuzumab (TZ; trade name Herceptin®) is a humanised monoclonal antibody
that specifically binds to the extracellular domain of HER2 to prevent tumour cell
proliferation (Cho et al. 2003). TZ was approved for clinical use in the treatment of breast
cancer by the US Food and Drug Administration (FDA) in 1998 (Shak et al. 1998). The
administration of TZ in combination with chemotherapy results in a 5-month median
increase in survival but with a small increased risk of severe cardiotoxicity due to the
mechanism of action of doxorubicin (Rossi et al. 2016). Other HER2-targeted therapies
have been developed to decrease toxicity and improve efficacy, including pertuzumab,
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another humanised monoclonal antibody that binds to the HER2 extracellular domain,
and lapatinib, a small-molecule tyrosine kinase inhibitor that targets HER2 kinase activity
(Higa & Abraham 2007). Current clinical trials are testing the use of a combination of
these HER2-targeted therapies in an effort to improve overall clinical efficacy and reduce
the incidence of therapeutic resistance (Ahn & Vogel 2012), which is now recognised as
a significant clinical problem despite TZ therapy still being the standard of care for
HER2-positive breast cancer.

Resistance to targeted therapies can develop via a number of mechanisms and may be
intrinsic to the patient or acquired over time with the progression of treatment. Intrinsic
resistance can arise from a lack of expression of a drug target, a mutated drug target or
via target-independent signalling mechanisms (Masoud & Pages 2017). For example,
some patients are intrinsically resistant to HER2-targeted therapies because of the ability
of HER2 to form heterodimers with other human epidermal growth factor receptors,
allowing differential intracellular signalling (Croucher et al. 2016). Intrinsic resistance to
TZ affects a significant proportion of patients, with only 30% of HER2-positive breast
tumours responding initially to TZ therapy (Ludyga et al. 2013). In contrast, acquired
(also known as pleiotropic or evasive) resistance can develop in patients that were once
responsive to treatment and can arise from de novo mutations or from clonal selection of
intrinsically resistant clones (Wood 2015). The development of acquired resistance
renders HER2-targeted therapies ineffective, and subsequent cancer recurrence often
results in death from metastatic disease (Menyhart et al. 2015). Of the tumours that
initially respond, acquired resistance to TZ therapy develops in approximately 70% of
patients within the first year of treatment (Nahta & Esteva 2006). Several mechanisms of
acquired TZ resistance have been hypothesised, including the expression of truncated
forms of HER2 that prevent binding of TZ (Scaltriti et al. 2007), the activation of
alternative signalling pathways (Ludyga et al. 2013) and the clonal selection and
expansion of HER2-negative tumour cells as a result of the intratumoural heterogeneity
of breast cancer (Gerlinger et al. 2012).

1.4 Tumour heterogeneity and therapeutic resistance
The genomic, functional and spatiotemporal heterogeneity that is characteristic of many
solid tumours plays a key role in the development of resistance to targeted therapies (Fig.
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1.3) (Alizadeh et al. 2015; Venkatesan & Swanton 2016). Mechanisms of acquired
resistance to molecular-targeted therapies have been extensively reviewed elsewhere
(Holohan et al. 2013; Lackner et al. 2012). The intratumoural heterogeneity of tumours
provides a template for the clonal selection and expansion of target-negative tumour cells
(Eirew et al. 2015) and is a known mechanism of acquired resistance to targeted therapies
(Gerlinger et al. 2012; Sebolt-Leopold & English 2006). Individual tumours are
comprised of a mixture of both target-positive and target-negative tumour cells
(Solomayer et al. 2006). The administration of a targeted therapy inevitably places a
selection pressure on a genetically and functionally heterogeneous population of tumour
cells, resulting in the selection of tumour cells that are no longer responsive to the targeted
therapy (Gillies et al. 2012). With time and the continuation of therapy, the targetnegative tumour cell population is able to expand so that the tumour becomes
predominately target-negative, at which point the patient no longer shows a response to
the original targeted therapy (Zardavas et al. 2015). In this way, the intratumoural
heterogeneity of cancer can reduce the potential efficacy of targeted therapies and thus
contributes to cancer recurrence and metastasis (Hayes 2016).

Figure 1.3: Schematic representation of tumour heterogeneity. Tumour heterogeneity includes
intertumoural and intratumoural (biomarker) heterogeneity, receptor heterogeneity and signalling
heterogeneity. Figure from Belfiore et al. (2018a).
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The intratumoural heterogeneity of breast cancer suggests that a multiple biomarker
targeting strategy may be of benefit in order to target a broader range of tumour cell
subtypes (Doolittle et al. 2015). This concept has been demonstrated by dual knockdown
of HER2 and the commonly co-overexpressed protein tyrosine kinase 6, which showed a
reduction of breast cancer cell migration, invasion and proliferation in vitro and a
reduction of tumour growth in vivo (Ludyga et al. 2013). As the binding of TZ to HER2
results in the internalisation of the complex through receptor-mediated endocytosis
(RME), TZ may be used as a targeting ligand to deliver cytotoxin to HER2-positive
tumour cells. Phase II clinical trials using a TZ-drug conjugate demonstrated selective
targeting and enhanced efficacy of this approach in HER2-positive breast cancer patients
(Burris et al. 2011). Simultaneous targeting of another breast cancer biomarker in addition
to HER2 in a cytotoxin-delivery approach may provide a means to overcome therapeutic
resistance and improve the efficacy of HER2-targeted therapies. Several potential
biomarkers of cancer progression have been identified (Weigelt et al. 2005) to help guide
decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer
(Harris et al. 2007). Additionally, recent evidence has shown that other cell types that
support tumour cell growth and play key roles in facilitating metastasis, including
endothelial cells, fibroblasts and immune cells, may also be potential targets for novel
multi-targeted therapies (Thoma et al. 2014). For example, the superior efficacy of
independently targeting both tumour and immune cells in various cancer types has been
demonstrated previously (Bracci et al. 2014; Emens & Middleton 2015).

As previously mentioned, several receptor-targeted molecular therapies have been
developed to treat cancer, including a range of monoclonal antibodies and antibody
fragments that derive an anti-tumour effect through binding to cell surface receptors in
order to inhibit tumour cell proliferation (Nahta & Esteva 2006) and/or to induce a
cytotoxic immune response (Verschraegen 2012). Another tumour cell targeting approach
involves the use of monoclonal antibodies, proteins or other ligands to facilitate targeted
cell uptake of specific molecules to achieve an anti-tumour effect. For example, if the
binding of a ligand to its target receptor results in the RME of the ligand-receptor
complex, the targeting ligand – which may be a currently used targeted molecular therapy
– can be used for the intracellular delivery of covalently attached cytotoxins or other
molecules to tumour cells that express the ligand receptor (Perez et al. 2014; Sievers &
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Senter 2013). This tumour targeting approach may help to circumvent intrinsic resistance
driven by alternative signalling mechanisms (Menyhart et al. 2015). While the plasma
half-life of most targeted molecular therapies tends to be relatively short, the association
of these molecules with larger nanostructures, such as lipid-based nanoparticles or
liposomes, can significantly extend the plasma circulation time of the targeted therapy
and increase the therapeutic payload delivered to the tumour site (Vine et al. 2014). Such
receptor-targeted nanoparticulate therapies may incorporate currently used targeting
molecules, such as antibodies, onto the surface of the nanoparticle to be used as targeting
ligands. These targeting ligands can direct the nanoparticle to receptor-positive tumour
cells and facilitate cellular uptake of the nanoparticle, achieving intracellular delivery of
the nanoparticle cargo for an anti-tumour effect (Section 1.6).

1.5 Urokinase plasminogen activator system
The urokinase plasminogen activator system (uPAS) has a demonstrated role in tumour
cell invasion and metastasis (Fig. 1.4). In this system, the urokinase plasminogen activator
(uPA), a serine protease, becomes active upon binding to its cell membrane-bound
receptor, the urokinase plasminogen activator receptor (uPAR) (Didiasova et al. 2014).
Active uPAR-bound uPA (uPA/uPAR) converts plasminogen, an inactive zymogen, to
plasmin at the cell surface. Plasmin is a broad spectrum serine protease that degrades a
range of extracellular proteins to facilitate remodelling of the ECM (Dass et al. 2008).
The endogenous plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2) specifically
bind to the active site of uPAR-bound uPA and inhibit the uPA-mediated conversion of
plasminogen to plasmin (Fig. 1.4). PAI-1, the main physiological inhibitor of uPA, has
additional cell signalling roles that facilitate tumour cell invasion (Croucher et al. 2008;
Dass et al. 2008), and overexpression of PAI-1 in cancer is correlated with a poor patient
prognosis (Cochran et al. 2011; Croucher et al. 2008). In contrast, overexpression of PAI2 in cancer is correlated with a good patient prognosis and prolonged survival (Croucher
et al. 2008). Under normal physiological conditions, the uPA-mediated remodelling of
the ECM is essential to promote immune cell migration, wound healing and other
important extracellular processes (Gonias & Hu 2015). However, under pathological
conditions such as cancer, the degradation of extracellular physiological barriers enables
tumour cells to migrate out of the region, promoting the invasion of tumour cells into
surrounding tissues and facilitating metastasis (O'Halloran et al. 2013).
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Figure 1.4: Urokinase plasminogen activator system. The urokinase plasminogen activator (uPA)
becomes active upon binding to its receptor, the urokinase plasminogen activator receptor (uPAR).
Active uPA converts plasminogen to plasmin, a broad-spectrum serine protease that degrades the
extracellular matrix (ECM) to promote tumour cell invasion and metastasis. Plasminogen activator
inhibitor-1 and inhibitor-2 (PAI-1 and PAI-2) can bind to uPAR-bound uPA to prevent the uPAmediated conversion of plasminogen to plasmin and subsequent downstream effects promoting
metastasis. Figure adapted from Didiasova et al. (2004).

Numerous studies and clinical evidence have indicated a key role for uPAS in breast
cancer metastasis (Giannopoulou et al. 2007). Amplification and overexpression of uPA
and uPAR are recognised biomarkers of metastasis and are indicative of an overall poor
patient prognosis for several cancer types (Dass et al. 2008; Duffy et al. 2014). In breast
cancer, progression-free survival is inversely correlated with uPA and uPAR expression
(Duffy et al. 2014; Harris et al. 2007). Patients with high uPA mRNA levels are more
likely to suffer from metastatic disease (Urban et al. 2006), and overexpression of uPAR
by tumour cells and/or stromal cells is associated with poor prognosis for metastatic breast
cancer (Bianchi et al. 1994). In TNBC, uPAR has been shown to increase the malignant
potential (Huber et al. 2016) and has been identified as a potential novel target for
treatment of this breast cancer subtype (Al-Mahmood et al. 2018; Aubele et al. 2015).
Tumour hypoxia has been shown to induce uPAR overexpression, and uPAR
overexpression can confer tumour cell resistance to chemotherapy (Gonias & Hu 2015).
In addition, uPAR overexpression can promote tumour cell migration through signal
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transduction (Carriero & Stoppelli 2011). Intracellular uPAR-dependent signalling can
promote epithelial-mesenchymal transition, causing changes to tumour cell morphology
and inducing stem cell-like properties that facilitate a metastatic tumour cell phenotype
(Indira Chandran et al. 2015).

Within the HER2-positive breast cancer subtype, recent evidence suggests a cooperative
effect of uPA/uPAR and HER2 on disease progression. In patients with metastatic HER2positive breast cancer, amplification of both HER2 and uPAR often occurs in the same
tumour cells (Pierga et al. 2005), and the overexpression of uPAR in breast cancer cells
within the HER2-positive subtype facilitates tumour cell invasion and a metastatic
phenotype (Berg et al. 2012; Meng et al. 2006). In HER2-normal and HER2-amplified
subsets of breast cancer patients, uPAR overexpression significantly reduced the
probability of metastasis-free survival, more significantly so in the short-term for HER2
amplified breast cancer (Indira Chandran et al. 2015). The presence of HER2positive/uPAR-negative

and

HER2-negative/uPAR-positive

cells

due

to

the

intratumoural heterogeneity of in vivo tumours suggests that targeting both HER2 and
uPAR may be an effective way to target multiple clonal populations of tumour cells and
improve the efficacy of drug-based treatments for metastatic HER2-positive breast cancer
(Sugiyama et al. 2013). In vitro studies using RNA interference showed that
downregulation of both HER2 and uPAR in breast cancer cells was synergistic in
supressing tumour cell growth and inducing tumour cell death, and was more effective
than downregulating either receptor alone (Li et al. 2010). Given the role of uPAS in the
promotion of metastasis, targeting uPA/uPAR may be a promising therapeutic strategy
for metastatic breast cancer (Matthews 2011; Mazar et al. 2011). The protective effect of
PAI-2 in breast cancer progression indicates that the use of PAI-2 in uPA-targeted
therapies for cancer may be a promising novel strategy for targeting uPAR in breast
cancer.

1.5.1 Plasminogen activator inhibitor-2
PAI-2, also known as SerpinB2, is a serine protease inhibitor that exists as a 43 kDa
intracellular form and a 60 kDa extracellular glycosylated form (Fig. 1.5). While PAI-2
is expressed by most cell types, expression is upregulated in pregnancy, in the immune
response and in tumour cells (Croucher et al. 2008). As the binding of extracellular PAI12

2 to uPAR-bound uPA results in the RME of the PAI-2/uPA/uPAR complex, PAI-2 can
be used as a targeting ligand for the intracellular delivery of covalently attached cytotoxin
to uPAR-positive tumour cells (Cochran et al. 2011). Previous work has shown PAI-2 to
be non-toxic, stable and selective for uPA inhibition. It has been shown that the CD-loop
(a 33 amino acid loop situated between α-helices C and D of the protein) of PAI-2 is not
relevant in cell targeting of uPA/uPAR. Recombinant ΔCD-loop PAI-2 retains its
inhibitory activity against uPA, and is also easier to express and purify (Cochran et al.
2009). ΔCD-loop PAI-2 has four cysteine residues (C5, C145, C161 and C405) that are
not involved in the inhibitory function of PAI-2 (Wilczynska et al. 2003) and can
therefore be used as sites of conjugation to other molecules for targeting and delivery to
uPA/uPAR-positive cells.

Figure 1.5: Plasminogen activator inhibitor-2. Plasminogen activator inhibitor-2 (PAI-2) is a serine
protease inhibitor that exists as a 43 kDa intracellular form and a 60 kDa extracellular glycosylated
form. As the binding of extracellular PAI-2 to urokinase plasminogen activator receptor (uPAR)bound urokinase plasminogen activator (uPA) results in the receptor-mediated endocytosis of the PAI2/uPA/uPAR complex, PAI-2 can be used as a targeting ligand via conjugation of molecules to
cysteine residues C5, C145, C161 or C405. Figure adapted from Wilczynska et al. (2003).

ΔCD-loop PAI-2 has been previously used to target uPA/uPAR for drug delivery
applications. PAI-2 has been successfully conjugated to the alpha-emitting radioisotope
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Bi213 (Stutchbury et al. 2007) and to an N-alkylisatin (N-AI)-based cytotoxin (Section
1.6.1), a potent microtubule destabilising agent (Vine et al. 2007) that can evade Pglycoprotein (P-gp)-mediated efflux in multi-drug resistant cancer cell lines (Vine et al.
2016). The PAI-2-N-AI conjugate showed selective targeting to and cytotoxicity against
uPA/uPAR-positive breast cancer cells in vitro and effective inhibition of primary tumour
regrowth in an in vivo model of breast cancer metastasis at 1/20th of the concentration of
free N-AI (Vine et al. 2012). The attachment of PAI-2 to larger molecules, such as
polyethylene glycol (PEG), can significantly extend the plasma half-life of PAI-2 and
increase tumour retention in vivo (Vine et al. 2014). The use of a PEG-coated drug
delivery carrier, such as a lipid-based nanoparticle, may further increase the in vivo
circulation time of PAI-2 bound to the nanoparticle surface to enhance targeting of uPARpositive tumour cells in drug delivery applications.

1.6 Liposomes for tumour targeting and drug delivery
Liposomes have emerged as a useful delivery system for the transport of drugs and other
molecules to solid tumours (Allen & Cullis 2013). Liposomes are spherical lipid-based
vesicles, typically 100-200 nm in diameter, comprised of associating phospholipids that
form a lipid bilayer surrounding an aqueous core (Pattni et al. 2015) (Fig. 1.6). This
unique structure allows for the encapsulation of hydrophobic or hydrophilic drugs, or
other small molecules, in the lipid bilayer or aqueous core, respectively (Gubernator
2011). Encapsulated drugs can then be delivered to target cells for intracellular drug
release and anti-tumour effect. The circulation time of liposome particles is largely
dependent on their lipid composition, size, surface charge, morphology and other
physicochemical characteristics. The dominant mechanism by which liposomes are
typically cleared from the bloodstream is based on interactions with the phagocytic cells
of the mononuclear phagocyte system (MPS). The inclusion of hydrophilic polymers,
most commonly PEG, at the outer surface of the liposome can increase the in vivo
circulation time by reducing recognition and clearance by the MPS (Uster et al. 1996).
For this reason, PEGylated liposomes have long been considered a clinically useful
nanoparticle for drug delivery applications.
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Figure 1.6: General structure of liposomes. Drug-loaded liposomes may be non-ligand (passively
targeted), single-ligand or dual-ligand (actively targeted). Phospholipids associate to form a
hydrophobic lipid bilayer surrounding a hydrophilic aqueous core. Drugs may be encapsulated in the
liposome bilayer or core, depending on solubility. Polyethylene glycol (PEG) is incorporated into the
bilayer to neutralise surface charge and decrease the rate of clearance from the bloodstream. Targeting
ligands may be covalently attached to the terminal ends of PEG chains to enable selective binding of
the liposome to cell surface receptors for targeted drug delivery.

Liposome-based drug formulations can offer several distinct advantages over free drug
formulations in addition to an increased in vivo circulation time, including improved
stability and solubilisation of the encapsulated drug, reduction in systemic toxicity of the
drug and increased drug delivery to the tumour site (Estanqueiro et al. 2014). The superior
activity of drug-loaded liposomes relies on a multi-step process involving both passive
and active targeting mechanisms. Passive targeting is primarily mediated by the enhanced
permeability and retention (EPR) effect (Fig. 1.7), defined as the extravasation and
retention of particles less than 380-780 nm in size into the tumour interstitial space due
to highly porous tumour vasculature and poor lymphatic drainage from the tumour site
(Gerlowski & Jain 1986; Matsumura & Maeda 1986). The encapsulated drug can be
released from liposomes in the tumour interstitium and can then be taken up by the tumour
cells, or liposomes containing the drug can be internalised by the tumour cells or other
tumour-associated cells (Barenholz 2012). Therefore, in theory, passive targeting enables
targeting to tumours via the EPR effect. In addition, liposome formulations reduce
exposure of normal tissues to the drug as liposomes cannot pass through intact continuous
endothelium (except for the liver and spleen, which have a different anatomy of
vasculature) and so do not localise there, minimising associated off-target effects while
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simultaneously providing a mechanism for enhanced accumulation in the tumour site
(Abdalla et al. 2018).

Figure 1.7: The enhanced permeability and retention effect. The extravasation and retention of
nanoparticles into the tumour interstitial space occurs due to highly porous tumour vasculature and
poor lymphatic drainage from the tumour site. Figure from Abdalla et al. (2018).

1.6.1 N-alkylisatins
N-alkylisatins are a class of molecules derived from isatin (1H-indole-2,3-dione) with a
broad range of cytotoxic and anticancer properties (Matesic et al. 2008). The N-alkyl-5,7dibromoisatins, including 7-dibromo-N-(p-hydroxymethylbenzyl)isatin (N-AI) (Fig. 1.8),
are microtubule-destabilising cytotoxins with a potent anti-tumour cell effect against
cancer cell lines in vitro (Vine et al. 2007), and an anti-tumour growth effect in vivo (Vine
et al. 2012). The potency of these compounds against tumour cells is comparable to
clinically used drugs such as doxorubicin and paclitaxel, but unlike many clinically used
drugs, the N-alkylisatins are not substrates for P-gp-mediated efflux, meaning that this
class of compounds has potential application in the treatment of multi-drug resistant
cancers (Vine et al. 2016).

16

Figure 1.8: Chemical structure of N-alkylisatin. 5,7-dibromoisatin and the N-alkylisatin derivative
5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin.

N-AI has been previously conjugated to PAI-2 in order to target uPA/uPAR-positive
tumour cells for targeted drug delivery. The N-AI-PAI-2 conjugate, which had an average
of 1-2 cytotoxin molecules per PAI-2 molecule, demonstrated a selective increased
cytotoxic effect against uPA/uPAR-positive tumour cells in vitro, and was efficacious in
vivo in reducing primary tumour growth in mice (Vine et al. 2012). Given the potency
and previous validation of N-AI as a cytotoxin for use in anticancer applications, N-AI is
a promising candidate for further development in drug delivery research. As a
hydrophobic molecule, N-AI has a low aqueous solubility that limits the amount of drug
that can be administered intravenously (Grimaldi et al. 2016). However, N-AI is amenable
to encapsulation within liposomes in order to improve solubility and physicochemical
stability. While liposomal formulations of N-AI have not been previously reported in the
literature, the loading of similar hydrophobic anticancer drugs, such as paclitaxel and
colchicine, into the liposome bilayer has been achieved (Koudelka & Turánek 2012;
Kulkarni et al. 1997).

1.6.2 Ligand-directed liposomes for active tumour cell targeting
In addition to their versatile drug encapsulation capabilities, liposomes permit the active
targeting of specific cell types via the conjugation of ligands, such as monoclonal
antibodies, antibody fragments, proteins, peptides, carbohydrates, glycoproteins,
aptamers and small molecules, to the liposome surface for drug delivery to cells
expressing the target surface receptor(s) of interest (Messerschmidt et al. 2008). Active
targeting using liposomes is achieved via conjugation of one or more ligands to the
liposome surface to form liposomes that bind to a target receptor expressed on the tumour
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cell surface. Following liposome extravasation into the tumour interstitial space,
subsequent ligand-directed surface binding and internalisation (usually via RME)
promotes liposome and drug entry into specific cell types. As actively targeted liposome
formulations combine both passive and active drug delivery mechanisms, ligand-directed
liposomes should show superior drug delivery compared to non-ligand liposomes,
depending on the tumour type (Wilhelm et al. 2016).

Currently, all clinically approved liposome drug formulations are non-ligand directed,
with efficacies relying solely on passive targeting to achieve tumour accumulation.
Despite extensive research into nanomedicine-based therapeutics, and the preclinical
development of dozens of liposome drug formulations spanning several decades, less than
a dozen liposomal drug formulations have been approved by the FDA for clinical use to
date (Bobo et al. 2016; Shi et al. 2017). Of these FDA-approved liposomes, only several
distinct formulations have been approved for the treatment of cancer, including Kaposi’s
sarcoma, acute lymphoblastic leukaemia, pancreatic cancer, ovarian cancer, multiple
myeloma and metastatic breast cancer (Table 1.2). Evidently, there is a bottleneck in the
translation of liposomes from preclinical development through to clinical utility, with
many preclinical formulations never proceeding to clinical trials and only a small
percentage of those that do eventually making it onto the market. This bottleneck is even
more profound for the development of ligand-directed liposomes, where there are
currently no clinically approved formulations available (van der Meel et al. 2013).

Active targeting strategies using ligand-directed liposomes have been explored
extensively in the preclinical setting, showing improved efficacy over non-ligand
liposomes in in vitro and in vivo models. For example, in vitro testing of doxorubicinloaded liposomes (analogous to Doxil®) that were surface-functionalised with an antiHER2 monoclonal antibody fragment demonstrated effective binding to breast cancer
cells expressing HER2 and a 700-fold increase in drug uptake compared to non-ligand
directed liposomes in vivo (Park et al. 2001). MM-302, a HER2-targeted liposomal
formulation of doxorubicin, showed efficacy in xenograft models of breast cancer and
proceeded through to clinical trials (Espelin et al. 2016). A phase II/III clinical trial of TZ
therapy in combination with either MM-302 or chemotherapy of physician’s choice was
recently terminated as the TZ/MM-302 treatment did not show improved efficacy over
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the current standard of care for HER2-positive breast cancer (Miller et al. 2016). This
may be due to the current lack of understanding around how actively targeted liposomes
behave in immune-competent animals (i.e. humans). While the development of actively
targeted liposomes to improve the efficacy of their passively targeted predecessors has
been explored preclinically, there has been limited progression of such formulations
through to clinical trials (Table 1.2) (van der Meel et al. 2013). Given the long history of
ligand-directed liposome development and the significant investment of research into this
area, it is important to explore the reasons why there has been limited translation of
actively targeted liposomes in the field of cancer therapy. Following an overview of
previous research in the field, we will highlight and discuss some of the likely reasons for
this bottleneck in clinical progression.

1.6.3 Dual-ligand liposomes for dual-targeting of tumour cells
Liposomes have been used for tumour targeting for several decades, and while no singleligand or dual-ligand liposomes have yet been clinically adopted, actively targeted
liposome formulations have been reported extensively in the literature. The utilisation of
a dual-targeted approach has a range of reported purposes: most commonly, for
overcoming intratumoural heterogeneity by targeting multiple tumour cell subtypes and
targeting tumour-associated cells; for targeting tumour vasculature as a means to halt
tumour growth; and for facilitating nanoparticle delivery across biological barriers, such
as the blood-brain barrier (BBB), for drug delivery to the brain.

Given the demonstrated performance of non-ligand liposomes in drug delivery and the
large number of studies describing the design of ligand-bearing liposomes to target
tumour-associated receptors, the development of liposomes that can target more than one
tumour cell subtype in a heterogeneous tumour may help to overcome therapeutic
limitations of current therapies (Fig. 1.9). Previous in vitro and in vivo studies have
demonstrated that ligand-directed liposomes targeting two different cell surface receptors
can increase the total amount of liposomes binding to the cancer cells within a tumour as
the liposomes are able to bind to any target cell expressing either receptor, which
increases the breadth of targeting.
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Table 1.2: Passively and actively targeted liposomes. Non-ligand and ligand-directed liposomes in clinical use, clinical trial and preclinical development for cancer
treatment. EMA, European Medicines Agency; FDA, Food and Drug Administration. The ClinicalTrials.gov identifier is listed as the reference for liposomes in clinical
trials.
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Figure 1.9: Targeting multiple tumour cell subtypes using ligand-directed liposomes. Dualligand-directed liposomes may help overcome therapeutic limitations caused by intratumoural
heterogeneity of cancer. Liposomes bearing two disparate ligands enable liposome uptake via
receptor-mediated endocytosis by tumour cells bearing either (or both) target receptors, thus increasing
the range of tumour cell targeting. Single-ligand liposomes only enable targeting of the tumour cells
bearing the single target receptor. Given the intratumoural heterogeneity of cancer, some tumour cells
will not be targeted by the single-ligand liposome, and instead that tumour cell population may be able
to expand. Ligand-directed liposomes may also be designed to target stromal cells for an intended antitumour effect. Figure from Belfiore et al. (2018a).

Several preclinical studies have successfully modified liposomes with two surface-bound
moieties to create dual-ligand-directed, drug-loaded liposomes that show specific binding
to receptor-bearing tumour cells and a resultant higher tumour cell uptake and kill than
non-targeted or single-ligand liposomes (Lukyanov et al. 2004). For example, the cellular
uptake and cytotoxicity of dual-ligand liposomes targeting lymphoma biomarkers CD19
and CD20, or an equal combination of the two single-ligand liposomes at equal antibody
amounts, were greater than for either single-ligand liposome alone (Sapra & Allen 2004).
Similarly, a pH-sensitive doxorubicin-loaded liposome formulated to promote
intracellular drug release was surface-functionalised with folic acid and AS1411 aptamer
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(targeting the folate receptor and nucleolin, respectively), and showed increased cancer
targeting and efficacy relative to single-ligand and non-ligand liposomes (Lale et al.
2014). Dual-ligand liposomes showed enhanced cellular uptake, higher intracellular
delivery of doxorubicin and greater apoptosis in human breast and pancreatic cancer cell
lines than single-ligand liposomes, and had no adverse doxorubicin-related effects on a
non-cancerous human cell line. Using a murine model of human B-cell lymphoma, drugloaded liposomes functionalised with antibodies targeting CD19 or CD20 showed an
improved outcome compared to non-ligand liposomes, with a trend of increased
therapeutic efficacy for a combination of the two compared to each alone (Sapra & Allen
2004).

Liposomes containing paclitaxel and bearing both a cell ligand peptide and cell
penetrating peptide to target lung cancer showed greater liposome internalisation in lung
cancer cells, greater accumulation of paclitaxel in tumour spheroids, and significantly
greater inhibition of tumour growth in a mouse model of lung cancer than single-ligand
and non-ligand liposomes (Wang et al. 2015). Dual-ligand paclitaxel-loaded liposomes
containing the integrin avβ3 peptide and an anti-microbial peptide showed increased
cellular toxicity and improved tumour growth inhibition in a colon carcinoma mouse
model relative to single-targeted liposomes (Zhang et al. 2016). This improved delivery
effect of dual-ligand over single-ligand targeting was also demonstrated using a
nanostructured lipid carrier containing plasmid DNA that was surface-functionalised with
both transferrin and hyaluronic acid, which showed increased transfection efficiency over
single-ligand or non-ligand carriers in a mouse model of lung cancer (Zhang et al. 2017).
While the ligand density and stoichiometry were not quantified in any examples, liganddirected liposomes targeting two different cell surface receptors may be able to increase
the total amount of liposome binding to the tumour cell surface within a heterogeneous
tumour as the liposome is able to bind to any target cell expressing either receptor (Fig.
1.9). This is likely to increase the breadth of cellular targeting beyond a single receptor
or cell type, subsequently enhancing drug uptake, dose and hence the anti-tumour effect
(Laginha et al. 2005). Furthermore, dual-ligand liposomes could act to unify the
pharmacokinetic and biodistribution properties of different ligand-functionalised
liposomes for precise delivery to target cells, rather than using two individual ligandfunctionalised liposomes with disparate targeting moieties and pharmacological profiles.
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In the context of glioma treatment, ligand-directed liposomal drug formulations may
enhance drug transport across the BBB for drug delivery to the brain (Gulati & Wallace
2012). Dual-ligand liposomes containing daunorubicin and surface-functionalised with
both transferrin and p-aminophenyl-α-D-manno-pyranoside showed increased transport
across the BBB, increased cellular uptake and increased survival compared to treatment
with free daunorubicin in a rat model of brain glioma (Ying et al. 2010). Another study
using doxorubicin-loaded liposomes surface-functionalised with both transferrin and one
of two different cell-penetrating peptides showed improved delivery of doxorubicin
across the brain-endothelial barrier (BEB) compared to single-ligand and non-ligand
liposomes in vitro, and efficient translocation across the BEB in an in vitro brain tumour
model (Sharma et al. 2014). Similarly, docetaxel-loaded nanoparticles that were surfacefunctionalised with IL-13 and RGD peptide to target both tumour cells and
neovasculature showed greater uptake in a glioma cell line than single-ligand and nonligand nanoparticles, and the dual-ligand nanoparticle induced higher apoptosis of cells
in the glioma site in vivo, indicating an improvement in cell uptake and anti-tumour effect
by dual-targeting (Gao, H. et al. 2014). This was further supported by experiments using
dual-ligand liposomes bearing both an aptamer and a peptide moiety to target glioma and
the BBB in an in vitro glioma model designed to recapitulate the tumour
microenvironment (Gao, Huile et al. 2014). Collectively, the aforementioned studies
demonstrate the potential utility of dual-ligand-directed liposomal drug formulations for
cancer therapy, with an increased degree of liposome uptake acting to improve the antitumour effect.

1.6.4 Dual-ligand liposomes for targeting the tumour microenvironment
The tumour microenvironment, which consists of fibroblasts, immune cells, vasculature,
and ECM components such as collagen and fibrin, is increasingly being found to play a
key role in tumour progression, metastasis and response to therapy. Treatment strategies
that target aspects of the tumour microenvironment, such as anti-angiogenic and
immunostimulatory therapies, show promising preclinical and clinical results; however,
factors such as lack of drug penetration into the tumour, non-specific drug delivery, rapid
clearance from serum, or toxic side effects contribute to the failure of many conventional
therapies to completely eliminate the tumour. Dual-ligand liposomes offer a potential
solution to some of the aforementioned problems, as many recent studies have shown
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encouraging results using nanomedicines to target the tumour vasculature, the ECM and
cancer-associated immune cells (Siegler et al. 2016).

For example, Doolittle et al. (2015) described the creation of dual-ligand liposomes
targeting two different angiogenesis-specific receptors overexpressed at different stages
of metastatic disease. Given that tumours display a dynamic, heterogeneous
microenvironment that undergoes spatiotemporal changes in the expression of cellsurface biomarkers during disease progression, the authors reasoned that targeting Pselectin and αvβ3 integrin would target the liposome towards blood vessels associated
with metastases at different stages of disease progression. Here, a metastatic site
transitions, after initial adhesion of circulating tumour cells onto the endothelium, from
P-selectin-dependent cell rolling on the endothelium to firm attachment that is αvβ3
integrin-mediated (McCarty et al. 2000). In a resectable mouse model of metastatic
TNBC, their dual-ligand strategy achieved complementary targeting of different tumour
sites that was missed using two independent single-ligand liposomes. This was attributed
to poor colocalisation of both single-ligand liposomes at metastatic sites at the same point
in time (Doolittle et al. 2015). This approach was similarly demonstrated by Kluza et al.
in the context of magnetic resonance imaging of angiogenesis (Kluza et al. 2010).

Spatiotemporal changes in the expression of cell-surface molecular markers are also
observed in cancer stem cells (CSCs), a small population of cells within a tumour with
the ability to undergo both self-renewal and differentiation. These cells are now
recognised for their role in driving the initiation, invasion, metastasis, resistance and
recurrence of a tumour, and the development of targeted nanotherapies that disrupt the
maintenance and survival of CSCs are the subject of intense research (Chen et al. 2013).
For example, a multi-functional nanoparticle conjugated to a ligand targeting a specific
CSC marker and a chemosensitiser (such as an ABC transporter inhibitor) to overcome
drug resistance has been proposed (Chen et al. 2013). Altogether, these studies further
support the potential advantage of a multiple receptor-targeting strategy using dual-ligand
liposomes to better target the spatiotemporal changes in receptor expression that occur
during metastatic disease progression. Additional examples of potential target
combinations for the design of dual-ligand liposomes are listed in Table 1.3.
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Table 1.3: Dual receptor targeting using liposomes. Potential target receptors for the design of dualligand liposomes with the ability to concomitantly target the tumour and its dynamic
microenvironment.
Cancer
Breast

Biomarker 1
HER2
ER
EGFR

Cell population targeted
Tumour (Ross et al. 2009)
Tumour (Ariazi et al. 2006)
Tumour (Diéras et al. 2003)

Biomarker 2
ALDH-1
CTLA-4
uPAR

Pancreatic

EGFR
uPAR
CD109

CD133
CD44
CD24

Melanoma

AXL receptor
tyrosine
kinase

Tumour (Troiani et al. 2012)
Tumour (Nielsen et al.
2005)
Tumour (Haun et al. 2014)
Tumour (Boshuizen et al.
2018)

CD20+

VEGFR
Prostate

PSMA

Colorectal

uPAR

Tumour and new blood
vessels (Ghosh & Heston
2004)
Tumour and tumourinfiltrating macrophages
(Pyke et al. 1994)

CD44/CD133
VEGFR
EpCAM

Cell population targeted
CSC (Pan et al. 2015)
CSC (Velasco-Velazquez
et al. 2011)
Activated fibroblasts and
tumour-associated
macrophages (GrondahlHansen et al. 1995),
invasive tumour cells
(LeBeau et al. 2013) and
CSC (Jo et al. 2010)
CSC (Hermann et al. 2007)
CSC (Li et al. 2015)
CSC (Sagiv et al. 2008)
Tumour-associated B cells
(in cutaneous melanoma)
(Garg et al. 2016)
Endothelial cells (Mehnert
et al. 2007)
CSC (Collins et al. 2005)

Endothelial cells (Shaheen
et al. 1999)
CSC (Dalerba et al. 2007)

HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; EGFR, epidermal growth
factor receptor; ALDH-1, aldehyde dehydrogenase 1; CTLA-4, cytotoxic T-lymphocyte-associated
protein 4; uPAR, urokinase plasminogen activator receptor; CSC, cancer stem cell; CD, cluster of
differentiation; VEGFR, vascular endothelial growth factor receptor; PSMA, prostate-specific
membrane antigen; EpCAM, epithelial cell adhesion molecule.

1.7 Thesis rationale
Despite a growing understanding of the molecular biology of breast cancer metastasis,
there is currently no cure for metastatic breast cancer. The HER2-positive and TNBC
subtypes have high rates of metastasis and disease recurrence, and a generally poor
prognosis, and therefore effective therapies are urgently required. HER2-positive breast
cancer is characterised by high levels of intratumoural heterogeneity, which makes
resistance to targeted therapies a common problem affecting the success of treatment. In
contrast, TNBC is characterised by a lack of validated biomarkers and therefore limited
effective treatment options for this breast cancer subtype. Targeting uPAS in metastatic
cancer is a promising approach, given the role of this system in breast cancer progression
and the cooperative effect of uPA and HER2 in the HER2-positive breast cancer subtype.
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This thesis tested the hypothesis that targeting uPAS using drug-loaded liposomes is an
advantageous way to enable targeting and delivery of potent anticancer drugs to tumour
cells via uPAR-directed ligands at the liposome surface. Therefore, the rationale of this
thesis was the development and evaluation of drug-loaded liposomes targeting uPAS as
a novel way of treating breast cancer, and for the future development of dual-targeted
(uPA/HER2) liposomes for targeting heterogeneous tumour cell populations to overcome
therapeutic resistance of HER2-positive breast cancer treatment.

1.8 Aims
The overall aim of this thesis was to create and characterise novel N-AI-loaded liposomes
surface-functionalised with PAI-2 as a ligand for targeting uPAR, and to evaluate the
targeting ability and anti-tumour efficacy of these liposomes using various in vitro and in
vivo models of uPAR-positive breast cancer. Therefore, the specific aims of this thesis
were to:
1. Prepare and characterise, for the first time, N-AI-loaded PAI-2-functionalised
(N-AI PAI-2) liposomes by optimising previously reported methods (Chapter 2);
2. Determine the cellular uptake, cellular localisation and receptor-dependent
cytotoxicity of N-AI PAI-2 liposomes using monolayer cell culture and
multicellular tumour spheroid models of breast cancer (Chapter 3);
3. Evaluate the biodistribution, pharmacokinetic profile and anti-tumour efficacy of
N-AI PAI-2 liposomes in human xenograft mouse models of primary and
metastatic breast cancer (Chapter 4); and
4. Develop a single-molecule fluorescence microscopy technique to determine the
density and stoichiometry of protein ligands attached to the surface of
functionalised liposomes to support the future development of uPAR and HER2
dual-ligand liposomes (Chapter 5).
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Chapter 2:
Preparation and Characterisation of
N-alkylisatin-Loaded Liposomes Targeting the
Urokinase Plasminogen Activator System

Nanoparticle tracking analysis of liposomes

Portions of this chapter have been included in the following work for publication:
Belfiore, L, Saunders, DN, Ranson, M & Vine, KL 2019, ‘N-alkylisatin-loaded
liposomes targeting the urokinase plasminogen activator system in breast cancer’,
manuscript in preparation.

Author contributions: LB, DNS, MR and KLV designed the experiments; LB and KLV
performed the experiments and analysed the data; LB wrote the manuscript; DNS, MR
and KLV edited the manuscript for submission.
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2.1 Introduction
The first clinically approved liposome formulation, Doxil®, has been in use for over 20
years and is still regarded as an effective and safe treatment for several cancer types.
However, the liposome field has not evolved into translating effective actively targeted
liposomes as all current clinically used liposomes are passively targeted (Chapter 1,
Section 1.6). In the context of cancer therapy, the utility of liposome technologies is
promising as ligand-directed liposomes have the potential to further increase the
selectivity of therapy, improving efficacy and reducing the potential for harmful side
effects. Therefore, the development of novel drug-loaded liposomes with surface-bound
targeting ligands for active tumour targeting is warranted. Central to the successful
evaluation of novel actively targeted liposomes is the use of high-throughput and scalable
methods to produce and characterise them prior to in vitro and in vivo testing. This chapter
explored and developed these methods to produce and characterise novel actively targeted
liposomes for tumour cell targeting.

2.1.1 Preparation of drug-loaded liposomes
Liposomes have emerged as a useful delivery system for the transport of drugs and other
molecules to solid tumours (Allen & Cullis 2013). Liposomes are spherical lipid-based
vesicles, typically 100-200 nm in diameter, comprised of associating phospholipids that
form a lipid bilayer surrounding an aqueous core (Pattni et al. 2015). This unique structure
allows for the encapsulation of hydrophobic or hydrophilic drugs, or other small
molecules, in the lipid bilayer or aqueous core, respectively (Gubernator 2011). Drugloaded liposomes can be produced using a range of methods, including the thin film
hydration method, the solvent injection method, and more recently, automated production
using microfluidic devices (Pattni et al. 2015). The thin film hydration method involves
dissolving liposome constituents and a hydrophobic drug in organic solvent, which is then
evaporated to form a dry lipid thin film that is reconstituted in aqueous solution and
extruded to create unilamellar liposomes with the encapsulated hydrophobic drug within
the liposome bilayer (Fig. 2.1). For hydrophilic drug encapsulation, alternative methods,
such as the ammonium sulfate active loading method, can be used for the encapsulation
of hydrophilic drugs in the liposome core (Zhigaltsev et al. 2010).
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Figure 2.1: Preparation of drug-loaded liposomes using thin film hydration. Phospholipids and
the anti-mitotic drug (N-AI) are dissolved in an organic solvent, which is then removed by rotary
evaporation. The resultant thin film is hydrated with an aqueous buffer and stirring results in the
formation of drug-loaded liposomes. Serial extrusion of the heterogeneous multilamellar liposome
mixture through a 100 nm pore filter produces a homogenous solution of unilamellar liposomes
approximately 100 nm in diameter.

2.1.2 Preparation of actively targeted liposomes
Actively targeted liposomes can be prepared by utilising simple coupling chemistry
methods to covalently attach ligands to the liposome surface, typically via polyethylene
glycol (PEG) chains present on the surface of the liposome (Cheng & Allen 2010). For
example, free sulfhydryl groups of a protein ligand can covalently attach to maleimidefunctionalised PEG phospholipids, which places the targeting ligand at the terminal end
of the PEG chain at the liposome surface, allowing uninhibited access of the liposomebound ligand to its target receptor on the cell surface (Allen et al. 1995). This coupling
technique is used in two different methods of targeted liposome preparation (Fig. 2.2).
The conventional (CO) method uses maleimide-functionalised PEG phospholipid groups
in the initial liposome formulation, and subsequent thiolation of the ligand and incubation
with preformed liposomes permits covalent attachment of the ligand to the terminal ends
of the liposome PEG chains (Allen et al. 1995). Alternatively, the post-insertion (PI)
method first utilises small micelles composed of maleimide-functionalised PEG
phospholipids to covalently bind to the thiolated ligand before the micelles are incubated
with preformed liposomes at a high temperature to facilitate insertion of the PEG
phospholipid-bound targeting ligands into the outer leaflet of the liposomes (Moreira et
al. 2002). The PI method forms stable liposomes with negligible drug leakage during the
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post-insertion step, and similar in vitro cytotoxicity and in vivo therapeutic efficacy to
liposomes prepared using the CO method (Iden & Allen 2001). The PI method also offers
a practical approach to creating liposomes that bear two or more different targeting
ligands to further enhance the targeting selectivity of the liposome. Dual-ligand or multiligand liposomes can be created by incubating liposomes with differently functionalised
micelles at varying concentrations to control ligand stoichiometry (Saul et al. 2006).

Figure 2.2: Conventional and post-insertion methods for ligand conjugation. The conventional
method involves incubation of preformed liposomes with thiolated ligands, which attach covalently to
the liposome surface via terminal maleimide-functionalised polyethylene glycol (PEG) groups. The
post-insertion method involves attaching thiolated ligands to maleimide-functionalised PEG
phospholipid micelles, which are then incubated with preformed liposomes at 60°C to facilitate the
transfer of micelle phospholipids with covalently attached proteins into the outer leaflet of the
liposome bilayer.

2.1.3 Characterisation of targeted liposomes
It is well understood that the biophysical characteristics of targeted liposomes influence
their stability, in vivo circulation time, clearance properties, tumour uptake and
therapeutic efficacy. Therefore, various methods for liposome characterisation have been
reported (Honary & Zahir 2013). Commonly measured characteristics include liposome
size and polydispersity by dynamic and static light scattering, surface charge by
measuring zeta potential, degree of drug encapsulation by spectrophotometry or highperformance liquid chromatography (HPLC), and morphology and physical state by
cryogenic-transmission electron microscopy (cryo-TEM) or atomic force microscopy
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(Kang et al. 2015). While the methods for characterisation of passively targeted liposomes
are relatively well developed, characterisation methods for more complex liposomes,
particularly ligand-directed liposomes, are lacking, and this may be a potential barrier to
the feasible and practical development of actively targeted liposomes for clinical utility
(Saul et al. 2006). Therefore, the validation of methods to comprehensively characterise
actively targeted liposomes is an important aspect of actively targeted liposome
production and evaluation.

2.1.4 Experimental rationale
Previous research has shown that plasminogen activator inhibitor-2 (PAI-2) can be used
to target urokinase plasminogen activator/urokinase plasminogen activator receptor
(uPA/uPAR)-positive breast cancer cells in vitro and in vivo. PAI-2 has been conjugated
to the potent anti-tumour cytotoxin and anti-mitotic agent N-alkylisatin (N-AI) (Chapter
1, Section 1.6.1). The N-AI-PAI-2 conjugate, which had an average of 1-2 N-AI
molecules per PAI-2 molecule, showed targeting of and a selective cytotoxic effect
against uPA/uPAR-positive cells in vitro, and anti-tumour growth effects in vivo (Vine et
al. 2012). In order to increase the in vivo circulation time and payload of N-AI to the
tumour site for increased anti-tumour effect, N-AI can be encapsulated in the bilayer of
PEGylated liposomes for drug delivery, and PAI-2 can be attached to the liposome
surface in order to actively target and deliver N-AI to uPAR-positive tumour cells. As NAI-encapsulated liposomes have not been reported previously, there is a need to utilise
and build upon previous liposome preparation methods to formulate and characterise
novel N-AI-loaded PAI-2-functionalised liposomes before proceeding to in vitro and in
vivo evaluation.

2.1.5 Aims
The overall aim of this chapter was to prepare and characterise novel N-AI-loaded PAI2-functionalised (N-AI PAI-2) liposomes. Specifically, the aims of this chapter were to:
1. Prepare N-AI PAI-2 liposomes using modifications to previously published
methods for forming ligand-directed, drug-loaded liposomes; and
2. Determine the biophysical characteristics of N-AI PAI-2 liposomes, including
liposome size, particle concentration, surface charge, drug encapsulation
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efficiency, PAI-2 ligand attachment to the liposome surface and the ability of
PAI-2 liposomes to inhibit uPA activity.

2.2 Methods
2.2.1 Liposome preparation
Liposomes were prepared using the thin film hydration method, as described previously
(Ishida et al. 1999). Liposomes were composed of 20 mM soy PC (L-αphosphatidylcholine) and 0.6 mM mPEG2000-DSPE (1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[(polyethylene glycol)-2000]) (Avanti Polar Lipids, AL, USA),
with the addition of either 5 mM cholesterol (Sigma-Aldrich, MO, USA) to form empty
liposomes, or 5 mM 5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin (N-AI) (prepared inhouse (Vine et al. 2016)) to form N-AI-loaded liposomes. Reagents were weighed out
into a round-bottom flask and dissolved in a 2:1 (v/v) mixture of chloroform/methanol
(Sigma-Aldrich, MO, USA). Organic solvents were removed by rotary evaporation and
subsequent freeze drying to form a lipid film. Dried liposome films were rehydrated in
deoxygenated 25 mM HEPES buffer (115 mM NaCl, 20 mM HEPES, 2.4 mM K2PO4,
1.2 mM CaCl2, 1.2 mM MgCl2; pH 7.4) at a phospholipid concentration of 20 mM by
shaking for 1 h at room temperature (RT) with intermittent sonication. Once reconstituted,
liposomes were passed through a 0.22 µm polyvinylidene fluoride (PVDF) membrane
(Merck Millipore, Germany) and then serially extruded 11 times through a 0.1 µm PVDF
membrane using a syringe-driven extruding apparatus (Avanti Polar Lipids, AL, USA) at
RT.

2.2.2 PAI-2 conjugation to liposomes
Liposomes were surface-functionalised with PAI-2 using either the conventional (CO)
method or post-insertion (PI) method (Allen et al. 2002). Human recombinant PAI-2,
ΔCD-loop, prepared as described previously (Cochran et al. 2009), has free cysteine
residues for conjugation to terminal maleimide groups of maleimide-functionalised PEG
(Oswald et al. 2016). For the CO method, preformed liposomes were incubated with PAI2 at a molar ratio of 3333:1 liposome phospholipid:protein for 2 h at RT. For the PI
method, micelles composed of 0.8 mM mal-PEG2000-DSPE (1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[maleimide(polyethylene

glycol)-2000])

and

0.2

mM
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mPEG2000-DSPE were prepared as per previously reported methods (Moreira et al. 2002),
and PAI-2 was added to the micelles at a molar ratio of 10:1 (mal-PEG2000-DSPE:protein)
to form PAI-2-functionalised micelles. PAI-2-functionalised micelles were added to
preformed liposomes and heated to 60°C for 1 h to facilitate the post-insertion of micelle
lipids into the outer leaflet of the liposomes. Following the liposome functionalisation
steps, unbound PAI-2 was removed from liposomes by either size-exclusion
chromatography (SEC) using Sepharose CL-4B (Sigma-Aldrich, MO, USA) according to
the manufacturer’s protocol, or repeated centrifugation at 20,000 x g for 1.5 h at 4°C.

2.2.3 Liposome characterisation
2.2.3.1 Dynamic light scattering
Liposome size distribution, peak intensity and polydispersity index (PDI), as well as
stability over time using repeated measurements, were determined by dynamic light
scattering (DLS) using a Zetasizer APS instrument (Malvern Instruments, UK). Liposome
samples (60-100 µL) in phosphate-buffered saline (PBS) or HEPES were added to 96well plates and analysed at 25°C using the manufacturer’s measurement protocol for
liposomes (13 reads per sample, triplicate measurements). Data were presented as the
intensity distribution for liposomes and the number distribution for micelles in order to
enable visualisation of small particles. Zeta potential (surface charge) of liposomes was
determined by DLS using a Zetasizer Nano ZS instrument (Malvern Instruments, UK)
(10-100 reads per sample, triplicate measurements).

2.2.3.2 Nanoparticle tracking analysis
Liposome size distribution and particle concentration were determined using a NanoSight
LM 10 instrument (Malvern Instruments, UK) according to the manufacturer’s protocol.
Liposomes were diluted to a concentration of between 1×108 and 25×108 particles/mL in
PBS to ensure an optimal concentration for accurate analysis of samples (NanoSight Ltd,
UK). Imaging of 20-100 particles per field of view was performed using an optical
microscope fitted with a charge-coupled device camera at 25°C. Particle movement was
recorded at 20 frames per second for 60 seconds. Average particle size and concentration
were calculated using Nanoparticle Tracking Analysis (NTA) software (version 2.3,
NanoSight Ltd, UK) from triplicate measurements.
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2.2.3.3 Phospholipid assay
Liposome phospholipid concentration was determined using a commercial phospholipid
kit (Sigma-Aldrich, MO, USA), as per the manufacturer’s instructions. Briefly,
phosphatidylcholine standards were prepared 0-20 µM, 20 µL of each standard was added
to a 96-well plate in duplicate, as well as 20 µL of each liposome sample (at various
dilutions). 80 µL of reaction mix containing assay buffer, enzyme mix, phospholipase D
enzyme and dye reagent, was added to each well and incubated at RT for 30 min.
Absorbance was measured at 570 nm using a Spectramax spectrophotometer (Molecular
Devices, CA, USA). The absorbance values of the phospholipid standards were used to
create a standard curve and unknown sample concentrations were determined by
interpolation.

2.2.3.4 N-AI encapsulation in liposomes
Drug

encapsulation

efficiency

was

determined

by

high-performance

liquid

chromatography (HPLC). N-AI-loaded liposomes were mixed with water/acetonitrile
(60:40 v/v) and centrifuged. The N-AI concentration was determined using an Atlantis
T3 reverse-phase C18 analytical column (Waters, UK) and a Waters HPLC machine
(Waters, MA, USA). Analysis was performed using an injected volume of 10 µL with a
gradient elution and monitored with a photodiode array at 435 nm. Concentration was
determined by interpolating from a standard curve after analysis of standards and samples
using Empower Pro V2 software (Waters, UK).

2.2.3.5 Lowry assay
Protein concentration of PAI-2 and PAI-2-functionalised liposomes was determined
using the DC Protein Assay kit (Bio-Rad Laboratories, CA, USA) according to the
manufacturer’s protocol. Bovine serum albumin (BSA) was used as a standard (0-2
mg/mL) and 5 µL of standard or sample was added to a 96-well plate. Bio-Rad reagent A
(25 µL) and reagent B (200 µL) were added to each well, the plate incubated at RT for
10 min, and the absorbance measured using a Spectramax spectrophotometer (Molecular
Devices, CA, USA) at 750 nm. The absorbance values of the BSA were used to create a
standard curve and unknown sample concentrations were determined by interpolation.
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2.2.3.6 BCA assay
The Bicinchoninic Acid (BCA) assay is one of the most sensitive colourimetric protein
assays and can detect protein at concentrations as low as 5 µg/mL (Walker 1996). Due to
phospholipid interference in the Lowry analysis of liposome samples, protein
concentration of PAI-2-functionalised liposomes was additionally determined using the
BCA assay according to previously published methods. Solution A, consisting of 20 g/L
sodium carbonate, 9.5 g/L sodium bicarbonate and 1.6 g/L sodium tartrate, was brought
to pH 11.25 with the addition of 1 M sodium hydroxide. Immediately prior to use, 0.5 g
BCA powder (Sigma-Aldrich, MO, USA) was dissolved in 50 mL of solution A. Solution
A was combined with solution B, which was made up of 4% (w/v) copper sulfate in water,
in a ratio of 50:1 to produce BCA working reagent (solution C). BSA protein standards,
ranging in concentration from 0-1 mg/mL, were prepared in PBS, and 10 μL of each
protein standard was added to a 96-well plate in triplicate. Various dilutions of samples
in PBS were prepared and 10 μL of each solution was added to the plate in triplicate. 80
μL of solution C was added to each well and the plate incubated at 60°C for 15 min. The
absorbance of the solutions within the wells was determined using a FLUOstar OPTIMA
plate reader (BMG Labtech, Germany) at a wavelength of 544 nm. The absorbance of the
BSA was used to create a standard curve and unknown sample concentrations were
determined by interpolation.

2.2.3.7 SDS-PAGE
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis,
loading buffer (containing 50% (v/v) glycerol, 2% or 6% (w/v) sodium dodecyl sulfate
and 0.02% (v/v) bromophenol blue in distilled water) was added to samples. For reducing
conditions, 5 μL of β-mercaptoethanol (Sigma-Aldrich, MO, USA) was added to samples.
Samples were denatured by heating to 100°C for 5 min and were then loaded into a 10%
gel to run by SDS-PAGE at 100 V for 2 h.

2.2.3.8 Western blotting
Western blotting was used to detect and quantify PAI-2 conjugated to liposomes. Proteins
in SDS-PAGE gels were transferred to PVDF membranes using Bio-Rad transfer
equipment (Bio-Rad Laboratories, CA, USA) at 100 V for 1.5 h. Membranes were rinsed
in TBST (1X TBS buffer with 0.05% v/v Tween-20) and blocked using 10% skim milk
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in TBST for 1 h at RT. After rinsing membranes twice with TBST, membranes were
incubated with primary antibody (anti-SerpinB2; Abcam, Cambridge, UK) at 1:2000
dilution in 2% skim milk/TBST at 4°C overnight. Membranes were washed with TBST
four times (10 min each wash) and then incubated with secondary antibody (anti-rabbitHRP; Abcam, Cambridge, UK) at 1:5000 dilution in 2% skim milk/TBST for 2 h at RT.
Membranes were then washed in TBST three times for 5 min and then in TBS (no Tween20) three times for 5 min. Membranes were developed using ECL peroxidase reaction
(Pierce PicoWest ECL reagent; Thermo Fisher Scientific, MA, USA), according to the
manufacturer’s instructions. Membranes were visualised using x-ray film after
developing and fixing (Bio-Rad Laboratories, CA, USA) or using a Gel Logic 2200
Digital Imager (Carestream Molecular Imaging, CT, USA). Band intensities were
quantified using ImageJ (National Institutes of Health, MD, USA).

2.2.3.9 Flow cytometric analysis of liposomes
Flow cytometry was used to further assess liposome size and quantify the efficiency of
micelle insertion into preformed liposomes. Fluorescent liposomes were prepared by
loading with rhodamine-123 (R123) (Sigma-Aldrich, MO, USA) or by post-inserting
micelles that were prepared in the absence or presence of varying percentages of FITCDSPE-PEG (Avanti Polar Lipids, AL, USA). Events (50,000) were collected using an
LSR II flow cytometer (BD Biosciences, NJ, USA; excitation 488 nm, emission collected
with a 515/20 band-pass filter). Data were analysed using FlowJo software version 10
(FlowJo LLC, OR, USA).

2.2.3.10 Fluorogenic uPA activity assay
To determine whether PAI-2 conjugated to the surface of liposomes retained inhibitory
activity against uPA, the activity of PAI-2-functionalised liposomes was quantified using
a fluorogenic uPA activity assay, as described previously (Cochran et al. 2009). Briefly,
liposomes were diluted in 100 μL reaction buffer (20 mM HEPES, pH 7.6, 100 mM NaCl,
0.5 mM EDTA, 0.01% (v/v) Tween 20) containing 0.25 mM uPA fluorogenic substrate
(Z-Gly-Gly-Arg-AMC; Merck Millipore, MA, USA). After a brief pre-incubation at 37
ºC, high molecular weight urokinase plasminogen activator (HMW-uPA) (final
concentration 0.675 nM) was added to start the reaction and fluorescence emission was
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measured at 37 ºC using a microplate reader (POLARstar Omega; BMG Labtech,
Germany). All assays were performed in triplicate and values corrected by subtracting
the background well values (reaction buffer and substrate only).

2.2.4 Data analysis
All data analysis, including the generation of graphs and statistical tests, was performed
using GraphPad Prism version 7 for Windows (GraphPad Software, CA, USA), unless
stated otherwise. Data are presented as the mean ± standard deviation (s.d.) or standard
error of the mean (s.e.m.) as stated. Pairwise comparisons were made using Student’s ttest and multiple comparisons were made using one-way ANOVA with Tukey’s posttest.

2.3 Results
2.3.1 Preparation of empty and N-AI-loaded liposomes
Modifications to previously reported methods (Allen et al. 1995) were used to prepare
and characterise soy PC PEGylated liposomes containing the potent microtubuledestabilising cytotoxin N-alkylisatin (N-AI). Empty and N-AI-loaded liposomes were
prepared by the thin film hydration method and were analysed by dynamic light scattering
(DLS) (Table. 2.1). Empty (EMP) liposomes were 137.6 ± 5.6 nm in diameter, while NAI-loaded liposomes were 139.9 ± 3.9 nm in diameter. The polydispersity index (PDI)
for both liposomes was < 0.1 for both samples, indicating monodispersity. Both
liposomes had a peak intensity of 100%, further indicating the liposome populations were
monodisperse and the absence of aggregation or large particle populations in the samples.
EMP and N-AI liposomes exhibited an equivalent zeta potential (small negative surface
charge) and equivalent phospholipid concentrations.

Table 2.1: Characterisation of empty and N-AI PEGylated liposomes. Empty (EMP) liposomes
and N-AI-loaded liposomes were prepared by the thin film hydration method and analysed by dynamic
light scattering. Values are means ± s.d. (n = 3).
Liposome

Diameter
(nm)

Polydispersity
index

Intensity
(%)

Zeta potential
(mV)

Phospholipid
(mM)

EMP

137.6 ± 5.6

0.067 ± 0.035

100

–3.63 ± 0.80

16.44

N-AI

139.9 ± 3.9

0.093 ± 0.023

100

–3.64 ± 0.59

16.45
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The size and morphology of N-AI liposomes were further confirmed by cryogenic
transmission electron microscopy (cryo-TEM), performed by Delfine Cheng at the
Sydney Microscopy & Microanalysis Facility of the University of Sydney. Cryo-TEM
indicated that the N-AI liposomes had an average diameter of 138.7 ± 18.4 nm (Fig. 2.3).
Cryo-TEM additionally revealed N-AI liposomes to be spherical, monodisperse and
unilamellar. The N-AI loaded in the liposome bilayer showed no evidence of
crystallisation. The concentration of N-AI encapsulated in the liposomes could not be
determined by spectrophotometry and interpolation from a standard curve as the liposome
phospholipid interfered with the peak absorbance of N-AI at 310 nm and 435 nm
(Appendix A). Therefore, the concentration of N-AI loaded into liposomes was
determined by high performance liquid chromatography (HPLC), which revealed an NAI concentration of 2.2 mM, equating to 43.1% drug loading (% w/w) based on the
starting amount of N-AI used in the liposome preparation (Appendix B).

Figure 2.3: Cryo-TEM of N-AI-loaded liposomes. N-alkylisatin (N-AI)-loaded liposomes were
prepared using the thin film hydration method, and cryogenic transmission electron microscopy (cryoTEM) was performed to visualise liposome size and morphology. (A) Representative image of N-AIloaded liposomes. (B) Determination of average liposome diameter from cryo-TEM image analysis.

2.3.2 Preparation of recombinant human PAI-2
Recombinant human PAI-2 for covalent attachment to the liposome surface was prepared
using established protocols (Cochran et al. 2009). SDS-PAGE analysis showed that the
PAI-2 produced was pure, with a single band corresponding to the size of PAI-2 of
approximately 45 kDa (Fig. 2.4A). Prior to conjugating PAI-2 to liposomes, a fluorogenic
uPA activity assay was used to confirm that the recombinant PAI-2 was active. PAI-2
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activity was indicated by the complete inhibition of uPA at a 2-fold molar excess of PAI2:uPA compared to the positive control (no PAI-2) (Fig. 2.4B).

Figure 2.4: Production of recombinant human PAI-2. (A) SDS-PAGE analysis of purified
plasminogen activator inhibitor-2 (PAI-2) fractions (1, 2); M = marker. (B) Urokinase activity assay
to confirm inhibitory activity of purified PAI-2 over 30 min. + = positive control, - = negative control.

2.3.3 Conjugation of PAI-2 to liposomes using the conventional method
To attach PAI-2 to the surface of liposomes using the conventional method, recombinant
human PAI-2 was incubated with preformed liposomes for 2 h at RT, and unconjugated
PAI-2 was removed using size-exclusion chromatography (SEC) (Fig. 2.5). Analysis of
fractions by spectrophotometry at 280 nm to detect protein revealed the presence of two
peaks, indicating that unconjugated PAI-2 had separated from PAI-2 that had covalently
attached to liposomes.

Figure 2.5: Size-exclusion chromatogram of liposomes after PAI-2 conjugation. After
conjugation, free plasminogen activator inhibitor-2 (PAI-2) was removed from PAI-2 liposomes using
size-exclusion chromatography. The absorbance of the fractions at 280 nm was used to detect PAI-2.
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Following SEC, the fractions corresponding to the liposome peak were pooled and the
sample was analysed by DLS. DLS revealed that the average diameter of the N-AI-loaded
PAI-2-functionalised (N-AI PAI-2) liposomes was 141.1 ± 5.0 nm, while that of the
empty PAI-2-functionalised (EMP PAI-2) liposomes was 139.7 ± 4.9 nm (Table 2.2). The
diameter and the PDI of both samples remained similar to the measurements before the
PAI-2 conjugation step (Table 2.1). The peak intensity of both liposome preparations was
100%, indicating that the final liposome formulations were monodisperse. The zeta
potential of the PAI-2-functionalised liposomes became more negative (Table 2.2),
shifting slightly for both empty and N-AI-loaded liposomes. The phospholipid
concentration of both EMP PAI-2 and N-AI PAI-2 liposomes was equivalent at 16.67
mM and 16.62 mM, respectively.

Table 2.2: Characterisation of liposomes prepared by the conventional method. Empty
plasminogen activator inhibitor-2 (PAI-2)-functionalised liposomes (EMP PAI-2) and N-alkylisatin
(N-AI)-loaded PAI-2-functionalised liposomes (N-AI PAI-2) were prepared by the conventional
method and analysed by dynamic light scattering. Values are means ± s.d. (n = 3).
Liposome

Diameter
(nm)

Polydispersity
index

Intensity
(%)

Zeta potential
(mV)

Phospholipid
(mM)

EMP PAI-2

139.7 ± 4.9

0.109 ± 0.017

100

–4.05 ± 0.53

16.67

N-AI PAI-2

141.1 ± 5.0

0.086 ± 0.030

100

–4.66 ± 0.52

16.62

2.3.4 Quantification of PAI-2 bound to liposomes by protein assays
The quantification of PAI-2 attached to liposomes was attempted using two common
laboratory assays: the BCA assay and the Lowry assay. Empty non-functionalised and
empty PAI-2-functionalised liposomes at an equivalent phospholipid concentration were
analysed to determine protein concentration according to the manufacturer’s protocols for
the assays. The protein concentration resulting from interpolation of a standard curve
(using bovine serum albumin) revealed the protein concentration of both liposome
preparations to be just over 1 mg/mL in both assays, with protein concentration between
the non-functionalised and PAI-2-functionalised liposomes not significantly different in
both assays (Fig. 2.6). This indicated a high degree of interference in the assay from the
liposome phospholipid. Therefore, the PAI-2 concentration of liposome samples could
not be determined using biochemical protein assays.
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Figure 2.6: Phospholipid interference in protein assays. Non-functionalised (NF) and plasminogen
activator inhibitor-2 (PAI-2) liposomes were analysed via the BCA assay and Lowry assay, and protein
concentration was determined by interpolation from a bovine serum albumin standard curve. ns = not
significant. Data are the mean ± s.d. (n = 3).

2.3.5 Detection of liposome-bound PAI-2 by Western blotting
As PAI-2 could not be detected or quantified using commercial biochemical protein
assays, Western blotting was used to confirm successful conjugation of PAI-2 to
liposomes and to attempt to quantify protein amount post-conjugation. Following SEC to
remove free PAI-2 from PAI-2 liposomes, fractions corresponding to the PAI-2 liposome
(peak 1) and free PAI-2 (peak 2), as well as a sample of unpurified PAI-2 liposomes, were
analysed via Western blotting (Fig. 2.7). Covalent conjugation of PAI-2 to liposome
phospholipid (PEG-DSPE; molecular weight ~2940 kDa) to form PAI-2-PEG-DSPE was
confirmed by a lag in gel migration of PAI-2 in the peak 1 fraction (Fig. 2.7, sample #1)
relative to the peak 2 fraction (Fig. 2.7, sample #2), which corresponded with the 45 kDa
molecular weight of free PAI-2. The absence of a band corresponding to free PAI-2 in
peak 1 indicated that removal of unbound PAI-2 was successful. The bands revealed in
the unpurified PAI-2 liposome sample (Fig. 2.7, sample #3) appeared as a combination
of the two former, further indicating separation via size-exclusion was successful. It was
observed that liposome-bound PAI-2 migrates differently through a gel compared to pure
PAI-2, causing a smearing effect and multiple PAI-2 bands, limiting the accuracy of
densitometry for quantification of liposome-bound protein using a PAI-2 standard curve.
Estimates using densitometry indicated that the ratio of mean grey value between the PAI2 bands in peaks 1 and 2 was 53:47 (Appendix C). This ratio was roughly reflected in the
OD280 peak height of the size-exclusion chromatogram (56:44). The amount of protein
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in sample 2 (unconjugated PAI-2) was determined to be 37 ng (via BCA assay), which
indicated that the amount of PAI-2 associated with the liposome fraction in sample 1 was
approximately 42 ng, based on the densitometry ratio between the two samples.

Figure 2.7: Western blot analysis of PAI-2 liposomes. (A) Size-exclusion chromatograph of PAI-2
liposome fractions after, including PAI-2 liposomes (peak 1) and unbound PAI-2 (peak 2). (B)
Western blot detection of PAI-2 in size-exclusion fractions (1, 2), unpurified liposomes (3), and
purified PAI-2 (50, 25 and 12.5 ng). OD = optical density, M = marker, PEG = polyethylene glycol.
Data are representative from two experimental repeats.

2.3.6 Fluorogenic urokinase plasminogen activator inhibition assay
To confirm that the PAI-2 attached to the surface of liposomes was still able to inhibit
uPA activity, a fluorogenic uPA activity assay was performed (Cochran et al. 2009).
Empty (EMP) liposomes were used instead of N-AI-loaded liposomes as N-AI is slightly
fluorescent and may interfere with the assay (Chapter 3, Section 3.3.2). Liposome
phospholipid had a positive interfering effect in fluorescence measurements, with both
EMP and EMP PAI-2 liposomes showing a shift above baseline at the start of
measurements. The rate of fluorescence (RFLU) was 4026.9 ± 206.2 FLU/min for EMP
liposomes and 43.5 ± 24.9 FLU/min for EMP PAI-2 liposomes, and the mean
fluorescence intensity of the EMP liposomes was 3.7-fold higher than the EMP PAI-2
liposomes at the 30 min time point (Fig. 2.8). The 92.6-fold reduction in RFLU for EMP
PAI-2 liposomes relative to EMP liposomes indicates that the former inhibits uPA activity
whereas the latter does not, demonstrating that PAI-2 is present and active in the PAI-2
liposome sample.
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Figure 2.8: Fluorogenic uPA activity assay of PAI-2 liposomes. Liposomes were prepared and
added to assay to see if PAI-2 bound to the surface of liposomes would still be active in inhibiting
uPA over a period of 30 minutes at 37°C as compared to unconjugated PAI-2. Values are means ± s.d.
(n = 3).

2.3.7 Centrifugation of liposomes to remove unbound PAI-2
SEC is the most commonly used method to remove free protein from liposomes following
conjugation. Although standard in the field, research has noted that liposome loss using
SEC may be a concern as liposomes may non-specifically adsorb to the resin (Ruysschaert
et al. 2005). Further, this method causes dilution of the sample, takes time if performed
by gravity, and only allows for analysis of one sample at a time. There are reports in the
literature of using high-speed centrifugation to spin and pellet liposomes, primarily for
the purpose of removing unencapsulated soluble drug (Zhigaltsev et al. 2010). As small
soluble protein ligands, such as 45 kDa PAI-2, do not pellet out of solution under highspeed centrifugation, it was posited that unbound PAI-2 could be removed from
liposomes by high-speed centrifugation, which would increase the efficiency of liposome
production and potentially increase liposome recovery.

Firstly, to determine how liposomes pellet under different centrifugal forces, EMP
liposomes were spun at 20,000 x g for 0-4 h, with phospholipid in the pellet measured by
spectrophotometry at 350 nm. The results showed a time-dependent increase in OD350
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signal in the liposome pellet and a corresponding decrease in OD350 signal in the
supernatant (Fig. 2.9). Liposome size remained constant in the pellet, deviating little from
the starting diameter of 145 nm. However, size decreased linearly with time up to the 2 h
time point as larger particles settled to form the pellet first, leaving smaller particles
behind in the supernatant and leading to a smaller average diameter. All samples
displayed 100% peak intensity, as determined by DLS.

Figure 2.9: Centrifugation of liposomes over time. (A) Liposomes were centrifuged at 20,000 x g
for up to 4 h and OD350 measured of pellet and supernatant to locate which fraction the phospholipid
(liposome) resided. (B) Liposome samples taken at different time points from either the supernatant
or pellet were analysed by dynamic light scattering to determine changes in average liposome diameter
with high-speed centrifugation. Data are the mean ± s.e.m. (n = 3).

To examine the effect of centrifugation on empty PAI-2-functionalised liposomes,
liposomes were centrifuged for 4 h and then analysed by nanoparticle tracking analysis
(NTA) to determine average particle diameter and concentration relative to noncentrifuged liposomes (Table 2.3). The centrifuged liposomes showed a small but not
significant (P > 0.05) increase in average diameter from 148.0 ± 4.2 nm to 153.9 ± 5.9
nm and a significant (P < 0.01) 22.9% reduction in particle concentration relative to noncentrifuged liposomes. NTA images revealed the distributions and monodispersity of the
centrifuged and non-centrifuged liposomes to be similar (Fig. 2.10).
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Table 2.3: Effect of centrifugation on liposome diameter and particle concentration. Liposomes
were centrifuged at 20,000 x g at 4°C for 4 h and analysed by nanoparticle tracking analysis. Data
are the mean ± s.d. (n = 3).
Liposome

Diameter
(nm)

Concentration
(particles/mL)

Non-centrifuged PAI-2 liposomes

148.0 ± 4.2

2.40 x 1013 ± 4.24 x 1011

Centrifuged PAI-2 liposomes

153.9 ± 5.9

1.85 x 1013 ± 1.36 x 1012

Figure 2.10: Nanoparticle tracking analysis of liposomes after centrifugation. Liposomes were
centrifuged at 20,000 x g for a total of 4 h. (A) Control (non-centrifuged) and (B) centrifuged
liposomes were analysed using nanoparticle tracking analysis (NTA) to determine particle size and
concentration. Images are representative frames from 60 second analysis via NTA. Images are
representative from triplicate measurements.

2.3.8 Conjugation of PAI-2 to liposomes using the post-insertion method
The post-insertion method of liposome functionalisation requires the formation of
functionalised micelles that are then inserted into preformed liposomes (Fig. 2.2).
Micelles were prepared using PEG2000-DSPE and analysed by DLS. Prior to 0.22 µm
filtration, the average diameter of the micelles was approximately 300 nm, and this was
reduced following filtration to remove large aggregates, where the average diameter was
14.1 nm (Table 2.4). Size distributions of the filtered micelles showed the presence of
larger peaks in the intensity distribution but a single peak in the volume and number
distributions, indicating the presence of small micelles as the predominant population
with some larger aggregates (Fig. 2.11). To form PAI-2-functionalised micelles, PAI-2
was added to PEG2000-DSPE micelles containing 20% maleimide-functionalised PEG2000DSPE to enable attachment of PAI-2 via cysteine residues to the terminal end of PEG.
DLS analysis of PAI-2 micelles showed that the average diameter was 15.9 nm. Micelles
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before and after PAI-2 conjugation showed similar PDI values of 0.165 and 0.178,
respectively (Fig. 2.11).

Table 2.4: Characterisation of PEG2000-DSPE micelles. Micelles were prepared by thin film
hydration, filtered using a 0.22 µm membrane and analysed by dynamic light scattering. Values are
means ± s.d. (n = 3). NF = non-functionalised.

Micelle

Diameter (nm)

Polydispersity index

NF micelle

14.1 ± 0.526

0.165 ± 0.014

PAI-2 micelle

15.9 ± 0.273

0.178 ± 0.031

PAI-2 micelles were then added to preformed N-AI-loaded liposomes to create PAI-2functionalised liposomes. Following the post-insertion step, liposomes were purified by
SEC as for conventional liposomes. DLS revealed 100% peak intensity across all
distributions, indicating no remaining micelles were present in the liposome sample (Fig.
2.12).

Figure 2.11: Dynamic light scattering analysis of PEG2000-DSPE micelles. Micelles were
prepared by thin film hydration, filtered using a 0.22 µm membrane and analysed by dynamic light
scattering to determine average liposome diameter. Traces are replicate measurements (n = 3).
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There was a noticeable and significant (P < 0.01) increase in average liposome diameter
from 141.2 ± 4.7 nm to 154.1 ± 1.3 nm following N-AI-loaded liposome incubation with
PAI-2 micelles (the post-insertion step) (Fig. 2.13). A small increase in diameter was
observed for N-AI liposomes that were incubated with maleimide-PEG micelles alone
(145.0 ± 1.7 nm) or with a mixture of micelles that contained non-maleimidefunctionalised PEG and PAI-2 (145.4 ± 4.7 nm), but this was not significantly different
to the liposome diameter prior to the post-insertion step.

Figure 2.12: Dynamic light scattering analysis of post-insertion liposomes. Liposomes were
prepared using the post-insertion method and analysed by dynamic light scattering. Traces are
replicate measurements (n = 3).
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Figure 2.13: N-AI PAI-2 liposomes prepared by the post-insertion method. Liposomes were
functionalised with PAI-2 via the post-insertion method using micelles. Dynamic light scattering was
used to determine average liposome diameter. Values are the mean ± s.d. (n = 3). ns = not significant;
** = P < 0.01.

2.3.9 Flow cytometric analysis of micelle post-insertion into liposomes
To further confirm the insertion of micelle phospholipids into the liposome bilayer using
the post-insertion method, the transfer of fluorescent micelles into liposomes was detected
using flow cytometry (Mack et al. 2012). Firstly, to determine whether liposomes could
be detected using the flow cytometer and to optimise settings, empty liposomes and
fluorescent rhodamine-123 (R123)-loaded liposomes were prepared and analysed by DLS
(Table 2.5) before being run on the flow cytometer to detect fluorescence of the particles
(Fig. 2.14). R123-loaded liposomes were slightly larger than empty liposomes, but both
had low polydispersity and 100% peak intensity of the particle population. Flow
cytometry revealed the liposome populations of both samples, with similar forward and
side scatter profiles. The R123 liposome population (MFI = 43.8 ± 0.5) showed a peak
shift and 20.7-fold increase in MFI relative to that of empty liposomes (MFI = 2.1 ± 1.3),
indicating that the fluorescence of R123 liposomes could be detected by flow cytometry.
Analysis of PBS only showed a minimal presence of small particles at the detection
settings used to analyse the liposomes.
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Table 2.5: Characterisation of R123-loaded liposomes. Empty liposomes and liposomes containing
rhodamine-123 (R123) were prepared by the thin film hydration method and analysed by dynamic
light scattering. Values are means ± s.d. (n = 3).
Liposome

Diameter (nm)

Polydispersity index

Intensity (%)

Empty

135.3 ± 6.0

0.080 ± 0.038

100

R123-loaded

148.1 ± 3.6

0.066 ± 0.010

100

Figure 2.14: Detection of R123-loaded liposomes by flow cytometry. (A) Empty or (B) rhodamine123 (R123)-loaded liposomes were analysed by flow cytometry using a 515 band-pass filter for
detection of rhodamine. (C) PBS was used to adjust the threshold for the detection of particles and to
minimise signal noise. (D) Fluorescent signal of R123 was detected as a peak shift relative to empty
liposomes and PBS samples. Data are representative from n = 3 samples. FSC, forward scatter; SSC,
side scatter.

Once it was confirmed that liposomes could be detected by flow cytometry using the
optimised settings, micelles composed of 0%, 10% or 30% FITC-labelled phospholipid
(FITC-PEG-DSPE; 30% of total micelle phospholipid) were incubated with preformed
empty liposomes as per the post-insertion method of targeted liposome preparation (Allen
et al. 2002). DLS analysis revealed a small increase in average liposome diameter for all
three preparations following the post-insertion step relative to liposomes that had not been
incubated with micelles (Table 2.6). The PDI of the three post-insertion preparations
increased slightly, but peak intensity remained at 100%, indicating the absence of
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unincorporated micelles in the liposome preparations. Analysis of the liposomes by flow
cytometry revealed a significant increase (P < 0.01) in the mean fluorescence intensity
(MFI) for liposomes that had been incubated with 10% or 30% FITC-labelled micelles
compared to liposomes incubated with non-fluorescent micelles (Fig. 2.15). There was
no significant difference in MFI between the 10% FITC and 30% FITC liposome
preparations.

Table 2.6: Characterisation of FITC-labelled liposomes. Liposomes were prepared by the thin film
hydration method, and micelles composed of 0%, 10% or 30% FITC-PEG2000-DSPE were
incorporated into the liposomes using the post-insertion method. Liposomes were analysed by
dynamic light scattering. Values are means ± s.d. (n = 3).
Liposome

Diameter (nm)

Polydispersity index

Intensity (%)

No micelle

136.0 ± 2.1

0.055 ± 0.033

100

0% FITC micelle

140.6 ± 2.4

0.089 ± 0.003

100

10% FITC micelle

140.1 ± 2.4

0.086 ± 0.041

100

30% FITC micelle

143.1 ± 2.7

0.079 ± 0.021

100

Figure 2.15: Detection of post-insertion of FITC micelles into liposomes. Liposomes were
incubated with (A) 0% FITC micelles, (B) 10% FITC micelles or (C) 30% FITC micelles and analysed
by flow cytometry (FSC = forward scatter; SSC = side scatter). (D) PBS only was used to select an
appropriate voltage to minimise the signal from small non-liposome particles and noise signal. (E)
Histograms of the mean fluorescence intensity (MFI) of the samples. (F) MFI values for each sample.
Values are means ± s.e.m. (n = 3). ns = not significant; ** = P < 0.01. FSC, forward scatter; SSC, side
scatter; FITC, fluorescein isothiocyanate.
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2.4 Discussion
In this chapter, N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were prepared
and characterised for the first time using optimisations to previously reported methods.
N-AI PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, monodisperse (PDI of 0.086 ±
0.030), had a zeta potential of –4.66 ± 0.52 mV and contained N-AI at a concentration of
2.2 mM, equating to 43.1% encapsulation efficiency. PAI-2 conjugation to the surface of
N-AI-loaded liposomes was achieved using conventional and post-insertion methods of
liposome functionalisation and was confirmed using SEC and Western blotting. A PAI-2
inhibitory activity assay confirmed that PAI-2 attached to the surface of liposomes
remained active against its target uPA after conjugation, which indicated that N-AI PAI2 liposomes are suitable for further in vitro and in vivo evaluation against breast cancer
cells.

The empty (non-drug-loaded), empty PAI-2-functionalised, N-AI-loaded and N-AIloaded PAI-2-functionalised liposomes prepared in this work ranged between 130 nm and
150 nm in diameter, which is in the size range of previously reported PEGylated
phosphatidylcholine liposomes (Chang & Yeh 2012). This liposome size range has been
reported to avoid rapid clearance by the mononuclear phagocyte system (MPS) in
circulation and to utilise the enhanced permeability and retention effect to extravasate and
accumulate at the site of tumours for drug delivery (Maeda 2015). The zeta potential, or
surface charge, of liposomes is dependent on a number of factors, including the
composition of the liposome (Smith et al. 2017). It has been reported that while PEG itself
does not affect the surface charge of liposomes, PEG-DSPE introduces a negative surface
potential due to the phosphate diester moiety (Barenholz 2012). This is reflected by the
zeta potential measurements of the four liposome formulations reported in this chapter,
which ranged between –3.63 mV and –4.66 mV (Tables 2.1 and 2.2). This indicates that
the liposomes have a slightly negative, but near-neutral, surface charge, which did not
vary greatly with N-AI encapsulation and/or PAI-2 conjugation to the liposome surface,
although it was noted that PAI-2-functionalised liposomes had a slightly more negative
surface charge than non-functionalised liposomes (Tables 2.1 and 2.2). This is expected,
given that PAI-2 has a predicted isoelectric point of 5.4 and therefore a negative charge
at physiological pH (Croucher et al. 2007). Liposomes with mildly charged or nearneutral surfaces have a propensity to aggregate faster than liposomes with a strong surface
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charge as the latter have greater particle-particle repulsion and hence are more
electrostatically stabilised in suspension (Safhi et al. 2017). However, strongly positively
charged particles lead to rapid elimination by the MPS (Litzinger et al. 1996), whereas
near-neutral liposomes have an increased circulation half-life (Allen & Cullis 2013).
Importantly, histological analysis of the localisation of liposomes within in vivo tumours
has shown that negatively charged and neutral liposomes are able to extravasate at the
site of the tumour, while positively charged liposomes remain associated with the
vascular endothelium, limiting their suitability for tumour targeting applications (Krasnici
et al. 2003).

The successful encapsulation of a hydrophobic drug into liposomes can greatly enhance
the aqueous solubility and bioavailability of the molecule, and therefore increase the
suitability for its use in drug delivery applications. In this work, the thin film hydration
method was used to load N-AI into the bilayer of soy phosphatidylcholine PEGylated
liposomes. The N-AI loading into liposomes appeared to be stable and not crystallise out
of the liposomes (Fig. 2.3), and the encapsulation efficiency was determined to be
approximately 43.1% of the starting amount of N-AI used in the formulation. Drug
loading into liposomes depends on many factors, and in the case of loading into the
bilayer, liposome size is a key factor (Swenson et al. 2001). One of the drawbacks of the
thin film method is the typically low drug loading, as compared to other methods, as the
space in the bilayer limits how much drug can be loaded (Pattni et al. 2015). In this work,
N-AI was substituted for cholesterol in the formulation of N-AI-loaded liposomes in order
to increase the drug-loading capacity of the bilayer. As the molecular weights of N-AI
and cholesterol are similar (425.07 g/mol and 386.65 g/mol, respectively) and both are
hydrophobic molecules that act to stabilise the liposome bilayer (Leonenko et al. 2004),
a greater encapsulation of N-AI in the liposomes was achieved without affecting liposome
size or surface charge (Table 2.1). Alternative methods can be used to load drugs into the
liposome core, which typically has a larger volume and therefore a greater capacity for
drug loading (Gubernator 2011). For example, the commonly used anticancer drug
docetaxel, which is strongly hydrophobic and poorly water soluble, has previously been
loaded into the bilayer of liposomes. This was achieved by creating a weak base derivative
of the drug molecule, and the use of ion gradients in the liposome formulation were used
to actively load the drug into the liposome core, increasing the trapping efficiency to close
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to 100% at a drug-to-lipid ratio of up to 0.4 mg/mg (Zhigaltsev et al. 2010). Such an
approach could be explored in the future to increase the loading of N-AI in liposomes if
required.

The main advantage of the thin film method is that it is relatively straightforward and
easy to produce reasonable and consistent quantities of liposomes for laboratory testing.
However, upscaling of liposome production – as required for clinical use – is challenging
since lab-based liposome production methods are generally not amenable to scale up
beyond the millilitre scale. The formation of liposome thin films via the use of rotary
evaporation is limited by the size of the flask used to create the film, and flask overloading
may increase liposome polydispersity and alter other physicochemical characteristics of
the resultant sample (Wagner & Vorauer-Uhl 2011). The extrusion of liposomes through
membranes as required to achieve a desired size distribution is another labour-intensive
step in the production process as preparations need to be passed repeatedly across a
membrane and usually on a 1-20 millilitre scale. In the laboratory setting, the preparation
of multiple separate batches of liposomes can be used to overcome these issues, although
batch-to-batch variability must be considered. This is particularly important for ligandfunctionalised liposome formulations as variations in the physicochemical characteristics
of the preparation may influence stability, in vivo circulation time, clearance properties,
tumour uptake, therapeutic efficacy and toxicity (Honary & Zahir 2013). Therefore,
adequate characterisation of liposomes intended for further in vitro and in vivo evaluation
is essential.

The conjugation of PAI-2 to the surface of empty and N-AI-loaded liposomes via PEG
was performed using standard coupling chemistry as described previously (Vine et al.
2014). Removal of unconjugated PAI-2 was achieved using SEC, as is standard in the
liposome field (Grimaldi et al. 2016). When unconjugated PAI-2 was removed from PAI2 liposomes following the conjugation step by SEC, the absorbance at 280 nm revealed
the presence of two distinct peaks (Fig. 2.5). The first peak corresponded to the largest
particles eluting from the column: PAI-2-functionalised liposomes. The second peak
corresponded to the smaller, unconjugated PAI-2 molecules, which had a longer elution
time. This pattern was also observed in the OD350 readout, where liposome phospholipid,
but not protein, showed absorption. Phospholipid signal was observed for the first peak
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(fractions 4-9) but not in the second peak (fractions 34-40), corroborating the OD280
readout and suggesting that liposomes eluted from the column first, followed by
unconjugated protein (Fig. 2.5). However, due to the broad absorbance spectrum of
phospholipids, including at 280 nm (Appendix A), it was impossible to determine whether
PAI-2 was covalently attached to those liposomes.

The quantification of covalently attached PAI-2 in the liposome samples was attempted
using two biochemical copper-based protein assays. However, protein could not be
detected due to the following factors: 1) liposomal phospholipid interferes in both Lowry
and BCA assays, resulting in an overestimation of protein concentration (Kessler &
Fanestil 1986) (Fig. 2.6); 2) the amount of protein in the liposome sample is expected to
be low and therefore is likely below the limit of detection (the minimum amount of protein
that can be detected in the Lowry and BCA assays is reported as 5 µg/mL and 8 µg/mL,
respectively); and 3) after SEC, the liposome sample is diluted considerably, further
compounding the former two factors. Therefore, Western blotting of the size-exclusion
fractions was performed to detect PAI-2 in those fractions as an indirect measure of
successful PAI-2 conjugation to the liposomes.

Western blot detection of PAI-2 in fractions from the two size-exclusion peaks confirmed
that PAI-2 was conjugated to the liposome phospholipid (PEG-DSPE) in the first peak,
while the second peak contained unconjugated PAI-2 (Fig. 2.7). The latter peak presented
as a band at 45 kDa, the same as the molecular weight observed for purified PAI-2
(positive control). In the liposome fraction, PAI-2 presented at a molecular weight higher
than 45 kDa. This shift upwards in the gel is the consequence of a lag in migration of the
PAI-2-PEG-DSPE molecules through the gel due to steric hindrance of the PEG and
interaction with SDS. Therefore, PAI-2-PEG-DSPE does not migrate through the gel as
quickly as free PAI-2, resulting in a higher apparent molecular weight (Vine et al. 2014).
The appearance of a second higher molecular weight band in the liposome sample
suggests the presence of PAI-2 bound to two or more PEG-DSPE molecules, which is
possible since PAI-2 has four available cysteine residues that can bind to the maleimide
group of PEG-DSPE (Chapter 1, Section 1.5.1). Native PAGE eliminates the PEG-SDS
interaction and provides a higher band resolution, so this technique could be used as an

54

alternative to SDS-PAGE for further analysis of ligand-functionalised PEG liposomes
(Zheng et al. 2007).

The Western blot of size-exclusion samples showed that there was no detectable band at
45 kDa, indicating that unconjugated PAI-2 was successfully removed from the liposome
sample by SEC (Fig. 2.7). Quantification of PAI-2 on liposomes was attempted using
densitometry of Western blots, and although an approximate ratio of bound and unbound
PAI-2 was determined to be 50:50 (Appendix C), the irregular pattern of the liposome
PAI-2 band on the blot indicated that densitometry was not a reliable tool to quantify PAI2 conjugation. However, as outlined above, Western blotting was successful in
qualitatively confirming the conjugation of PAI-2 to liposomes and in confirming the
absence of unconjugated PAI-2 in the purified liposome sample prior to further testing.
These findings highlight a distinct limitation in the research field of actively targeted
liposomes: the lack of robust methodology to quantify small amounts of liposome-bound
protein in liposome formulations (Belfiore, L. et al. 2018). In this chapter, quantifying
small amounts of PAI-2 was not achieved using biochemical assays due to phospholipid
interference, although it is important to note that even if such methods were successful,
they could only provide a quantification of the total protein in a liposome sample rather
than a quantification of the average number of protein ligands bound to each liposome.
This lack of published methods necessitates the development of alternative methods to
quantify protein conjugation of actively targeted liposome formulations.

As outlined in Chapter 1, Section 1.6, the majority of clinically approved nanotherapies
are arguably quite simplistic in their composition and structure. In the context of liganddirected liposomes, controlling for batch-to-batch variability is difficult without effective
methods for characterisation, and the inability to control or correct for variability in ligand
attachment to liposomes may become an issue in the regulatory processes required for
clinical translation of a novel formulation. Without robust methods to enable detection of
ligand conjugation and quantification of surface ligands, variation between batches may
lead to deviations in the physicochemical characteristics of the preparation, which would
ultimately influence stability, in vivo circulation time, clearance properties, tumour
uptake, therapeutic efficacy and toxicity of a targeted liposome formulation (Honary &
Zahir 2013). Adequate methods for the confirmation and quantification of ligand
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attachment to liposomes have not been developed (Saul et al. 2006), which poses a larger
challenge for dual-ligand and multi-ligand liposomes, where the determination of
stoichiometry of ligand attachment, in addition to density, is an important step in the
characterisation process. Theoretical values of ligand conjugation and ligand ratios have
been reported, but this has not been demonstrated empirically for most liposome
formulations as the methods used to generate such data are technically challenging. The
development of new methods to quantify ligand attachment to liposomes will enable a
more complete characterisation of targeted liposome formulations to facilitate
optimisation and assist with standardising nanoparticle characterisation in the research
field more broadly (Faria et al. 2018). This concept is explored further in Chapter 5, where
single-molecule fluorescence microscopy was evaluated as a method to quantify ligands
attached to the surface of liposomes.

An important step in characterising ligand-functionalised liposomes is to confirm whether
the targeting ligand(s) conjugated to the liposome surface retain activity against the target
receptor once bound to the liposome surface and following all the processes of production
and purification. In a fluorogenic activity assay, PAI-2 liposomes successfully inhibited
the enzymatic activity of uPA, while non-functionalised liposomes did not show
inhibition, as expected (Fig. 2.8). While there was no observed uPA inhibitory effect due
to liposome phospholipid alone, there was an observed interference effect from the
presence of the liposome phospholipid in the assay for both non-functionalised and PAI2-functionalised liposomes, which was revealed as a positive shift from the baseline in
both samples. Despite this, the rate of inhibition as indicated by fluorescence (RFLU) of
4026.9 ± 206.2 FLU/min for non-functionalised liposomes was significantly reduced to
43.5 ± 24.9 FLU/min for PAI-2 liposomes, which confirms that PAI-2 bound to the
surface of liposomes retains its inhibitory action against uPA. This is a crucial aspect for
utilising PAI-2 liposomes for uPA/uPAR targeting in vitro and in vivo.

Given that SEC results in considerable dilution of liposome samples, centrifugation was
explored as a potential method to concentrate liposomes and remove unconjugated
protein from liposomes in a high-throughput manner. Centrifugation of liposomes is
reported in the literature, particularly in the context of removing unencapsulated soluble
drug from liposomes, such as in protocols for the active-loading method of drug
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encapsulation (Gubernator 2011). In this study, centrifugation of liposomes for up to 4 h
showed a time-dependent pelleting of liposomes, with a plateau after 2 h of centrifugation
at 20,000 x g (Fig. 2.9). In the supernatant of these samples, DLS revealed that while the
pelleted liposome diameter remained relatively constant, the average diameter of the
liposomes remaining in the supernatant decreased over time. As centrifugation causes the
largest particles in a solution to pellet before the smallest particles, the largest liposomes
pelleting between 0 h and 2 h of centrifugation corresponded with the smallest liposomes
remaining in solution, shifting the size distribution considerably. DLS analysis of pelleted
liposomes after 4 h of centrifugation revealed a small but not significant (P > 0.05)
increase in the average diameter compared to non-centrifuged liposomes (153.9 ± 5.9 nm
and 148.0 ± 4.2 nm, respectively) and a 77.1% retention of liposomes after 4 h of
centrifugation (Table 2.3). The centrifuged liposomes appeared to remain intact and had
not aggregated as determined by nanoparticle tracking analysis (Fig. 2.10). While these
results indicate that centrifugation of empty liposomes does not change the liposome
population significantly, it is unknown whether prolonged centrifugation of N-AI-loaded
liposomes would affect drug loading. This would need to be determined specifically for
N-AI-loaded liposomes prior to adopting centrifugation as a standard purification method
for drug-loaded liposomes. Additionally, the development of a robust method to quantify
PAI-2 attachment to liposomes is needed in order to elucidate whether centrifugation
results in changes to PAI-2 ligand attachment on the surface of liposomes.

As outlined in Section 2.1.2, the post-insertion method is an alternative method of
conjugating ligands to the surface of liposomes, with the greatest advantage of this
method being the ease with which a range of dual-ligand or multi-ligand liposomes can
be produced from a single batch of liposomes (Moreira et al. 2002). Previous work
comparing these two methods indicates that liposomes prepared by conventional and
post-insertion methods are equivalent (Iden & Allen 2001). In this chapter, PAI-2functionalised liposomes prepared via the post-insertion method were significantly larger
(P < 0.05) in diameter than those prepared by the conventional method (154.1 ± 1.3 nm
and 141.1 ± 5.0 nm, respectively) (Fig. 2.13). This appears to be a result of the postinsertion step specifically, as N-AI liposomes incubated with maleimide-PEG micelles
alone (145.0 ± 1.7 nm) or with a mixture of micelles that contained non-maleimidefunctionalised PEG and PAI-2 (145.4 ± 4.7 nm) did not show a significant increase in
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diameter compared to the liposome diameter prior to the post-insertion step (141.2 ± 4.7
nm). It is possible that the post-insertion method led to more efficient conjugation of PAI2 and mal-PEG compared to the conventional method, perhaps due to the higher
temperature of the conjugation step, meaning that the observed increase in liposome size
could be due to post-insertion liposomes having a greater average number of PAI-2
proteins attached to the surface than conventional liposomes. This was further explored
in Chapter 5 (Section 5.3.6). DLS analysis of micelles alone prior to the post-insertion
step showed small amounts of aggregation in the sample (Fig. 2.11). However, following
the post-insertion step and SEC of liposomes, DLS analysis revealed 100% peak intensity
(Fig. 2.12), indicating the absence of unincorporated micelles or aggregates.

Flow cytometry was used as an indirect confirmation that post-insertion of micelle
phospholipids (and any covalently conjugated ligands) into the liposome outer leaflet was
successful, as per previously reported methods (Mack et al. 2012). Rhodamine-123loaded liposomes showed a 20.7-fold increase in MFI (43.8 ± 0.5) relative to nonfluorescent liposomes (2.1 ± 1.3), indicating that fluorescently labelled liposomes could
be detected by flow cytometry (Fig. 2.14). Analysis of post-insertion liposomes by flow
cytometry revealed a significant increase (P < 0.01) in MFI for liposomes that had been
incubated with 10% or 30% FITC-PEG-DSPE micelles compared to liposomes incubated
with non-fluorescent micelles (Fig. 2.15). This work detected the association of
fluorescent micelle phospholipids in liposomes after the post-insertion step, indirectly
confirming successful post-insertion. However, as this method is only semi-qualitative, it
remains unknown if and how well protein ligands are transferred into the outer liposome
bilayer using the post-insertion method.

As the post-insertion method requires the extra step of firstly preparing ligandfunctionalised micelles, the conventional method is more straightforward for preparing
single-ligand liposomes. The post-insertion step also involves heating, which may affect
the structure or activity of some protein ligands, so this would need to be determined for
the individual ligands used. The main advantage of the post-insertion method is in the
context of creating dual-ligand liposomes to target multiple tumour cell receptors, such
as in the case of liposomes targeting tumour heterogeneity (Chapter 1, Section 1.6). As
dual-ligand liposomes can increase the number of targetable receptors at the cell surface,
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a greater number of liposomes can bind to tumour cells to enhance the therapeutic efficacy
of the encapsulated drug (Laginha et al. 2005). Therefore, the findings presented in this
chapter can be considered in future work exploring the creation of dual-ligand liposomes
using the post-insertion method.

2.5 Conclusion
The work presented in this chapter demonstrates the successful preparation and
characterisation of liposomes encapsulating the N-AI cytotoxin, with PAI-2 covalently
attached to the liposome surface as a targeting ligand for binding to uPAR-positive cells.
Previously published liposome analysis methods were optimised in order to allow the
successful characterisation of liposomes as required for in vitro and in vivo evaluation.
N-AI-loaded

PAI-2-functionalised

liposomes

were

monodisperse,

contained

encapsulated N-AI, had PAI-2 successfully conjugated to the liposome surface, and
importantly, were active in inhibiting target uPA in an activity assay. Therefore, further
testing of these liposomes against uPAR-positive breast cancer cells using in vitro and in
vivo models is warranted.
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Chapter 3:
In Vitro Evaluation of N-alkylisatin-Loaded
Liposomes Targeting the Urokinase Plasminogen
Activator System

N-AI-loaded liposome-mediated destruction of a multicellular tumour spheroid

Portions of this chapter have been included in the following work for publication:
Belfiore, L, Saunders, DN, Ranson, M & Vine, KL 2019, ‘N-alkylisatin-loaded
liposomes targeting the urokinase plasminogen activator system in breast cancer’,
manuscript in preparation.
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performed the experiments and analysed the data; LB wrote the manuscript; DNS, MR
and KLV edited the manuscript for submission.
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3.1 Introduction
The work described in Chapter 2 of this thesis detailed the preparation and
characterisation of N-alkylisatin (N-AI)-loaded plasminogen activator inhibitor-2 (PAI2)-functionalised (N-AI PAI-2) liposomes. In order to evaluate how these liposomes
interact with and affect breast cancer cells, N-AI PAI-2 liposomes were tested against
breast cancer cells in vitro. This is an important step to confirm the cellular uptake,
cellular localisation and cytotoxicity of N-AI PAI-2 liposomes before evaluating their
potential as an anticancer therapeutic using more complex in vivo models of breast cancer.

3.1.1 Cell-based models of cancer
A diverse range of cancer cell lines derived from tumour biopsies have been established
in the laboratory and retain many – but not all – of the genotypic and phenotypic
properties of the original tumour cells, making them useful representative models for
testing targeted therapies (Holliday & Speirs 2011; Subik et al. 2010) and for studying
mechanisms of therapeutic resistance (Boulbes et al. 2015). Cells grown on dishes are
amenable to high-throughput approaches for determining morphological changes and
cytotoxicity resulting from treatment with novel drugs, and endpoint cell viability assays
can be used to measure changes in cell proliferation and metabolism in a high-throughput
manner. In vitro cell-based models of cancer are also useful for measuring the targeting
ability of novel nanotherapies and the localisation of nanoparticles within cells.

Cancer cells can be grown as two-dimensional (2D) cell monolayers or three-dimensional
(3D) cell aggregates or spheroid structures. While 2D cell culture is high-throughput,
robust and widely validated, 3D cell culture better recapitulates several key elements of
in vivo tumours, including tumour architecture, tumour cell interactions, tumour-stroma
interactions, and the various proliferative and metabolic gradients that form when tumour
cells exist as a 3D structure (Li & Lu 2011). Multicellular tumour cell spheroids are
cancer cells that are grown in a large spherical association, resembling small tumours and
micrometastases (Senavirathna et al. 2013) (Fig. 3.1). The ability of cancer cells to form
spheroids is strongly related to the expression of several cell-cell adhesion molecules
(Ivascu & Kubbies 2007), and spheroid formation can be facilitated by culturing cells in
conditions that prevent adherence to cell culture plates (Friedrich et al. 2009). Changes in
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spheroid morphology and diameter in response to a drug treatment can be measured using
manual or automated imaging techniques (Karacali et al. 2007), and end-point
biochemical assays allow for the determination of cell viability (Friedrich et al. 2007). As
drug sensitivities of cell lines can vary depending on whether the cells are grown in 2D
or 3D (Godugu et al. 2013), it is important to utilise 3D cell culture models in the
screening of novel drug formulations.

Figure 3.1: Cross-section view of a multicellular tumour cell spheroid. Spheroids recapitulate
several key elements of in vivo tumours, including three-dimensional (3D) tumour architecture, cellcell interactions and the various proliferative and metabolic gradients that form when tumour cells
exist as a 3D structure. Figure adapted from Lin et al. 2008.

3.1.2 Experimental rationale
The targeting ability, cellular localisation and cytotoxicity of N-AI PAI-2 liposomes can
be determined using 2D monolayer cell culture and 3D multicellular tumour spheroid
models (Thoma et al. 2014). The commonly used breast cancer cell lines MCF-7 (Soule
et al. 1973) and MDA-MB-231 (Olivé et al. 1974) serve as representative urokinase
plasminogen activator receptor (uPAR)-negative and uPAR-positive cells (Huber et al.
2016), respectively, for the testing of uPAR-targeted liposomes. The in vitro evaluation
of N-AI PAI-2 liposomes will serve to justify and guide further evaluation in vivo.

3.1.3 Aims
This chapter tested the hypothesis that N-AI-loaded PAI-2-functionalised (N-AI PAI-2)
liposomes exhibit increased cellular uptake and increased cytotoxic effect in uPARpositive breast cancer cells relative to uPAR-negative breast cancer cells. Therefore, the
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overall aim of this chapter was to evaluate the in vitro properties of N-AI PAI-2 liposomes
in two breast cancer cell lines that vary in expression of uPAR. The specific aims of this
chapter were to:
1. Determine the cellular uptake of N-AI PAI-2 liposomes in breast cancer cells;
2. Elucidate the cellular localisation of N-AI PAI-2 liposomes in breast cancer
cells; and
3. Characterise the cytotoxicity of N-AI PAI-2 liposomes against breast cancer
cells grown as either monolayers or multicellular tumour spheroids.

3.2 Methods
3.2.1 Cell lines and culture conditions
The human mammary epithelial invasive ductal carcinoma cell lines MCF-7 and MDAMB-231 were originally purchased from the American Type Culture Collection (ATCC,
VA, USA). Cells were cultured in RPMI-1640 medium (Life Technologies, CA, USA)
containing 24 mM NaHCO3 and supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (FBS; Thermo Fisher Scientific, MA, USA). Cells were maintained in
culture at 37°C in a 95% humidified atmosphere with 5% CO2 in a HERAcell incubator
(Kendro Laboratory Products, Germany). For passaging, cells were harvested by
treatment with 0.05% trypsin-EDTA (Life Technologies, CA, USA), followed by
centrifugation at 300 x g for 5 min. For experiments, cells were harvested by treatment
with PBS containing 5 mM EDTA (pH 7.4), followed by centrifugation at 300 x g for 5
min. Viable cells were counted with a haemocytometer using the Trypan Blue (SigmaAldrich, MO, USA) exclusion method. Cell lines were routinely tested and confirmed
negative for mycoplasma contamination (in-house testing conducted by the IHMRI
Technical Services Unit). Cell lines were confirmed negative for cross contamination by
short-tandem repeat (STR) sequencing (performed by the Garvan Institute of Medical
Research, Darlinghurst, Australia).

3.2.2 Cell surface uPA and uPAR expression
Expression of urokinase plasminogen activator (uPA) and uPAR on the surface of MCF7 and MDA-MB-231 cells was determined by flow cytometry. Cells (1 x 105) in 100 µL
PBS (pH 7.4, with 1% w/v BSA) were incubated with mouse anti-human uPA
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monoclonal antibody (ADI #394; Alpha Diagnostic International, TX, USA) at 10
µg/mL, mouse anti-human uPAR monoclonal antibody (DAKO #7294; Agilent
Technologies, CA, USA) at 10 µg/mL or mouse IgG1 monoclonal antibody (isotype
control) (Merck #MABC002; Merck, Germany) at 10 µg/mL for 45 min on ice, followed
by three washes with ice-cold PBS (with 1% w/v BSA) and centrifugation at 300 x g for
5 min after each wash. Cells were then incubated with donkey anti-mouse IgG-Alexa
Fluor 488 polyclonal antibody at 2 µg/mL for 45 min on ice, followed by three washes
with ice-cold PBS (with 1% w/v BSA) as above. Cells were resuspended in 100 µL PBS
and the fluorescence intensity of the Alexa-488-conjugated antibody analysed by flow
cytometry (LSR II; BD Biosciences, CA, USA) (excitation 488 nm, emission collected
with 515/20 band-pass filter). FlowJo software (version 10; Tree Star Inc., OR, USA) was
used to evaluate cell-surface expression of uPA and uPAR relative to the IgG isotype
control to account for non-specific antibody binding to cells.

3.2.3 Cellular uptake of liposomes by flow cytometry
Uptake of fluorescently labelled non-functionalised and PAI-2-functionalised liposomes
by MCF-7 and MDA-MB-231 cells was assessed using flow cytometry. Cells (2 x 105
cells per well) were seeded into 12-well plates and allowed to attach for 24 h at 37°C.
Liposomes containing 1% (mol/mol) FITC-PEG2000-DSPE were prepared as described in
Chapter 2, Section 2.2 and added to cells in culture media (RPMI-1640 + 10% (v/v) FBS)
at dilutions ranging from 1:20 to 1:5. At specified time intervals ranging between 15 min
and 60 min, the supernatant was removed, cells washed once with PBS and then harvested
using PBS containing 5 mM EDTA (pH 7.4). Cells were then centrifuged (300 x g for 5
min) and washed three times with PBS before being resuspended in 200 µL PBS for
analysis. The fluorescence intensity was determined by flow cytometry (LSR II flow
cytometer; BD Biosciences, CA) (excitation 488 nm, emission collected with 515/20
band-pass filter). FlowJo software (V10; Tree Star Inc., OR, USA) was used to evaluate
the mean fluorescence intensity (MFI) to determine cellular uptake of liposomes.

3.2.4 Cellular localisation of liposomes by confocal microscopy
Uptake and cellular localisation of fluorescently labelled liposomes were determined by
confocal microscopy as reported previously (Ducat et al. 2011). For monolayer cell
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culture experiments, 50,000 cells per well were seeded into 8-well µ-Slide chambered
coverslips (ibidi, Germany) and incubated for 24 h at 37°C. Cells were allowed to reach
80% confluence before the addition of liposomes. Liposomes containing 1% or 10%
(mole % of liposome phospholipid) FITC-PEG2000-DSPE, or 0.625% (mole % of
liposome phospholipid) octadecyl rhodamine B chloride (R18; Invitrogen, CA, USA)
were prepared as described in Chapter 2, Section 2.2. Liposomes were added to cells in
culture media (RPMI-1640 + 10% (v/v) FBS) at dilutions ranging from 1:5 to 1:10 and
incubated for 30 min to 2 h at 37°C. Supernatant was removed and wells were rinsed three
times with PBS before LysoTracker Green DND-26 (excitation/emission 504/511 nm) or
LysoTracker Red DND-99 (excitation/emission 577/590 nm) (Thermo Fisher Scientific,
MA, USA) was added to each well (50 nM final concentration) immediately prior to
imaging. Live imaging of cells in PBS was performed using a Leica TCS SP5 Confocal
Microscope (Leica Microsystems, Germany) and images were acquired using a 63X oil
immersion lens. Images were analysed using Leica Application Suite (V10; Leica
Microsystems, Germany).

3.2.5 2D monolayer cytotoxicity assays
In vitro cytotoxicity assays were performed in 96-well flat-bottom microtitre plates as
described previously (Vine et al. 2016). MCF-7 or MDA-MB-231 cells were seeded at a
density of 5000 cells per well into sterile 96-well flat-bottom plates and incubated at 37°C
for 24 h in an IncuCyte Zoom automated imaging instrument (Essen BioScience, MI,
USA). Empty and N-AI-loaded liposomes were prepared as outlined in Chapter 2, Section
2.2 and were serially diluted in PBS before being added to cells (each concentration tested
in triplicate). Liposomes were incubated with cells for 72 h and wells were imaged every
24 h by the automated IncuCyte imaging system. To determine cell viability at the
experimental endpoint, CellTiter 96 Aqueous One Solution Cell Proliferation Assay MTS
reagent

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-

2H-tetrazolium; Promega Corporation, WI, USA) was added to each well at a final
concentration of 10% (v/v). Plates were incubated at 37°C for 3 h and the absorbance at
490 nm was measured using a Spectramax spectrophotometer (Molecular Devices, CA,
USA). The IC50 (dose required to inhibit the metabolic activity of 50% of the cell
population) was calculated from logarithmic sigmoidal dose-response curves fitted to the
data using GraphPad Prism V7 for Windows (GraphPad Software, CA, USA). The
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absorbance readings of wells containing media only were subtracted from sample
readings to correct for background absorbance. Data were normalised to absorbance
readings for cells treated with PBS only (positive control).

3.2.6 3D multicellular tumour spheroid cytotoxicity assays
MCF-7 or MDA-MB-231 cells were seeded into ultra-low attachment 96-well plates
(Sigma-Aldrich, MO, USA) at a density ranging between 625 and 5000 cells per well and
incubated at 37°C to promote spheroid formation. Empty and N-AI-loaded liposomes
were serially diluted in PBS and incubated with cells for up to 96 h (each concentration
tested in triplicate). To determine cell viability at the experimental endpoint, an acid
phosphatase (APH) assay (Friedrich et al. 2007) or calcein staining (Leary et al. 2016)
was performed. For the APH assay, spheroids were carefully washed twice with PBS and
the spheroid plate centrifuged at 400 x g for 10 min after each wash step. The supernatant
was replaced with 100 µL APH assay buffer (2 mg/mL para-Nitrophenylphosphate and
0.1% (v/v) Triton-X-100 in 0.1 M sodium acetate). The plate was incubated at 37°C for
90 min and then 10 µL 1 M sodium hydroxide was added to each well. The absorbance
of each well at 405 nm was then measured using a Spectramax spectrophotometer
(Molecular Devices, CA, USA). For calcein staining, calcein-AM (Thermo Fisher
Scientific, MA, USA) was added to spheroids at a final concentration of 1 µM per well.
The plate was incubated at 37°C for 30 min and images were acquired using an IncuCyte
Zoom automated imaging instrument (Essen BioScience, MI, USA), with a 10X objective
and green filter (excitation 440-480 nm, emission 504-544 nm) to detect calcein
fluorescence associated with viable cells.

3.2.7 Data analysis
All data analysis, including the generation of graphs and statistical tests, was performed
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated.
Pairwise comparisons were made using Student’s t-test and multiple comparisons were
made using one-way ANOVA with Tukey’s post-test.
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3.3 Results
3.3.1 Profiling MCF-7 and MDA-MB-231 cells for uPA/uPAR expression
Two commonly used breast cancer cell lines, MCF-7 and MDA-MB-231, were profiled
for cell surface uPA and uPAR expression by flow cytometry prior to liposome testing
(Fig. 3.2). MDA-MB-231 cells showed positive expression of uPAR, with a significantly
(P < 0.001) higher (46-fold) MFI (11.82 ± 0.90) than that of uPAR-negative MCF-7 cells
(0.26 ± 0.03). Both cell lines showed positive expression of uPA, with uPA levels
significantly (P < 0.05) higher (2.7-fold) for MDA-MB-231 cells compared to MCF-7
cells (MFI values of 6.66 ± 0.97 and 2.49 ± 0.10, respectively).

Figure 3.2: Flow cytometry analysis of surface uPA and uPAR expression. MCF-7 cells and
MDA-MB-231 cells were incubated with antibodies against human urokinase plasminogen activator
(uPA), human uPAR (urokinase plasminogen activator receptor) or an isotype control antibody (IgG)
and analysed by flow cytometry to detect fluorescence of Alexa-488-conjugated secondary antibody.
MFI = mean fluorescence intensity (fold-increase of IgG control). Data are the mean ± s.d. (n = 3). *
= P < 0.05; *** = P < 0.001.

3.3.2 Measuring cellular uptake of PAI-2 liposomes by flow cytometry
The cellular uptake of fluorescently labelled liposomes can be determined by flow
cytometry (Ducat et al. 2011). To decide on an appropriate fluorophore for liposome
detection by flow cytometry in subsequent experiments, liposomes loaded with either NAI (in the liposome bilayer) or rhodamine 123 (in the liposome core), as well as FITClabelled liposomes (FITC-PEG-DSPE incorporated into the liposome bilayer), were
incubated with MDA-MB-231 cells at equivalent phospholipid concentrations (20 mM)
for 15 min or 60 min before analysis by flow cytometry (Fig. 3.3). Compared to untreated
control MDA-MB-231 cells, all fluorescently labelled liposomes showed an increase in
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MFI after 15 min and 60 min, although this difference was only significant for R123
liposomes. While the percentage of viable cells remained high after 15 min, the
percentage of cells in the viable gate dropped significantly from that of the untreated
control cells following the 60 min incubation, with a percentage of 46.8 ± 5.5 %. The
drop in cell viability was most pronounced for the N-AI and R123 liposomes, with the
percentage of viable cells at 60 min dropping to 1.5 ± 0.9 % and 0.07 ± 0.02 %,
respectively. The percentage of viable cells for cells treated with FITC-labelled liposomes
dropped to 25.6 ± 1.1 % at 60 min, indicating that FITC liposomes were the least cytotoxic
to cells out of the three fluorescently labelled liposomes.

Figure 3.3: Cellular uptake of fluorescently labelled liposomes. Liposomes were fluorescently
labelled with either N-AI, FITC or R123 and were incubated with MDA-MB-231 cells at an equivalent
phospholipid concentration (20 mM) for 15 min (left) or 60 min (right). Cells were analysed by flow
cytometry to determine the mean fluorescence intensity (MFI) (top) and percentage of cells within the
viable gate (bottom). Control cells were not treated with liposomes. Data are the mean ± s.d. (n = 3).
*** = P < 0.001, ** = P < 0.01, * = P < 0.05, n.s. = not significant (P > 0.05).

As the FITC-labelled liposomes were shown to be the least cytotoxic to MDA-MB-231
cells at the 60 min time point, FITC-labelled liposomes were further investigated to
determine the effect of liposome concentration and incubation time on MFI and on cell
viability. FITC-labelled liposomes (or non-FITC control liposomes at an equivalent
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phospholipid concentration) were incubated with MDA-MB-231 cells at concentrations
between 0 mM and 10 mM for either 15 min or 60 min and analysed by flow cytometry
(Fig. 3.4). The results showed a dose-dependent and time-dependent increase in MFI,
with significant (P < 0.05) increases in MFI between the 15 min and 60 min time points
for each concentration of FITC liposome tested. Cell viability was not significantly (P >
0.05) different at any FITC liposome concentration after either the 15 min or 60 min
incubation, indicating that MDA-MB-231 cells remained viable after 60 min treatment
with liposomes up to and including 10 mM concentration.

Figure 3.4: Cellular uptake of non-functionalised FITC-labelled liposomes. MDA-MB-231 cells
were incubated with FITC-labelled liposomes (or non-FITC control liposomes at an equivalent
phospholipid concentration) for 15 min or 60 min and analysed by flow cytometry. Data are the mean
± s.d. (n = 3). MFI = mean fluorescence intensity. **** = P < 0.0001, *** = P < 0.001, * = P < 0.05,
n.s. = not significant (P > 0.05).

In order to detect differences in the uptake of PAI-2-functionalised liposomes between
MCF-7 cells (low uPAR) and MDA-MB-231 cells (high uPAR), non-functionalised (NF)
FITC liposomes and PAI-2-functionalised FITC liposomes (152.6 ± 8.7 nm and 152.8 ±
11.7 nm, respectively) were incubated with MCF-7 and MDA-MB-231 cells for 45 min
and liposome uptake was determined by flow cytometry (Fig. 3.5). For MDA-MB-231
cells, there was a significant increase in FITC PAI-2 liposome uptake at the 5 mM and
2.5 mM liposome concentrations (P < 0.0001 and P < 0.001, respectively) relative to NF
PAI-2 liposomes, but not at the 1.25 mM liposome concentration. For MCF-7 cells, no
significant differences were observed between the uptake of NF and PAI-2 liposomes at
any liposome concentrations (P > 0.05).
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Figure 3.5: Uptake of PAI-2 FITC-labelled liposomes in breast cancer cells. MCF-7 cells (left)
and MDA-MB-231 cells (right) were incubated with non-functionalised (NF) FITC liposomes and
PAI-2-functionalised (PAI-2) FITC liposomes for 45 min and analysed by flow cytometry. Data are
the mean ± s.d. (n = 3). **** = P < 0.0001, *** = P < 0.001, n.s. = not significant (P > 0.05).

3.3.3 Cellular localisation of PAI-2 liposomes by confocal microscopy
Confocal microscopy can be used to detect the uptake and cellular localisation of
fluorescently labelled liposomes (Ducat et al. 2011). In initial experiments, 1% and 10%
(mol/mol) FITC liposomes were used, but the fluorescent signal was too low (data not
shown). Therefore, the intensely fluorescent fluorophore R18 was used to label liposomes
for the detectable accumulation of liposomes in cells. Non-functionalised (NF) and PAI2-functionalised liposomes containing 0.625% (mol %) R18 in the lipid bilayer were
prepared as outlined in Chapter 2, Section 2.2. Liposomes were analysed by dynamic light
scattering, which revealed average diameters of 131.3 ± 2.5 nm and 131.2 ± 6.6 nm for
NF and PAI-2 liposomes, respectively. Liposomes were incubated with MCF-7 and
MDA-MB-231 cells at a 2.5 mM phospholipid concentration at 37°C for 60 min prior to
imaging by confocal microscopy. Imaging showed a strong fluorescent signal from R18labelled liposomes, which was present at the cell membrane, within the cytoplasm and
within lysosomes (indicated by colocalisation of liposome and LysoTracker) for both cell
lines (Fig. 3.6).
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Figure 3.6: Cellular uptake and localisation of R18-labelled liposomes. Non-functionalised (NF)
and PAI-2-functionalised (PAI-2) liposomes were labelled with octadecyl rhodamine B chloride (R18)
and incubated with cells at a liposome concentration of 2.5 mM for 1 h. LysoTracker green was added
immediately prior to imaging via confocal microscopy to visualise lysosomes. Arrows indicate white
foci which indicate colocalisation of green and magenta signals. Representative images are shown.
Scale bars are 25 µm.
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3.3.4 Cytotoxicity of N-AI PAI-2 liposomes against breast cancer cells
To determine the cytotoxicity of N-AI-loaded PAI-2-functionalised (N-AI PAI-2)
liposomes against breast cancer cells in vitro, N-AI PAI-2 liposomes and empty (EMP)
PAI-2 liposomes at an equivalent phospholipid concentration were tested against MCF-7
and MDA-MB-231 cells. Treatment with N-AI PAI-2 liposomes showed changes in cell
morphology for both cell lines, consistent with intracellular delivery of the cytotoxic NAI (Fig. 3.7). Treatment with EMP PAI-2 liposomes did not induce a change in cell
morphology in either cell line. After incubating EMP PAI-2 liposomes or N-AI PAI-2
liposomes with MCF-7 and MDA-MB-231 cells for a period of 72 h, an endpoint MTS
cell viability assay showed a dose-dependent cytotoxic effect of the N-AI PAI-2
liposomes against both cell lines. The cytotoxic effect of N-AI PAI-2 liposomes against
MDA-MB-231 cells (IC50 of 5.40 ± 1.14 µM) was significantly greater (P < 0.01) than
that against MCF-7 cells (IC50 of 31.84 ± 8.20 µM). EMP PAI-2 liposomes did not elicit
a dose-dependent cytotoxic response but showed some degree of cytotoxicity in both cell
lines at the highest liposome concentrations tested.
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Figure 3.7: Cytotoxicity of N-AI PAI-2 liposomes. In vitro cytotoxicity testing of empty (EMP)
PAI-2 liposomes and N-AI PAI-2 liposomes against MCF-7 (low uPAR) and MDA-MB-231 (high
uPAR) breast cancer cell lines. (A) Representative images showing changes in cell growth and
morphology 72 h after treatment with liposomes at 62.0 µM N-AI or equivalent phospholipid
concentration (scale bars are 100 µm). (B) Dose-response cell viability curves via MTS assay at 72 h
post-treatment. Data are the mean ± s.d. (n = 3).

3.3.5 Cytotoxicity of N-AI PAI-2 liposomes against breast cancer spheroids
A range of cancer cell lines have been reported to spontaneously form spheroids under
low-attachment growth conditions (Friedrich et al. 2009). To determine whether MCF-7
and MDA-MB-231 cells could form multicellular tumour spheroids for testing of N-AI
PAI-2 liposomes, MCF-7 and MDA-MB-231 cells were seeded into ultra-low attachment
96-well plates at 5000, 2500, 1250 or 625 cells per well. Cells were incubated at 37°C for
5 days and bright-field images acquired every 24 h (Fig. 3.8). Imaging revealed that both
MCF-7 and MDA-MB-231 cells formed spheroids at all cell densities tested and spheroid
diameter at each cell density was comparable between the two cell lines. There were
notable differences in spheroid morphology between the two cell lines. MCF-7 cells
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formed tight spheroids with well-defined edges and high circularity compared to MDAMB-231 spheroids, which appeared looser with less definition of the spheroid surface. At
48 h post-cell seeding, the average spheroid diameters for 5000 cells were 488.0 ± 11.3
µm and 484.3 ± 9.3 µm for MCF-7 and MDA-MB-231 cells, respectively. For 625 seeded
cells at 48 h, the average spheroid diameters were 285.0 ± 7.6 µm and 230 ± 22.1 µm for
MCF-7 and MDA-MB-231 cells, respectively. Spheroid diameter measurements revealed
that MCF-7 spheroids continued to grow in diameter in a linear fashion over the
experiment. In contrast, MDA-MB-231 spheroid growth was less rapid at the higher cell
densities tested, and an initial decrease in diameter of the MDA-MB-231 spheroids
coincided with the observed slower spheroid formation relative to MCF-7 spheroids.

Figure 3.8: Cell titre for establishing breast tumour spheroids. MCF-7 and MDA-MB-231 cells
were seeded at different cell densities (5000, 2500, 1250 and 625 cells per well) to optimise conditions
for growing spheroids. Spheroids were imaged using light microscopy. (A) Representative spheroid
images at 48 h post-cell seeding (once all wells had formed spheroids). Scale bars are 100 µm. (B)
Spheroid diameter measurements for MCF-7 and MDA-MB-231 spheroids over time. Graphs are
representative from two experimental repeats. Presented data are the mean ± s.d. (n = 3).
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Once MCF-7 and MDA-MB-231 cells were confirmed to form spheroids, cells were
seeded in ultra-low attachment 96-well plates at a density of 1000 cells per well and
incubated at 37°C for 48 h to promote the formation of multicellular tumour spheroids
prior to liposome testing. As per Section 3.3.4, EMP PAI-2 and N-AI PAI-2 liposomes at
equivalent phospholipid concentrations were incubated with the preformed spheroids at
37°C for a period of 72 h, with spheroids imaged every 24 h (Fig. 3.9). MCF-7 and MDAMB-231 spheroids treated with N-AI PAI-2 liposomes showed a time-dependent and
concentration-dependent dissemination of the spheroid structure, with the complete
destruction of the spheroid by 96 h at N-AI concentrations above 62.5 µM for both cell
lines. At the 24 h time point, MDA-MB-231 spheroids treated with N-AI PAI-2 liposomes
appeared to be more greatly dissociated than MCF-7 spheroids. In contrast, MCF-7 and
MDA-MB-231 spheroids treated with EMP liposomes showed continued growth and an
increase in spheroid diameter over time.

At the experiment endpoint, an acid phosphatase assay was used to measure the metabolic
activity of the cells comprising the spheroids to determine the cytotoxic effect of the EMP
PAI-2 and N-AI PAI-2 liposomes after 72 h. The assay confirmed the cytotoxicity of the
N-AI PAI-2 liposomes on these spheroids in a dose-dependent manner, and also for the
EMP PAI-2 liposomes (Fig. 3.10). The IC50 values for N-AI PAI-2 liposomes tested
against MCF-7 and MDA-MB-231 spheroids were 30.9 ± 5.4 µM and 59.3 ± 7.5 µM,
respectively, and significantly different (P < 0.01). IC50 values for EMP PAI-2 liposomes
could not be determined as sigmoidal dose-response curves could not be fitted to the data,
but the trends indicated a dose-dependent decrease in cell viability with empty liposome
concentrations equal to and greater than a phospholipid concentration of 375 µM.
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Figure 3.9: Imaging of breast cancer spheroids treated with N-AI PAI-2 liposomes. Testing of
empty (EMP) PAI-2 and N-AI PAI-2 liposomes against MCF-7 and MDA-MB-231 multicellular
tumour spheroids over a period of 72 h at 62.0 µM N-AI or equivalent phospholipid concentration.
Representative images were captured at the same magnification (n = 3). Scale bars are 100 µm.
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Figure 3.10: Cytotoxic effect of N-AI PAI-2 liposomes on breast cancer spheroids. Empty (EMP)
PAI-2 liposomes and N-AI PAI-2 liposomes were tested against MCF-7 and MDA-MB-231
multicellular tumour spheroids over a period of 72 h. An endpoint acid phosphatase assay was used to
determine cell viability. Data are the mean ± s.d. (n = 3).

As the 2D and 3D cell testing revealed a cytotoxic effect of EMP PAI-2 liposomes at high
phospholipid concentrations, additional testing was conducted using non-functionalised
liposomes alongside PAI-2-functionalised liposomes at equivalent phospholipid
concentrations. MCF-7 and MDA-MB-231 spheroids were treated with empty liposomes
(EMP), empty PAI-2-functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (NAI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI PAI-2) for 96 h. Images
indicated that N-AI and N-AI PAI-2 liposomes showed similar effects on spheroid
morphology, with destruction of the spheroid structure at the experimental endpoint (Fig.
3.11). EMP and EMP PAI-2 liposomes had a similar effect on spheroids.
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Figure 3.11: Morphological effect of N-AI PAI-2 liposomes on spheroids. Testing of empty (EMP),
empty PAI-2 (EMP PAI-2), N-AI and N-AI PAI-2 liposomes against MCF-7 and MDA-MB-231
multicellular tumour spheroids over a period of 96 h. Representative images (n = 3) of treatment with
25 µM N-AI liposomes (or empty liposomes at equivalent phospholipid concentration). All images
were captured at the same magnification. Scale bar is 100 µm.

Spheroid diameter was measured every 24 h where spheroids were still intact and had a
distinct border (Fig. 3.12). Relative to control (untreated) spheroids, MCF-7 and MDA78

MB-231 spheroids showed a stable or slight increase in diameter over 96 h when treated
with EMP or EMP PAI-2 liposomes. For MCF-7 spheroids, a time-dependent decrease in
diameter was observed with treatment of 6.25 µM N-AI or N-AI PAI-2 liposomes. For
MDA-MB-231 spheroids, there was no trend of diameter decrease for spheroids treated
with 6.25 µM N-AI or N-AI PAI-2 liposomes. At the 24 h time point, there was a
significant (P < 0.01) difference in diameter for MDA-MB-231 spheroids treated with NAI PAI-2 liposomes (74.5 ± 3.4 µm) relative to N-AI liposomes (91.8 ± 5.1 µm).
Significant differences in diameter between N-AI and N-AI PAI-2 liposomes were not
observed at any other time points at the 6.25 µM N-AI concentration, and no significant
differences were observed at any time points for MCF-7 spheroids.

Figure 3.12: Diameter of liposome-treated breast cancer spheroids over 96 hours. MCF-7
spheroids and MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2functionalised (EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2functionalised (N-AI PAI-2) liposomes for 96 h. Images were taken every 24 h and spheroid diameter
measured at each time point. Data are shown for treatment with a 6.25 µM concentration of liposomal
N-AI (or equivalent liposome phospholipid concentration for empty liposomes). Data are means ± s.d.
(n = 3).
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To determine the viability of the spheroids at the experimental endpoint, spheroids were
incubated with calcein-AM at the 96 h time point and imaged to detect calcein
fluorescence (Fig. 3.13). Images indicated a change in cell viability across the different
liposome concentrations tested, with disseminated but viable clusters of MCF-7 and
MDA-MB-231 cells after treatment with 100 µM N-AI or N-AI PAI-2 liposomes. EMP
and EMP PAI-2 liposomes at an equivalent phospholipid concentration also showed
noticeable changes in the distribution of calcein staining for both cell lines.

Dose-response curves derived from the calcein staining revealed similar trends between
N-AI and N-AI PAI-2 liposomes for both cell lines, with no significant difference between
the two liposome treatments (Fig. 3.14). The IC50 values for both N-AI and N-AI PAI-2
liposomes were not significantly different between MCF-7 and MDA-MB-231 spheroids
(Table 3.1). The IC50 value for spheroids treated with EMP PAI-2 liposomes was
significantly (P < 0.05) lower for MCF-7 cells (80.3 ± 7.2 µM) relative to MDA-MB-231
cells (105.6 ± 12.3 µM).
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Figure 3.13: Calcein imaging of liposome-treated breast cancer spheroids. (A) MCF-7 spheroids
and (B) MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2functionalised (EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2functionalised (N-AI PAI-2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise
viable cells. Images are representative of triplicate samples of liposomes tested at three different
concentrations (0, 25 or 100 µM N-AI, or empty liposomes at equivalent phospholipid concentration).
Scale bars are 100 µm.
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Figure 3.14: Calcein viability of liposome-treated breast cancer spheroids. MCF-7 spheroids and
MDA-MB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-functionalised
(EMP PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-functionalised (NAI PAI-2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise viable cells. Data are
green fluorescence intensity means ± s.d. (n = 3).

Table 3.1: IC50 values for liposome-treated breast cancer spheroids. MCF-7 spheroids and MDAMB-231 spheroids were treated with empty (EMP) liposomes, empty PAI-2-functionalised (EMP
PAI-2) liposomes, N-AI-loaded (N-AI) liposomes and N-AI-loaded PAI-2-functionalised (N-AI PAI2) liposomes for 96 h. Calcein-AM was added to spheroids to visualise viable cells. Total fluorescence
was used to determine viability and IC50 values (µM). Data are means ± s.d. (n = 3). * = P < 0.05
(relative to MCF-7 EMP PAI-2 value).
EMP

EMP PAI-2

N-AI

N-AI PAI-2

MCF-7

not reached

80.3 ± 7.2

52.2 ± 6.2

40.2 ± 4.0

MDA-MB-231

156.1 ± 20.5

105.6 ± 12.3*

71.5 ± 7.6

60.4 ± 7.1

3.4 Discussion
Determining the in vitro properties of novel nanotherapies using cell-based models is
important for initially evaluating the cellular effects of a nanoparticle formulation before
proceeding to in vivo studies. In this chapter, the cellular uptake, localisation and
cytotoxicity of N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were
determined using two breast cancer cell lines that vary in their expression of cell surface
uPAR. PAI-2-functionalised liposomes showed a significantly greater uptake than nonfunctionalised (NF) liposomes in MDA-MB-231 cells (uPAR-positive) but not in MCF7 cells (uPAR-negative). Confocal microscopy revealed uptake of both NF and PAI-2
liposomes into both cell lines, with localisation in the cytoplasm and some accumulation
within lysosomes. N-AI PAI-2 liposomes showed a significantly increased cytotoxic
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effect against MDA-MB-231 cells compared to MCF-7 cells after 72 h when grown in
2D culture. N-AI PAI-2 liposomes were also cytotoxic to MCF-7 and MDA-MB-231
multicellular tumour spheroids, resulting in dissemination of the 3D structure and
cytotoxic effect, but with no significant differences in IC50 between the two cell lines after
96 h. Collectively, the results presented in this chapter form a basis for understanding the
in vitro properties of N-AI PAI-2 liposomes to guide further in vivo evaluation.

As reported previously, uPA and uPAR expression is low in MCF-7 cells and high in
MDA-MB-231 cells (Huber et al. 2016; Ma et al. 2001). The profiling results in this
chapter corroborated this, with MDA-MB-231 cells showing significantly greater uPAR
expression than MCF-7 cells and the IgG control (Fig. 3.2). This difference in uPAR
expression was associated with a significant increase in fluorescently labelled PAI-2
liposome uptake relative to non-functionalised liposomes by MDA-MB-231 cells, but not
by MCF-7 cells (Fig. 3.5). In these experiments, FITC-labelled empty liposomes were
used as N-AI is slightly fluorescent (Fig. 3.3) and empty liposomes do not have a
significantly different size or surface charge as compared to N-AI-loaded liposomes
(Chapter 2, Section 2.3.1). In addition, both N-AI (Vine et al. 2016) and rhodamine-123
(Krag et al. 1989) have been shown to be cytotoxic against tumour cells, and this was
observed as a decrease in the viable cell population after 60 min treatment with N-AI and
R123-loaded liposomes by flow cytometry (Fig. 3.3). This cytotoxic profile of N-AI and
R123 make their use in uptake studies unfavourable. In contrast to N-AI and R123
liposomes, FITC-labelled liposomes did not have a strong cytotoxic effect against MDAMB-231 cells at a 20 mM phospholipid concentration, and FITC liposomes at 10 mM did
not show a significant decrease in cell viability after incubation with cells for 60 min (Fig.
3.4). Therefore, this fluorophore was chosen to label liposomes for subsequent flow
cytometry experiments.

Liposomes can be taken into cells via several different mechanisms, including adsorption,
lipid exchange, intracellular membrane fusion and receptor-mediated endocytosis (RME)
(Ducat et al. 2011). The presence of a fluorescent signal from cells treated with nonfunctionalised (NF) fluorescently labelled liposomes (Fig. 3.3) indicates that NF
liposomes were taken up by cells, most likely by fusion or other non-specific mechanisms,
rather than by RME. In contrast, the uptake of PAI-2 liposomes by MDA-MB-231 cells
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was greater than the uptake of NF liposomes in MDA-MB-213 cells (Fig. 3.5). As the
average liposome diameters of the FITC-labelled NF and PAI-2 liposomes were
equivalent (152.6 ± 8.7 nm and 152.8 ± 11.7 nm, respectively), this difference in uptake
is likely due to the presence of PAI-2 at the liposome surface and interaction with
uPA/uPAR overexpressed on the surface of MDA-MB-231 cells. Competition binding
studies using excess PAI-2 or uPAR antibody could be used to further confirm this (Willis
& Forssen 1998; Xiao et al. 2011).

Confocal microscopy indicated that both NF and PAI-2 liposomes were internalised by
MCF-7 and MDA-MB-231 cells, which further supports the above flow cytometry uptake
results. Colocalisation of liposome signal with lysosomes in both cell lines confirmed that
liposomes were internalised by cells and accumulated in lysosomes, in addition to being
present elsewhere in the cell (Fig. 3.6). The R18 signal was also observed at the cell
membrane and within the cytoplasm, with the dispersed signal suggesting that some
degree of liposome fusion with the cell membrane occurred. This is not an unexpected
result given that the liposomes were incubated with cell monolayers at a high liposome
concentration, making it likely that liposomes in solution will passively fuse with cells
over time (Ducat et al. 2011). Collectively, the results indicate that NF and PAI-2
liposomes are taken into cells by fusion and potentially also by RME in the case of PAI2 liposomes. This could be further explored by using inhibitors of endocytosis to elucidate
mechanisms of liposome uptake (Lu et al. 2017; Un et al. 2012).

The work presented in this chapter highlights the need for adequate characterisation of
liposome ligand density to guide and interpret in vitro uptake experiments. For example,
for the N-AI PAI-2 liposome formulation, the exact number of PAI-2 ligands present at
the liposome surface and the proportion of liposomes that have one or more PAI-2 ligands
attached for cell binding is unknown. These factors will affect how the liposome
formulation behaves in vitro. Previous studies have demonstrated that modulating the
liposome ligand density by changing the starting maleimide-PEG concentration of the
formulation affects cellular binding and uptake (Chu et al. 2016; Gayong et al. 2016; Li,
H et al. 2016). As discussed in Chapter 2, Section 2.4, robust methods to quantify the
number of ligands present at the liposome surface are needed in order to optimise ligand
density for cell uptake and functional effect. Chapter 5 reports a novel single-molecule
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fluorescence microscopy method to quantify liposome ligand density, which could be
used in future experiments to determine the optimal number of ligands for maximal
receptor binding, cellular uptake and therapeutic effect (Belfiore, Lisa et al. 2018).

In the cytotoxicity testing against breast cancer cells grown as monolayers, N-AI PAI-2
liposomes showed a dose-dependent cytotoxic effect that was significantly (P < 0.01)
more potent against MDA-MB-231 cells compared to MCF-7 cells, with IC50 values of
5.40 ± 1.14 µM and 31.84 ± 8.20 µM, respectively. This appears to indicate PAI-2mediated targeting and an increased cytotoxic effect of PAI-2-functionalised liposomes
against uPAR-positive MDA-MB-231 cells (Fig. 3.7), which correlates with the flow
cytometric uptake data showing increased uptake of PAI-2 liposomes relative to NF
liposomes in MDA-MB-231 cells (Fig. 3.5). The less potent but still cytotoxic effect of
N-AI PAI-2 liposomes against the uPAR-negative MCF-7 cells indicates that the
liposomes were still taken up by cells via receptor-independent pathways in this cell line,
which correlates with the flow cytometry and confocal microscopy findings (Fig. 3.6). In
addition, EMP PAI-2 liposomes showed a cytotoxic effect against both cell lines at the
highest liposome concentrations tested, which is likely due to empty liposomes fusing
with cell membranes at high concentrations, resulting in cell lysis (Lu et al. 2017).

In the multicellular tumour spheroid experiments, imaging of spheroids over the course
of the experiment indicated a concentration-dependent and time-dependent destruction of
both MCF-7 spheroids and MDA-MB-231 spheroids when treated with N-AI PAI-2
liposomes (Fig. 3.9). Treatment with EMP PAI-2 liposomes did not result in
morphological changes to the spheroid structure. However, the effect of EMP PAI-2
liposomes on the viability of cells grown in 3D appeared to be greater than that observed
in the 2D experiments. EMP PAI-2 liposomes showed a dose-dependent cytotoxic effect
against both cell lines grown as spheroids, as revealed by an acid phosphatase (APH)
endpoint viability assay (Fig. 3.10). To determine whether this effect was due to the
phospholipid concentration or the presence of PAI-2 at the liposome surface, both EMP
(non-functionalised) and EMP PAI-2 liposomes were tested against MCF-7 and MDAMB-231 spheroids in a subsequent experiment, which revealed similar effects (Fig. 3.11).
An endpoint calcein viability stain revealed that the IC50 of spheroids treated with EMP
PAI-2 was significantly (P < 0.05) lower for MCF-7 spheroids (80.3 ± 7.2 µM) relative
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to MDA-MB-231 spheroids (105.6 ± 12.3 µM), but no significant differences in IC50 were
observed for the other liposome treatments (Table 3.1).

MCF-7 and MDA-MB-231 cells have been previously shown to form spheroids, with the
former developing into compact and highly rounded spheroids, and the latter forming
looser spheroid structures (Ivascu & Kubbies 2007). Similar findings were observed in
the cell titre experiment reported in this chapter (Fig. 3.8), with phase-contrast imaging
revealing that MCF-7 spheroids formed tighter and more circular spheroids, whereas
MDA-MB-231 spheroids appeared looser and less defined, despite both cell lines forming
spheroids of similar diameters. This difference in spheroid morphology was further
highlighted by the calcein imaging of spheroids (Fig. 3.13). Untreated MCF-7 spheroids
showed a decrease in fluorescence at the spheroid centre, indicative of a necrotic core
with few viable cells (Fig. 3.1). In contrast, untreated MDA-MB-231 spheroids were
smaller than MCF-7 spheroids and did not show evidence of a necrotic core via calcein
imaging. These observed differences in spheroid morphology may have effects on
liposome penetration and drug performance (Ivascu & Kubbies 2007). While MDA-MB231 spheroids treated with N-AI PAI-2 liposomes showed greater destruction of the
spheroid architecture than MCF-7 spheroids at the 24 h time point (Fig. 3.9), this
increased spheroid dissociation did not correlate with an increased cytotoxic effect (Fig.
3.11). The increased destructive effect may be the result of the weaker cell-cell junctions
that hold the spheroid together, as reported previously for MDA-MB-231 spheroids
(Ivascu & Kubbies 2007). In order to negate the effect of these inherent differences
between breast cancer cell lines, it would be advantageous to generate a stably transfected
cell line that overexpresses uPAR, or a knockout of a uPAR overexpressing line, and
compare spheroid testing with the parent cell line (Moirangthem et al. 2016).

The APH and calcein viability assays revealed an increase in MDA-MB-231 viability
above untreated control spheroids at mid-range liposome concentrations. At lower N-AI
concentrations, it appears that the liposomes did not kill the majority of MDA-MB-231
cells, but reduced the integrity of the spheroid. It is possible that these cells were still able
to proliferate in small clusters of the aggregate and remained viable even though the
spheroid was no longer intact. This light microscopy imaging of spheroids treated with
liposomes (Fig. 3.11) appears to indicate that the cells are not viable, but the calcein
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imaging at the experimental endpoint (Fig. 3.14) reveals that viable cell clusters are
present for MDA-MB-231 spheroids treated with liposomes at a 25 µM N-AI
concentration. Therefore, at lower N-AI concentrations, there may have been a greater
number of viable cells than in the untreated spheroids, since the cells were more spread
out and cell proliferation was not slowed down by the spheroid growing larger in size.

There was a high degree of corroboration between the APH assay and calcein-AM
staining in the determination of IC50 values for N-AI PAI-2 liposomes tested against
MCF-7 spheroids and MDA-MB-231 spheroids. The IC50 values for MCF-7 spheroids
treated with N-AI PAI-2 liposomes were 30.9 ± 5.4 µM (APH assay) and 40.2 ± 4.0 µM
(calcein staining). The IC50 values for MDA-MB-231 spheroids treated with N-AI PAI-2
liposomes were 59.3 ± 7.5 µM (APH assay) and 60.4 ± 7.1 µM (calcein staining). While
the 2D testing indicated that N-AI PAI-2 liposomes are approximately 6-fold more potent
against MDA-MB-231 cells relative to MCF-7 cells, the 3D testing did not reveal a
significant difference in potency for N-AI PAI-2 liposomes between the two cell lines
(Fig. 3.7). The observed differences in IC50 values between 2D and 3D testing is not
unexpected given the different pathways of liposome diffusion and uptake by cells grown
in 2D versus 3D (Katt et al. 2016), and the reported differences in cell morphology and
gene expression in 2D versus 3D cultures that can result in different responses to drug
treatment (Kenny et al. 2007). For example, the sensitivity of breast cancer cells to
trastuzumab, pertuzumab and lapatinib changes depending on whether the cells are grown
as 2D or 3D cultures (Weigelt et al. 2010), and the apparent differences in HER2
signalling observed between 2D and 3D cell culture models of breast cancer suggest that
3D models better recapitulate in vivo HER2 signalling pathways (Pickl & Ries 2009).
While uPAR profiling of other cancer cell lines has indicated that uPAR expression
remains similar between 2D and 3D culture (Ertongur et al. 2004), it remains unknown
whether the expression of uPA and uPAR by MCF-7 and MDA-MB-231 cells changes
when cells are grown as 3D structures.

Despite flow cytometry revealing an increase in the uptake of PAI-2-functionalised
liposomes over non-functionalised liposomes by MDA-MB-231 cells, the endpoint
viability assays revealed no significant differences in IC50 values between nonfunctionalised and PAI-2-functionalised N-AI liposomes. It is possible that at the
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experimental endpoints of 72 h or 96 h, any differences in cytotoxicity were masked as
remaining viable cells continued to proliferate over time. There appeared to be a greater
destruction of the spheroid structure for MDA-MB-231 spheroids than MCF-7 spheroids
after treatment with N-AI PAI-2 liposomes at the 24 h time point (Fig. 3.9), and a
significant decrease (P < 0.01) in the diameter of MDA-MB-231 spheroids treated with
N-AI PAI-2 liposomes (74.5 ± 3.4 µm) compared to N-AI liposomes (91.8 ± 5.1 µm) at
the 24 h time point (Fig. 3.12). However, these differences were lost at later time points
and at the experimental endpoints of 72 h and 96 h. As the flow cytometric uptake showed
a significant difference in the uptake of PAI-2 liposomes over NF liposomes after a 45
min incubation, differences in liposome uptake and cytotoxic effect may be apparent
initially but lost over time. For this reason, analysis of spheroid viability at earlier time
points and the use of real-time analysis of cell viability rather than (or in addition to)
endpoint viability assays would be advantageous in future experiments in order to
determine different mechanisms of liposome uptake into tumour spheroids. This could be
achieved by using fluorescent dyes that track viable cells to detect differences in viability
at various time points after liposome treatment (Tario et al. 2018; Yumoto et al. 2014).

A limitation of multicellular tumour spheroid models for testing new drug-loaded
nanotherapies is that these static models do not reproduce the complex vascular network,
hypoxia, interstitial fluid pressure and fluid shear observed in the in vivo tumour
microenvironment. Importantly, static spheroid models do not account for drug transport
across the vascular endothelium but rely exclusively on passive diffusion of liposomes
through the culture medium to permeate the spheroid (Li & Lu 2011). The use of high
local concentrations of drug-loaded liposomes to elicit a dose-dependent cytotoxic effect
on spheroids grown in vitro is not the best representation of the in vivo context, where the
enhanced permeability and retention (EPR) effect is at play and vascular permeability is
a relevant factor in liposome accumulation at the tumour site (Maeda 2015). The
development and validation of in vitro models that recapitulate aspects of the EPR effect
is an emerging field of research. Static 3D co-culture models comprised of vascular
network structures and breast tumour spheroids can be used for incorporating the effect
of vascularisation in drug testing experiments (Swaminathan et al. 2017). Microfluidicbased platforms can be used for monitoring nanoparticle delivery in a 3D environment
that recapitulates circulation, extravasation and delivery to the tumour across the
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interstitial space (Li et al. 2018). These models also permit examination of tumour cell
and vascular cell interactions and how these interactions affect drug delivery. For
example, in a microfluidic drug delivery model recapitulating the EPR effect, MDA-MB231 cells were shown to increase vascular permeability to liposomes compared to MCF7 cells, likely through the release of VEGF (Tang et al. 2017). The creation of clinically
relevant models to study the interactions between distinct cell types in the tumour
microenvironment and to test the effects of novel targeted therapies is vital for improving
the translation of results from the in vitro to the in vivo setting (Herrmann et al. 2014).

3.5 Conclusion
The work presented in this chapter confirmed the cellular uptake, cellular localisation and
cytotoxicity of N-AI PAI-2 liposomes. Liposomes were shown to be taken up by MCF-7
and MDA-MB-231 cells, with PAI-2-functionalised liposomes showing increased uptake
over non-functionalised liposomes by the uPAR-positive, but not uPAR-negative, MDAMB-231 breast cancer cell line by flow cytometry after 45 min incubation. Liposomes
were shown to be internalised by MCF-7 and MDA-MB-231 cells, with localisation at
the cell membrane, within the cytoplasm and some accumulation in the lysosomes. N-AIloaded liposomes were cytotoxic to breast cancer cells grown in both 2D and 3D, with
increased cytotoxicity against MDA-MB-231 cells over MCF-7 cells in 2D culture and
early time points (24 h) in 3D culture. Collectively, the in vitro results reported in this
chapter provide a rationale to proceed with pharmacokinetic, biodistribution and efficacy
testing of N-AI PAI-2 liposomes using clinically relevant in vivo models of uPARpositive breast cancer.
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Chapter 4:
In Vivo Evaluation of N-alkylisatin-Loaded
Liposomes Targeting the Urokinase Plasminogen
Activator System

Metastatic human tumour cells in mouse lung tissue
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liposomes targeting the urokinase plasminogen activator system in breast cancer’,
manuscript in preparation.

Author contributions: LB, DNS, MR and KLV designed the experiments; LB and KLV
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and KLV edited the manuscript for submission.
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4.1 Introduction
The work described in Chapter 3 of this thesis explored the cellular uptake and cytotoxic
effect of N-alkylisatin (N-AI)-loaded plasminogen activator inhibitor-2 (PAI-2)functionalised (N-AI PAI-2) liposomes on uPAR-positive breast cancer cells grown in
monolayer culture and multicellular tumour spheroid culture. Despite the approximations
of these cell models to in vivo tumours, there are limitations to how accurately cells grown
on tissue culture plates can represent the characteristics of real tumours. In particular,
modelling of the enhanced permeability and retention (EPR) effect – the primary means
by which liposomes are thought to accumulate at tumour sites – is not possible in the in
vitro setting. Additionally, metastatic disease cannot be adequately modelled and studied
without the use of whole organisms. Therefore, there is a need to use animal models to
better understand and validate the efficacy of novel anticancer nanotherapeutics in vivo.

4.1.1 In vivo tumour models
In vitro tumour cell models are informative insofar as they can be physiologically
relevant, but in certain respects, their utility is limited since they cannot adequately
replicate the complete nature of actual tumours (Katt et al. 2016). For example, in vitro
cell models are static models that rely on passive diffusion for drugs to reach and permeate
tumour cells or spheroids, which does not account for transport across the vascular
endothelium as happens in vivo. Notably for nanoparticle testing, in vitro models cannot
reproduce the complex vascular network, hypoxia, interstitial fluid pressure and fluid
shear observed in the in vivo tumour environment (Velasco-Velazquez et al. 2011).
Additionally, in order to understand the impact of the complexity of the tumour
microenvironment, including the extracellular matrix, stromal cells and immune cells, on
the performance of new drugs, models as similar to the in vivo situation as possible are
required. While ex vivo tumour models have been reported, such as microfluidic-based
platforms that recapitulate circulation, extravasation and drug delivery to tumours across
the interstitial space (Tang et al. 2017), evaluation of new nanotherapies and other drugs
in whole animals remains the standard for preclinical testing.

In vivo, the EPR effect enables the passive accumulation of liposomes to tumour sites,
although this effect is reported to be highly variable between different tumour types and
91

is not observed for all solid tumours (Hansen et al. 2015; Wang 2015). Generally, the
nanoparticle targeting of haematological and lymphoid tumours, particularly for liganddirected liposomes, has shown greater success in in vivo tumour models since tumour
cells in circulation are more directly accessible to liposomes than large solid tumours
immersed in complex microenvironments (Buxton 2009; Cho & Lee 2014). However, the
application of nanoparticles in the treatment of some solid tumours may have greater
potential for use in the adjuvant setting to target vascularised micrometastases rather than
(or in addition to) the primary tumour (Zhao, M et al. 2017).

Currently, metastatic disease is the leading cause of cancer mortality, accounting for
approximately 90% of cancer-related deaths, and remains untreatable (Sledge 2016).
Metastatic disease cannot be adequately modelled and studied without the use of whole
organisms. Modelling metastatic disease using mice is necessary to evaluate the potential
effect of a nanotherapeutic on the spread of cancer and growth rates of secondary tumours
(Fantozzi & Christofori 2006). The generation of such models usually involves the
injection of human cells into an immunocompromised mouse, forming a xenograft, and
after primary tumour formation, those human cells may metastasise. Many established
human cancer cell lines have a low metastatic potential, with the likelihood of
spontaneous metastasis in an animal being dependent on the model used. For example,
the standard MDA-MB-231 breast cancer cell line routinely used in vitro has been shown
to metastasise in an intraductal NODScidIL2gamma-/- (NSG) mouse model (Young et al.
2016) but remains poorly metastatic in a mammary fat pad BALB/c nude mouse model
(Stutchbury et al. 2007). This highlights the importance of selecting appropriate tumour
models for the evaluation of nanotherapies in vivo.

While mouse models are the most frequently used animal models of tumours and other
disease states, given the high degree of similarity between mice and humans, there are
several known differences between mouse tumour models and the human context. For
example, the rate of mouse model tumour growth and resultant angiogenesis is much
greater than the formation of a tumour in humans, which tends to increase the EPR effect
(Maeda 2015). Additionally, the lack of an adaptive immune system in
immunocompromised xenograft mouse models used to study nanotherapies means that
known immune system effects on tumour growth and metastasis are absent from testing
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(Budhu et al. 2014). Despite their limitations, mouse models enable the determination of
key characteristics of new nanotherapies, such as potential toxicity and off-target effects.
Importantly, mouse models allow the evaluation of pharmacokinetics to determine how
quickly a nanoparticle formulation is cleared from the bloodstream (plasma half-life),
which is an important indicator of how likely it is that the nanoparticle will successfully
reach the site of the tumour. Similarly, biodistribution studies provide information about
where the nanoparticle localises in the body and how the nanoparticle is cleared. These
characteristics can be measured by radiolabelling the nanoparticles and then detecting the
presence of radiolabel in plasma and tissues at various time points post-injection (Vine et
al. 2014). This information can then guide dosing for efficacy experiments, which can
help elucidate the effects of repeated nanoparticle treatments on primary tumour growth
rate and tumour metastases to major organs, giving an indication of potential therapeutic
effect in a clinical setting.

4.1.2 Experimental rationale
To better understand the behaviour and potential anti-tumour effects of PAI-2functionalised liposomes containing N-AI (N-AI PAI-2 liposomes) in vivo, it is necessary
to evaluate the properties of the liposomes in animal models of breast cancer. Toxicology
studies previously performed by our laboratory have shown that N-AI-loaded liposomes
are non-toxic in mice, with up to 100 mg/kg total dose of liposomal N-AI showing no
adverse effects (Appendix D). PAI-2 has also been shown to be safe and non-toxic in
mice when administered intravenously (Hang et al. 1998; Vine et al. 2012). The
biodistribution and pharmacokinetic properties of N-AI PAI-2 liposomes need to be
determined to guide treatment schedules for efficacy experiments in mouse breast tumour
models, which can be used to evaluate the potential therapeutic effect of N-AI PAI-2
liposomes in uPAR-positive breast cancer.

4.1.3 Aims
This chapter tested the hypothesis that N-AI-loaded PAI-2-functionalised liposomes (NAI PAI-2 liposomes) enhance the tumour cell uptake into and cytotoxic effect of N-AI
against uPAR-positive breast tumours. Therefore, the overall aim of this chapter was to
determine the pharmacokinetics, biodistribution and anti-tumour efficacy of N-AI PAI-2
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liposomes in human xenograft models of primary and metastatic uPAR-positive triplenegative breast cancer (TNBC) in order to evaluate the scope for future preclinical
analysis and clinical application of N-AI PAI-2 liposomes. The specific aims of this
chapter were to:
1. Determine the pharmacokinetic and biodistribution profiles of N-AI PAI-2
liposomes in female BALB/c nude mice bearing MDA-MB-231 orthotopic
breast tumour xenografts;
2. Determine the anti-tumour (primary tumour) efficacy of multiple doses of N-AI
PAI-2 liposomes in female BALB/c nude mice bearing MDA-MB-231
orthotopic breast tumour xenografts; and
3. Determine the anti-tumour (primary tumour and metastatic tumour) efficacy of
multiple doses of N-AI PAI-2 liposomes in NOD-SCID-IL2gamma-/- mice
bearing MDA-MB-231 intraductal breast tumour xenografts.

4.2 Methods
4.2.1 Pharmacokinetics and biodistribution of N-AI PAI-2 liposomes
4.2.1.1 Preparation of 3H-CHE-labelled liposomes
Liposome components (20 mM soy L-α-phosphatidylcholine (124.0 mg), 0.8 mM mPEGDSPE (18.7 mg), 0.2 mM mal-PEG-DSPE (4.7 mg), 5 mM hydroxymethylbenzyl-isatin
(17.0 mg)) were weighed out into glass vials and dissolved in chloroform/methanol (2:1
v/v). All solutions were transferred to a round-bottom flask using a glass pipette and 400
µCi

tritiated

cholesteryl

hexadecyl

ether

[cholesteryl-1,2-3H(N)]

(3H-CHE)

(PerkinElmer, MA, USA) (50 µCi per mL liposome) was added to the solution. Solvents
were removed by rotary evaporation. The flask was then filled with nitrogen, sealed with
parafilm and transferred to 4°C overnight. To reconstitute the thin film, 8 mL degassed
endotoxin-free PBS (pH 7.4; Sigma-Aldrich, MO, USA) was added to the flask. The flask
was placed in a shaking water bath at room temperature (RT) and left for 1 h to
reconstitute. The solution was filtered through a 0.22 µm PVDF membrane and extruded
through a 0.1 µm membrane a total of 11 times at RT using a syringe-driven mini-extruder
(Avanti Polar Lipids). Liposomes were characterised by dynamic light scattering (DLS)
analysis (NanoSight) to determine size and monodispersity. N-AI-loaded nonfunctionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI
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PAI-2) were prepared by adding 704 µL of either PBS (pH 7.4) or PAI-2 (2.3 mg/mL in
PBS, pH 7.4), respectively, to 3 mL of liposome solution and incubating at RT for 4 h.
The radioactivity of the preparations was measured using a scintillation counter (Tri-Carb
2810 TR Liquid Scintillation Counter; PerkinElmer, MA, USA) (10 µL liposome + 6 mL
Ultima Gold). Prior to injection, the liposome preparations were sterile-filtered through a
0.22 µm pore PVDF filter and kept sterile for subsequent in vivo studies.

4.2.1.2 Mice
Female BALB/c-Fox1nu/Ausb nude immunocompromised mice (5 weeks old)
(Australian BioResources, Moss Vale) were housed in isolator cages at the University of
Wollongong animal facility. Mice were given food and water ad libitum and kept on a 12
h light/dark cycle for the duration of the experiment. Mice were allowed to acclimatise
for 2 weeks before commencement of the experiment. All experiments were conducted
in accordance with the ‘NHMRC Australian Code for the Care and Use of Animals for
Scientific Purposes’, which requires 3R compliance (replacement, reduction and
refinement) at all stages of animal care and use, and the approval of the Animal Ethics
Committee of the University of Wollongong (Australia) under protocol AE13/18. MDAMB-231 cells (ATCC; mycoplasma negative and STR profiled) were cultured in RPMI1640 medium with 10% heat-inactivated FBS (incubated at 37°C). Cells were detached
from flasks with 0.05% trypsin/EDTA solution (Gibco, MA, USA) and incubated for 35 min at 37°C. Cells were collected in RPMI-1640 medium with 10% FBS and
centrifuged at 1200 rpm (~300 x g) for 5 min at RT. Cells were resuspended in PBS with
Ca/Mg (pH 7.4; Sigma-Aldrich, MO, USA) and centrifuged again as above. Cells were
then resuspended in PBS (no Ca/Mg; pH 7.4; Sigma-Aldrich, MO, USA) and counted
using Trypan blue (Sigma-Aldrich, MO, USA) and a haemocytometer. A cell suspension
at a concentration of 4 x 107 cells/mL was prepared to give 2 x 106 cells in a 50 µL
injection volume. Cell viability was checked after injections had been completed and was
found to be approximately 90%.

Mice were weighed prior to cell injection. Insulin syringe needles (29-gauge; BD
Biosciences, NJ, USA) were used to inject 50 µL of cell suspension (containing 2 x 106
cells) into the upper left mammary fat pad. Mice were injected one cage at a time and the
injection order of cages was randomised. Mice were monitored closely following
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injection of cells, and tumours were observed to form at approximately 3 weeks postinjection.

4.2.1.3 Treatment with liposomes
All mice were monitored and weighed prior to the start of treatments. Mice did not show
signs of distress or weight loss in the weeks prior to treatment commencement. Tumours
were apparent in most mice and were small (< 100 mm3) upon commencement of
liposome treatment. Mice were randomly allocated to treatment (N-AI liposome or N-AI
PAI-2 liposome) and time point (10 min, 3 h, 6 h, 24 h, 48 h or 96 h) groups (4 mice per
cohort). Treatments were administered intravenously via a single lateral tail vein
injection. Tails were warmed using a heat lamp to dilate the tail vein before injecting 100
µL (4 µCi) of liposome solution. Following injection, a small amount of pressure was
placed on the injection site to stem any bleeding. Mice that were deemed significantly (±
10%) smaller or larger in weight than their cage mates had their dose volume adjusted
proportionally based on their weight relative to the average of their cage mates.

Cohorts were euthanised at designated time points post-treatment (10 min (0.17 h), 3 h, 6
h, 24 h, 48 h or 96 h) via CO2 inhalation. Immediately after sacrifice, whole blood was
collected by cardiac puncture using 29-gauge insulin syringes and transferred into 1 mL
EDTA animal collection tubes (Greiner, Austria). Blood was centrifuged at 500 x g for
15 min at RT and 0.1 mL of plasma was transferred to a pre-weighed 7 mL glass
scintillation vial. Kidneys, liver, spleen, lungs and tumour, as well as the tail (to subtract
activity remaining at injection site) were removed from each animal and transferred to
individual pre-weighed 20 mL glass scintillation vials. Vials were sealed and stored at
4°C until tissues were processed.

4.2.1.4 Blood and tissue analysis
The 3H-CHE radioactivity (liposome) in the plasma, kidneys, liver, spleen, lungs, tumour
and tail (for injection correction) was quantified using previously published methods
(Vine et al. 2014). Vials were equilibrated to RT and the weight of each tissue was
determined by subtracting the pre-recorded weights of each empty vial. Solvable
(PerkinElmer, MA, USA) was added to each vial to dissolve the tissues: 0.4 mL for
plasma; 2 mL for kidneys, spleen, lungs and tail; 5 mL for liver; and 1 mL for tumours
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(where present). Vials were sealed and incubated at 60°C for 1-3 h with occasional
agitation to dissolve tissues. Vials were then cooled to RT and hydrogen peroxide (30%
v/v) was added to bleach the samples: 0.2 mL for plasma, kidneys, spleen, lungs and tail;
0.5 mL for liver; and 0.1 mL for tumour. Samples were allowed to stand for 30 min at RT
to complete the reaction. Vials were then sealed tightly and incubated at 60°C for 1 h.
Vials were cooled to RT and 0.5 mL of each sample (0.25 mL for liver due to residual
intense colouration) was transferred to a 7 mL glass scintillation vial. To this, 5 mL of
Ultima Gold LSC (PerkinElmer, MA, USA) was added, vials were inverted to mix and
samples were temperature-adapted (25°C) and dark-adapted for 1 h prior to counting.
Samples were analysed using a Tri-Carb 2810 TR Liquid Scintillation Counter
(PerkinElmer, MA, USA). Separate control vials for each tissue were prepared in parallel
and contained the same volumes of each reagent but in the absence of tissue. The raw
counts for each sample were corrected for the amount of radioactivity remaining in the
tail and are presented as the percentage of injected dose (ID) per gram of tissue (% ID/g)
or percentage of ID in the whole tumour (% ID). Pharmacokinetic profiles were
determined by plotting the % ID/mL remaining in the plasma over time and fitted to a
one phase decay model using GraphPad Prism V7 for Windows (GraphPad Software,
CA, USA).

4.2.2 Efficacy of N-AI PAI-2 liposomes in a primary tumour model
4.2.2.1 Liposome preparation
Liposomes were prepared as outlined in Section 4.2.1.1 in the absence of 3H-CHE. Empty
non-functionalised (EMP) liposomes were composed of 20 mM soy PC, 1 mM mPEGDSPE and 5 mM cholesterol. N-AI-loaded non-functionalised (N-AI) and N-AI-loaded
PAI-2-functionalised (N-AI PAI-2) liposomes were composed of 20 mM soy PC, 0.8 mM
mPEG-DSPE,

0.2

mM

mal-PEG-DSPE

and

5

mM

5,7-dibromo-N-(p-

hydroxymethylbenzyl)isatin (N-AI). Liposomes were serially extruded through a 0.1 µm
pore PVDF membrane using a thermobarrel batch extruder (Lipex) and characterised by
DLS (NanoSight).

4.2.2.2 Mice
Female BALB/c-Fox1nu/Ausb nude immunocompromised mice (5 weeks old)
(Australian BioResources, Moss Vale) were housed in isolator cages at the University of
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Wollongong Animal Facility. Mice were given food and water ad libitum and kept on a
12 h light/dark cycle for the duration of the experiment. Mice were allowed to acclimatise
for 3 weeks before commencement of the experiment. All experiments were conducted
in accordance with the ‘NHMRC Australian Code for the Care and Use of Animals for
Scientific Purposes’, which requires 3R compliance (replacement, reduction and
refinement) at all stages of animal care and use, and approval of the Animal Ethics
Committee of the University of Wollongong (Australia) under protocol AE13/18. Mice
were inoculated with MDA-MB-231 tumour cells as outlined in Section 4.2.1.2.

4.2.2.3 Treatment with liposomes
All mice were monitored and weighed prior to the start of treatments. Mice did not show
signs of distress or weight loss in the weeks prior to treatment commencement. Tumours
were apparent in most mice and were large (~200 mm3) at the start of treatments. Mice
were randomly allocated to one of three treatment groups (EMP, N-AI and N-AI PAI-2)
(8 mice per treatment group). Treatments (100 µL) were administered intravenously via
the lateral tail vein as described in Section 4.2.1.3 for a total of 6 injections over 2 weeks
(average total dose = 68.1 mg/kg N-AI). Mice that were deemed significantly (± 10%)
smaller or larger in weight than their cage mates had their dose volume adjusted
proportionally based on their weight relative to the average of their cage mates. Tumour
dimensions were measured three times per week using callipers and tumour volume was
calculated using the equation: volume (mm3) = (length (mm) x width (mm) x width (mm))
/ 2. Animals were weighed triweekly for the duration of the experiment. Mice were
sacrificed by CO2 inhalation upon reaching tumour end point (tumour dimensions of 15
mm x 15 mm) or at the experimental end point. Immediately after sacrifice, the kidneys,
liver, spleen, heart and lungs, and tumour were removed and weighed.

4.2.3 Efficacy of N-AI PAI-2 liposomes in a metastatic tumour model
4.2.3.1 Liposome preparation
Liposomes were prepared as outlined in Section 4.2.2.1 in the absence of 3H-CHE. The
four liposome preparations, empty non-functionalised (EMP), empty PAI-2functionalised (EMP PAI-2), N-AI non-functionalised (N-AI) and N-AI PAI-2functionalised (N-AI PAI-2) liposomes, were sterile-filtered through a 0.22 µm PVDF
membrane and kept sterile until treatment.
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4.2.3.2 Mice
Female immunocompromised NOD-SCID-IL2gamma-/- mice (5 weeks old) were housed
in the Biological Testing Facility at the Garvan Institute of Medical Research. Mice were
given food and water ad libitum and kept on a 12 h light/dark cycle for the duration of the
experiment. All animal procedures were approved by the Garvan/St Vincent’s Animal
Ethics and Experimentation Committee (approval number 14/27) according to the Animal
Research Act 1985, Animal Research Regulation 2010 and the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes, which requires 3R
compliance (replacement, reduction and refinement) at all stages of animal care and use.
Intraductal injections of MDA-MB-231 cells were performed by Samantha Oakes at The
Kinghorn Cancer Centre. 80,000 MDA-MB-231 cells were injected directly into the right
mammary duct in a total volume of 10 µL, as described previously (Young et al. 2016).
Mice were monitored twice weekly and tumour growth was measured for the duration of
the experiment. Tumours were measured immediately prior to each injection and volume
was calculated using the equation: volume (mm3) = (length (mm) x width (mm) x width
(mm)) / 2.

4.3.3.3 Treatment with liposomes
At 5 weeks post-tumour cell inoculation, mice were randomised into one of four treatment
groups (5 mice per treatment cohort): EMP (empty liposomes), EMP PAI-2 (empty PAI2-functionalised liposomes), N-AI (N-AI-loaded liposomes) or N-AI PAI-2 (N-AI-loaded
PAI-2-functionalised liposomes). Treatments (100 µL, dose of 4.7 mg/kg N-AI) were
administered intravenously via the lateral tail vein using a 25-gauge needle on a triweekly
schedule for a total of 3.5 weeks (11 injections in total; total dose of 51.7 mg/kg N-AI).
At 9 weeks post-tumour cell inoculation, mice were euthanised by CO2 inhalation and
cervical dislocation. The mammary glands, tumours, lungs and livers were harvested and
fixed for 4 h in 10% buffered formalin at RT for subsequent histology and/or
immunohistochemistry analysis.

4.3.3.4 Tissue analysis
All analyses were performed at The Kinghorn Cancer Centre histology laboratory.
Mammary glands were whole mounted and processed for histology. After fixation, lungs
and livers were sectioned and stained with vimentin (1:800; Leica NCL-L-VIM-V9), and
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tumours were sectioned and stained with cleaved caspase-3 (1:100; CST ASP175 9664)
using DAKO immunohistochemistry as per the manufacturer’s instructions. Images were
captured using a Leica DFC 450 microscope using 20X magnification. Images were
analysed using ImageJ (version 1.51s) with automated algorithms designed for IHC
analysis (Law et al. 2017).

4.2.4 Data analysis
All data analysis, including the generation of graphs and statistical tests, was performed
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated.
Pairwise comparisons were made using Student’s t-test, and multiple comparisons were
made using one-way ANOVA with Tukey’s post-test, or two-way ANOVA for grouped
comparisons.

4.3 Results
4.3.1 Pharmacokinetics and biodistribution
To determine the pharmacokinetic and organ distribution profiles of N-AI-loaded nonfunctionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes (N-AI
PAI-2) in tumour-bearing mice, liposomes were labelled with tritiated cholesteryl
hexadecyl ether (3H-CHE) to enable the detection of liposomes in plasma and tissues by
liquid scintillation counting. Following preparation, liposomes were characterised by
DLS, which revealed monodisperse populations with average diameters of 115 ± 34 nm
and 117 ± 39 nm for N-AI and N-AI PAI-2 liposomes, respectively. Scintillation counts
of the two liposome stock preparations were 319,698 CPM and 312,163 CPM for N-AI
and N-AI PAI-2 liposomes, respectively. The plasma half-life was determined to be 5.63
h and 5.82 h for N-AI and N-AI PAI-2 liposomes, respectively (Fig. 4.1). The plasma
clearance profiles of the two liposomes and the pharmacokinetic parameters from curve
fitting analysis were not significantly different (P > 0.05) (Table 4.1). N-AI and N-AI
PAI-2 showed no significant differences in the average final weight of the kidneys, liver,
spleen or lungs (Appendix E).
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Figure 4.1: Detection of radiolabelled liposomes in the plasma of mice over time. N-AI and N-AI
PAI-2 liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered
intravenously as a single bolus dose. Tritiated signal was measured in plasma at each time point.
Results are expressed as the percentage of injected dose (ID) per mL of plasma (%ID/mL). Error bars
are s.d. (n = 4).

Table 4.1: Pharmacokinetic parameters of N-AI and N-AI PAI-2 liposomes. N-AI and N-AI PAI2 liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered intravenously as
a single bolus dose. Tritiated signal was measured in plasma at each time point.

PK Parameter
Cmax (% ID/mL)
Kelim α (fast) min−1
Kelim β (slow) min−1
T1/2 α (fast) min
T1/2 β (slow) min
Correlation coefficient (R2)
AUC (% ID/min/mL)

N-AI
84.66 (± 9.79)
0.061
0.002
11.419
408.152
0.9629
860.3 (± 66.89)

N-AI PAI-2
83.76 (± 9.25)
0.058
0.002
12.050
410.843
0.9836
873.4 (± 50.79)

Liposome accumulation in the kidneys, liver, spleen and lungs at each time point was
similar between N-AI and N-AI PAI-2 liposomes (Fig. 4.2). The trends indicated
increased clearance via the liver and spleen over time and decreased clearance via the
kidneys and lungs over time. There was no significant difference (P > 0.05) in clearance
via the kidneys, liver or lungs between the two liposomes at any time point. Clearance
via the spleen was significantly higher (P < 0.05) at the 48 h time point for N-AI
liposomes (78.5 ± 32.2 % ID/g tissue) compared to N-AI PAI-2 liposomes (44.2 ± 6.7 %
ID/g tissue).
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Figure 4.2: Detection of radiolabelled liposomes in clearance organs. N-AI and N-AI PAI-2
liposomes were labelled with tritiated cholesteryl and administered intravenously as a single bolus
dose. Tritiated signal was measured in the (A) kidneys, (B) liver, (C) spleen and (D) lungs at each
time point. Results are expressed as the percentage of injected dose (ID) per gram of tissue (%ID/g).
Values are means ± s.e.m. (n = 4).

Comparison of the different clearance organs revealed similar patterns between N-AI and
N-AI PAI-2 liposomes (Fig. 4.3). The primary route of clearance after the 10 min time
point was via the spleen for both liposome formulations, which was 68.6 ± 19.3 % ID/g
tissue and 48.1 ± 10.1 % ID/g tissue at the 96 h time point for N-AI and N-AI PAI-2
liposomes, respectively. Clearance via the liver was also high, with 20.0 ± 2.2 % ID/g
tissue and 23.6 ± 1.8 % ID/g at the 96 h time point for N-AI and N-AI PAI-2 liposomes,
respectively. Clearance via the kidneys and accumulation in the lungs were minimal for
both liposome formulations.
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Figure 4.3: Comparison of N-AI and N-AI PAI-2 liposome clearance. N-AI and N-AI PAI-2
liposomes were labelled with tritiated cholesteryl and administered intravenously as a single bolus
dose. Tritiated signal was measured in the kidneys, liver, spleen and lungs at each time point. Results
are expressed as the percentage of injected dose (ID) per gram of tissue (%ID/g). Values are means ±
s.e.m. (n = 4).

Where present, tumours were removed from mice and analysed for tritiated liposome
signal in the same manner as for tissues (Fig. 4.4). The results showed rapid accumulation
of N-AI PAI-2 liposome signal in tumours compared to N-AI liposomes, as indicated by
significantly increased %ID at 10 min, 3 h and 6 h post-injection (P < 0.001). At 24 h, 48
h and 96 h, tumour uptake of N-AI and N-AI PAI-2 liposomes was not significantly
different (P > 0.05).

Figure 4.4: Accumulation of liposomes in uPAR-positive breast tumours. N-AI and N-AI PAI-2
liposomes were labelled with tritiated cholesteryl hexadecyl ether and administered intravenously as
a single bolus dose. Tritiated signal was measured in whole collected tumour (where present) for each
time point. Results are expressed as the percentage of the injected dose (ID) in the whole analysed
primary tumour. Error bars are s.e.m. (n = 4).
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4.3.2 Efficacy in a primary breast tumour model
In order to determine the potential effect of N-AI PAI-2 liposomes on primary tumour
growth, mice bearing MDA-MB-231 tumours were treated with empty liposomes (EMP),
N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised (N-AI PAI-2)
liposomes three times per week for two weeks. Mice in all cohorts continued to gain
weight for the duration of the experiment, suggesting no toxic effects of the multiple dose
schedule of the liposomes (Fig. 4.5). While average animal weights were not significantly
different between the three cohorts over the course of the experiment, the N-AI PAI-2
cohort showed a trend of a higher percentage weight gain compared to the other cohorts,
although this was not statistically significant (P > 0.05).

Figure 4.5: Animal weights over the duration of liposome treatment. Mice bearing MDA-MB-231
uPAR-positive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly
schedule for two weeks. (A) Average weight and (B) percentage weight change (relative to experiment
start) for each cohort for the duration of the experiment. Values are means ± s.e.m. (n = 8).

To assess the effect of the liposome treatments on primary tumour growth, tumours were
measured using callipers three times a week and tumour volume was calculated using the
equation: volume (mm3) = (length (mm) x width (mm) x width (mm)) / 2. Tumours
showed relatively linear growth across all cohorts, and the average tumour volume and
percentage change in tumour volume between the three cohorts was not significantly
different (P > 0.05) at any experimental time point (Fig. 4.6).
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Figure 4.6: Primary tumour volume measurements. Mice bearing MDA-MB-231 uPAR-positive
tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly schedule for two
weeks. (A) Tumour volume and (B) percentage change in tumour volume (relative to day 0 of
treatment) for each cohort for the duration of the experiment. Values are means ± s.e.m. (n = 8).

At the end of the experiment, the kidneys, liver, spleen, and heart and lungs of each mouse
were removed in whole and weighed. The final organ weights between the three cohorts
were not significantly different (P > 0.05), indicating no toxicity from the multiple dosing
schedule of the treatments (Fig. 4.7).
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Figure 4.7: Final organ weights of liposome-treated mice. Mice bearing MDA-MB-231 uPARpositive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes on a triweekly schedule
for two weeks. At the experimental endpoint, mice were euthanised and (A) kidneys, (B) liver, (C)
spleen and (D) heart and lungs were removed in whole and weighed. Values are means ± s.e.m. (n =
8). ns = not significant (P > 0.05).

Primary tumours were removed in whole and weighed. Primary tumour weights varied
greatly between individuals within each cohort, but the average primary tumour weight
between the three cohorts was not significantly different (Fig. 4.8). Comparison of
primary tumour weights and primary tumour volume (calculated from calliper
measurements) showed a high level of corroboration, but also showed no significant
differences between the three treatment cohorts.
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Figure 4.8: Final primary tumour measurements of liposome-treated mice. Mice bearing MDAMB-231 uPAR-positive tumours were administered with EMP, N-AI or N-AI PAI-2 liposomes three
times per week for two weeks. (A) At the experimental endpoint, mice were euthanised and primary
tumours were removed in whole and weighed. (B) Final primary tumour volume as determined by
calliper measurements. Values are means ± s.e.m. (n = 8). ns = not significant (P > 0.05).

4.3.3 Efficacy in a metastatic breast tumour model
To investigate the effect of N-AI PAI-2 liposomes on metastatic tumours, liposomes were
tested in a metastatic intraductal breast tumour model with mice bearing MDA-MB-231
tumours. Empty non-functionalised liposomes (EMP), empty PAI-2-functionalised
liposomes (EMP PAI-2), N-AI-loaded non-functionalised liposomes (N-AI) and N-AIloaded PAI-2-functionalised liposomes (N-AI PAI-2) were administered intravenously
from 5 weeks post-tumour cell inoculation when tumours were small (palpable, not
measurable) on a triweekly schedule. Tumour volume increased steadily over time in all
cohorts, with a more rapid increase observed from 20 days post-treatment (Fig. 4.9).
Primary tumour growth was not significantly different between the four treatment
cohorts, although mice treated with EMP PAI-2, N-AI or N-AI PAI-2 liposomes showed
a trend of decreased tumour growth relative to the EMP treatment cohort.
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Figure 4.9: Primary tumour measurements in an intraductal tumour model. Mice bearing
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2functionalised liposomes (N-AI PAI-2) (at equivalent N-AI and/or PAI-2 concentrations, where
applicable) 3 times a week for 5 weeks. Values are means ± s.e.m. (n = 5).

Animal weights fluctuated throughout the course of the experiment but did not
significantly change with progression of liposome treatment (Fig. 4.10). At the final time
point (25 days post-treatment), the average percentage weight change of the N-AI PAI-2
cohort was significantly higher than that of the other three cohorts (P < 0.05).

Figure 4.10: Animal weights in an intraductal model over duration of treatment. Mice bearing
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2functionalised liposomes (N-AI PAI-2). (A) Animals were weighed prior to each treatment. (B)
Animal weights normalised to day 0 post-treatment. Values are means ± s.e.m. (n = 5).
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At the experimental end point, primary tumours (where present; n = 18), mammary glands
(where possible; n = 15), lungs and livers were removed in whole. Mammary glands were
stained with carmine as described previously (Young et al. 2016) and imaged for
secondary tumour detection in the mammary gland once the primary tumour was removed
(Fig. 4.11). The proportion of mammary glands with secondary tumours present was
highest for the EMP cohort (4/5) and lowest for the N-AI PAI-2 cohort (0/2). There were
no significant differences (P > 0.05) in average positive tumour area between the cohorts
where secondary tumours were present (EMP, EMP PAI-2 and N-AI).

Figure 4.11: Mammary gland whole-mount analysis. Mice bearing intraductal MDA-MB-231
tumours were treated with empty liposomes (EMP), empty PAI-2-functionalised liposomes (EMP
PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised liposomes (N-AI PAI2). At the experimental endpoint, mammary glands were removed in whole where possible and
mounted for carmine staining. (A) Representative carmine-stained mammary gland images. (B)
Percentage of mice with tumour(s) present in mammary gland at experimental endpoint. (C) Tumour
area (positive stain) of mammary glands where tumours were present. Values are means ± s.e.m. (n =
2-4). n.s. = not significant (P > 0.05).
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To determine the potential cytotoxic anti-tumour cell effect of the N-AI and N-AI PAI-2
liposome treatments on primary tumours, primary tumour sections were stained with
cleaved caspase-3 to detect apoptotic cells (Fig. 4.12). Automated imaging analysis of
positively stained cells showed a considerable degree of variability between individuals
within each treatment cohort, but no significant differences (P > 0.05) in the average
positive area between the four cohorts in terms of cleaved caspase-3-positive cells.

Figure 4.12: Immunohistochemistry analysis of primary tumours. Mice bearing intraductal MDAMB-231 tumours were treated with empty liposomes (EMP), empty PAI-2-functionalised liposomes
(EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2-functionalised liposomes (N-AI
PAI-2). (A) Tumour sections were stained with cleaved caspase-3 (apoptotic cells). (B) Representative
total mask (all cells) using automated imaging analysis. (C) Representative positive mask (apoptotic
cells) using automated imaging analysis. (D) Percentage of cleaved caspase-3-positive area (apoptotic
cells) relative to total cell area. Values are means ± s.e.m. (n = 5). n.s. = not significant (P > 0.05).

To determine the effect of the four liposome treatments on metastasis to the lungs and
liver, lung and liver sections were stained with vimentin to detect metastatic cells (Fig.
4.13). Automated imaging analysis of positively stained cells showed a high degree of
variability between individuals within each cohort, but no significant differences (P >
0.05) in average positive area between the four cohorts in terms of vimentin-positive cells.
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Figure 4.13: Immunohistochemistry analysis of lung and liver metastasis. Mice bearing
intraductal MDA-MB-231 tumours were treated with empty liposomes (EMP), empty PAI-2functionalised liposomes (EMP PAI-2), N-AI-loaded liposomes (N-AI) or N-AI-loaded PAI-2functionalised liposomes (N-AI PAI-2). (A-B) Lung and liver sections were stained with vimentin
(metastatic cells). (C-D) Representative total masks (all cells) using automated imaging analysis. (EF) Representative positive masks (metastatic cells) using automated imaging analysis. (G-H)
Percentage of vimentin-positive area (metastatic cells) relative to total cell area. Values are means ±
s.e.m. (n = 5). n.s. = not significant (P > 0.05).
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4.4 Discussion
Determining the in vivo properties of novel nanotherapies using animal models is
important for evaluating how a new nanoparticle formulation can be expected to perform
in humans. In this chapter, the pharmacokinetics, biodistribution and anti-tumour efficacy
of N-AI-loaded PAI-2-functionalised (N-AI PAI-2) liposomes were evaluated using two
different breast cancer xenograft mouse models. The addition of PAI-2 to the surface of
N-AI-loaded liposomes did not significantly alter the in vivo clearance properties of the
formulation but did appear to increase accumulation of liposomes at the primary tumour
site in an orthotopic MDA-MB-231 BALB/c-Fox1nu/Ausb xenograft mouse model
relative to non-functionalised liposomes. Despite this increase in tumour uptake, the antitumour efficacy of N-AI PAI-2 liposomes relative to non-functionalised N-AI-loaded
liposomes and empty control liposomes was not significantly different in the two mouse
models used.

Understanding the pharmacokinetic properties and tissue distribution of nanoparticle
formulations is essential to determine circulation time, clearance mechanisms and how
well the nanoparticle reaches and accumulates at the site of primary and metastatic
tumours (Allen & Cullis 2013). Importantly, the pharmacokinetic profile reveals the
circulation half-life of a nanoparticle, a characteristic of particular importance for
nanotherapies as the enhanced permeability and retention (EPR) effect is the primary
mechanism by which nanoparticles are thought to target tumours and exhibit anti-tumour
effects (Maeda 2015). The plasma circulation time of liposomes has been shown to be
dependent on their lipid composition, size, surface charge, morphology and other
physicochemical characteristics, as the dominant mechanism by which liposomes are
typically cleared from the bloodstream is based on interactions with phagocytic cells of
the mononuclear phagocyte system (MPS). The inclusion of PEG at the outer surface of
the liposome can increase the in vivo circulation time by reducing recognition and
clearance by the MPS (Uster et al. 1996). Therefore, PEGylated liposomes reportedly
have decreased rates of clearance as PEG at the nanoparticle surface helps to shield the
nanoparticle from the innate immune response.

In this work, N-AI and N-AI PAI-2 PEGylated liposomes both exhibited an average
plasma half-life in mice of approximately 6 hours (5.63 h and 5.82 h, respectively) (Fig.
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4.1). This plasma half-life is comparable to other reports of PEGylated liposomes, which
typically exhibit a plasma half-life of several hours (Krishna et al. 2001; Vijayakumar et
al. 2016). The organ accumulation of N-AI and N-AI PAI-2 liposomes was in accordance
with the general clearance pattern typically seen for nanoparticles, with high degrees of
clearance from the spleen, liver and kidneys (Dams et al. 2000) (Fig. 4.2). The
biodistribution profile of the two liposome preparations correlates with the known general
patterns of clearance of PEGylated liposomes from the blood, with a drop in liposome
plasma concentration at the 6 h time point correlating with increased liposome clearance
primarily by the spleen (indicative of clearance via the MPS), in addition to the liver, and
comparatively low clearance by the kidneys and lungs (Litzinger et al. 1996) (Fig. 4.3).
Clearance via the spleen was significantly higher (P < 0.05) at the 48 h time point for NAI liposomes (78.5 ± 32.2 % ID/g tissue) compared to N-AI PAI-2 liposomes (44.2 ± 6.7
% ID/g tissue), which is not unexpected given that the presence of functional groups on
the surface of nanoparticles can affect clearance via the MPS (Alexis et al. 2008). While
the N-AI and N-AI PAI-2 liposomes were equivalent in diameter (115 ± 34 nm and 117
± 39 nm, respectively), the observed difference in spleen accumulation may be due to the
difference in surface charge between the liposomes (–3.64 ± 0.59 mV and –4.66 ± 0.52
mV, respectively) (Chapter 2, Section 2.3.3). However, the result obtained in this study
contrasts with the general trend observed in previous studies, which report that
nanoparticles with a greater negative charge show greater clearance via the spleen (He et
al. 2010) and liver (Xiao et al. 2011). The decreased spleen accumulation of N-AI PAI-2
liposomes relative to N-AI liposomes at the 48 h time point may be due to the increased
tumour accumulation of N-AI PAI-2 liposomes at earlier time points.

The accumulation of nanoparticles in tumours via the EPR effect is dependent on a
number of factors, including interstitial fluid pressure, vascularity of the tumour and the
in vivo circulation time of the nanoparticle formulation (Nichols & Bae 2014). The results
presented here indicate a trend of increased tumour uptake of N-AI PAI-2 liposomes over
N-AI liposomes. Tumour accumulation of N-AI PAI-2 liposomes was significantly higher
(P < 0.001) than N-AI liposomes at the 10 min, 3 h and 6 h time points (Fig. 4.4). After
the 6 h time point, the tumour accumulation of N-AI and N-AI PAI-2 liposomes was not
significantly different. As the plasma half-lives of the two liposomes were equivalent
(Fig. 4.1), the presence of PAI-2 at the liposome surface may have affected liposome
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extravasation and uptake at the tumour site. This may have been due to PAI-2 liposomes
binding to uPAR expressed by tumour cells, as was observed in Chapter 3 in the in vitro
uptake and cytotoxicity testing of non-functionalised and PAI-2-functionalised
liposomes. The difference in uptake may also be due to other differences between N-AI
and N-AI PAI-2 liposomes. For example, as mentioned above, N-AI PAI-2 liposomes had
a slightly more negative surface charge than N-AI liposomes, and surface charge has been
shown to affect tumour uptake of nanoparticles (Xiao et al. 2011).

The maximum tumour accumulation of the liposomes was 0.5% of the ID at the 10 min
time point for N-AI PAI-2 liposomes and 0.02% for N-AI liposomes (Fig. 4.4). These
values are comparable to other PEGylated nanoparticles, which typically show
approximately 1% or less of the total ID reaching the site of the primary tumour.
Generally, the percentage of the total ID of nanoparticles administered intravenously
reaching the target site is quite low: the median value has been reported as 0.7% (Wilhelm
et al. 2016). While the circulation time of nanoparticles is typically much longer than that
of small molecules (as would be expected for free N-AI), a longer half-life is optimal for
achieving tumour targeting, as the EPR effect relies on the nanoparticles remaining in
circulation long enough to reach tumours and extravasate at those sites, which in turn
drives enhanced tumour uptake, and accumulation and retention of liposomes for antitumour effect (Grimaldi et al. 2016). Notably, the high tumour accumulation of Doxil®
in humans (reported as high as 10% of the ID) is due in large part to the very long
circulation half-life (up to 45 h) of the formulation (Gabizon et al. 1994).

The biodistribution and pharmacokinetics experiment indicated that N-AI PAI-2
nanoparticles reached the site of the primary tumour from a single intravenous injection,
with an apparent increase in tumour localisation of the N-AI PAI-2 liposomes compared
to N-AI liposomes. To determine whether this tumour accumulation of N-AI PAI-2
liposomes would translate into a reduction in primary tumour growth rates, mice bearing
large tumours (approximately 200 mm3) were injected three times per week for 2 weeks
and tumour volume was measured to detect any changes to the tumour growth rate (Fig.
4.6). Final organ weights were the same across all treatment cohorts (Fig. 4.7), supporting
the results of a previous toxicology study that showed N-AI-loaded liposomes were not
toxic at the multiple dosing schedule used, and that the maximum tolerated dose (MTD)
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of N-AI-loaded liposomes was not reached at 100 mg/kg, the highest dose tested
(Appendix D). Despite the lack of toxicity, in this study, no significant differences were
observed in tumour growth rates, final tumour size or final tumour weight between the
EMP liposome, N-AI liposome and N-AI PAI-2 liposome treatments (Fig. 4.6 and Fig.
4.8). There may be several reasons for this observation.

In contrast to the biodistribution study, where the starting tumour volume was
approximately 100 mm3, tumours in this cohort were higher at the commencement of
treatment, which may have meant that treatment started too late to result in any significant
primary tumour growth delay. There was also a large degree of variability between
tumour volume and growth rates among individual animals within the same cohorts,
which made it difficult to determine differences between treatments, even with a sample
size of 8 animals per treatment cohort (Fig. 4.8). Additionally, it is unknown whether
primary tumours were sufficiently vascularised during the treatment timeframe, which
would be needed to allow the liposomes to enter and reach the tumour area to exert an
anti-tumour effect (Nichols & Bae 2014). This is an important factor, because for solid
tumours that are poorly vascularised, any significant accumulation of nanoparticles in the
vicinity of the tumour via the EPR effect is unlikely (Bahrami et al. 2017). The high
degree of variability in starting tumour size may have meant differing degrees of tumour
vascularisation, which may have translated to different degrees of the EPR effect and
therefore varied liposome delivery to the tumours. While N-AI and N-AI PAI-2 liposomes
were shown to accumulate at the site of primary tumours in this mouse model, given that
the plasma half-life of the liposomes was 6 h, the liposomes may not have accumulated
at the primary tumour site in large enough numbers to have a significant anti-tumour
effect at the biweekly dosing schedule used. Therefore, an increased frequency of
liposome administration may have been more suitable in increasing N-AI at the tumour
site for an anti-tumour effect. However, in addition to being impractical for the researcher,
frequent intravenous injections via the lateral tail veins may bring up ethical issues, as the
injection site should be allowed to heal adequately before additional injections are made
(Turner et al. 2011).

As uPAR-positive breast cancer cells have a high propensity to metastasise (Chapter 1,
Section 1.5), a mouse model of metastatic uPAR-positive breast cancer was used to assess
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the potential anti-tumour effect of N-AI PAI-2 liposomes on both primary tumours and
on micrometastases (Young et al. 2016). Mice were treated with EMP, EMP PAI-2, NAI and N-AI PAI-2 liposomes on a triweekly injection schedule for a total of 5 weeks.
Previous work has shown that free N-AI has a potent anti-tumour effect on primary
tumours at a dose of 10 mg/kg (Vine et al. 2012). In this experiment, N-AI or N-AI PAI2 liposomes administered at a total dose of 51.7 mg/kg did not demonstrate an anti-tumour
effect on primary tumours (Fig. 4.9). Further, the N-AI PAI-2 liposome treatment did not
differ significantly from N-AI liposomes or EMP PAI-2 liposomes, indicating that under
the treatment conditions used, the combination of N-AI and PAI-2 does not have a
synergistic anti-tumour effect in this model. As observed in the orthotopic breast tumour
xenograft model described in Section 4.3.2, this intraductal breast tumour xenograft
model also showed a high degree of variability in primary tumour growth and formation
of metastases of individual animals within each cohort (Fig. 4.9 and Fig. 4.13). Original
reports of this model using a variant of the MDA-MB-231 cell line also showed a high
degree of variability among tumour growth of mice within treatment cohorts, which was
reflected by a high variability (approximately 3 weeks) of the time to detection of initial
primary tumour development in control mice (Young et al. 2016). Therefore, the
statistical power of this model may have been limited by a high degree of biological
variability.

Previous experiments using the MDA-MB-231 intraductal xenograft model showed that
antagonism of the survival factor myeloid cell leukemia-1 suppressed metastasis in
TNBC xenografts (Young et al. 2016). Analysis of the mammary whole mounts in the
current work showed no significant differences in secondary tumour formation in the
mammary gland where the primary tumour was located (Fig. 4.11). This may be due to
the fact that mammary glands could not be dissected from all mice, only from those where
the primary tumour had not taken over entire mammary gland, limiting the total numbers
available for analysis. No significant differences between treatment cohorts were found
when primary tumours were stained with cleaved caspase-3 (Fig. 4.12), likely because
the tumours were large at the experimental endpoint and the majority of the tumour core
contained apoptotic cells. Vimentin was used to detect metastatic human cells in the lungs
and liver, the tissues where MDA-MB-231 cells have been reported to metastasise in this
mouse model (Young et al. 2016). While metastatic human cells were detected in the
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lungs and liver of some mice, the low levels of metastasis in the control mice (EMP
liposome treated) at the experimental endpoint meant that the number of vimentinpositive cells detected per animal was relatively low (Fig. 4.13). Due to this, as well as
the high degree of variability between individual animals in this model, significant
differences between treatment groups could not be detected. If experiments using this
model are repeated, an extended time frame should be used to ensure sufficient metastatic
burden to the lungs and liver in control mice in order to detect potential changes in the
number of metastatic cells of mice in the treatment groups. A superior way to conduct
these experiments would be to utilise bioluminescent live imaging techniques (for
example, using luciferase-tagged tumour cells) so that tumour growth and metastatic
burden could be monitored in real time, helping to inform the decisions of when to start
and end liposome treatments (Tung et al. 2016).
An additional rationale for the use of non-invasive imaging techniques in in vivo
experiments for testing liposomes is to elucidate the degree to which the EPR effect is
occurring in these models (Chapter 1, Section 1.6). This is important as the EPR effect is
reported to be highly variable and is not observed for all solid tumours, especially poorly
vascularised tumours (Nichols & Bae 2014; Wang 2015). The EPR effect is also known
to be highly variable between different animal models, different disease models, and
between animals and humans (Hare et al. 2017). As the rate of animal tumour growth and
resultant angiogenesis are reportedly much greater than the formation of tumours in
humans (Maeda 2015), this results in a more pronounced EPR effect in animal models,
which may partially explain why many nanotherapies that show promise in in vivo studies
fail in clinical trials (Nichols & Bae 2014). Further research is required to better
understand the EPR effect and elucidate the differences in this phenomenon between
animal and human tumours, and between different tumour types, in order to increase the
translation of nanoparticle-based therapeutics into the clinic (Lammers et al. 2016). This
could be achieved via imaging methods, such as the radionuclide imaging of liposomes
to determine their fate in vivo (van der Geest et al. 2016). Single photon emission
computed tomography (SPECT) and positron emission tomography (PET) have
previously been used to quantify the in vivo distribution of nanoparticles, including
accumulation of nanoparticles at the tumour site, in a non-invasive manner (Harrington
et al. 2001). The use of nanoparticles in conjunction with such imaging techniques may
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also have theranostic applications, whereby both diagnostic and therapeutic agents are
utilised in order to better guide and monitor treatment (Chen et al. 2017).

While the biophysical properties of a nanoparticle formulation affect the plasma
circulation time, clearance properties, and therefore tumour accumulation in vivo, it is
important for future research to consider and evaluate the interactions of nanoparticles
with cells of the immune system and clearance organs, since nanoparticles that are filtered
out of the blood and end up in liver and spleen do not reach their intended target, which
limits the therapeutic effect. The frequent use of xenograft models to allow the study of
human cancer cells in mouse models means that immunocompromised mice are used in
order to prevent rejection of the human xenografts. Given the known effect of the adaptive
immune system in tumour growth and metastasis (Kitamura et al. 2015), there is a need
for tumour models in immunocompetent animals in addition to the often used
immunocompromised models that eliminate potential effects of the immune system in the
evaluation of new anticancer therapies (Gomez-Cuadrado et al. 2017). The increasing use
of such models lends itself to the improved assessment of targeted therapies in the context
of cancer treatment (Budhu et al. 2014).

Previous studies have shown that the plasma circulation time is dependent not only on the
biophysical properties of the liposome formulation but also on the number of injections
administered (Dams et al. 2000). This phenomenon is relevant to efficacy studies, which
typically involve administration of multiple doses of a nanoparticle formulation to
maximise therapeutic effect. The accelerated blood clearance (ABC) phenomenon
describes how the first dose of a PEGylated nanoparticle may affect the pharmacokinetic
properties of subsequent doses. Specifically, ABC describes an increased clearance rate
of PEGylated nanoparticles from the blood with second and subsequent intravenous
injections of the nanoparticle formulation (Laverman et al. 2001; Oussoren & Storm
1999), and is dependent on the lipid dose administered and duration of the administration
interval (Gabizon et al. 2008; Laverman et al. 2001). In this context, reduced circulation
time correlates with increased liver and spleen accumulation (Laverman et al. 2001). The
ABC phenomenon has been described for PEGylated liposomes, polymeric nanoparticles
and PEGylated solid lipid nanoparticles delivered intravenously (Szebeni & Storm 2015).
While the exact mechanism of the ABC phenomenon remains unknown, a key identified
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mechanism is the production of anti-PEG IgM following the first injection, which
selectively binds to the surface of subsequently injected PEGylated particles and acts to
accelerate clearance by substantial complement activation (Szebeni 2014). In
immunocompromised mice, this mechanism is unlikely. However, Doxil® has been
reported to activate the complement system (innate immune system) in animals and
humans, leading to a hypersensitivity reaction known as complement activation-related
pseudoallergy (CARPA), which can impact upon the pharmacokinetic and
pharmacodynamic properties of the drug (Szebeni et al. 2016). Such research
demonstrates that the ABC phenomenon is an important factor to consider in the design
and development of PEGylated liposomes and other nanoformulations for repeat dosing
therapeutic applications.

Another key consideration for testing new nanotherapies, particularly those that are
actively targeted, is the use of models that recapitulate intratumoural heterogeneity. The
injection of a human cancer cell line into an animal to create an in vivo tumour model
largely fails to represent the heterogeneity observed in human tumours since cells within
a cell line are clonally similar (Alizadeh et al. 2015). This means that any treatment tested
is expected to affect most, if not all, cells in that model in the same way, which is not
representative of the clinical situation (Zardavas et al. 2015). Therefore, the use of these
models in developing and testing novel therapies, especially dual-targeted therapies that
are designed to address intratumoural heterogeneity, is limited as they do not permit
evaluation of the effects of differential cell targeting and therapeutic resistance when
determining anti-tumour efficacy. Patient-derived xenografts can be more representative
of the clinical situation as they capture some elements of intratumoural heterogeneity, as
well as the diversity observed between patients with cancer (Gomez-Cuadrado et al.
2017). In addition to intratumoural heterogeneity, the interpatient heterogeneity observed
in cancer also warrants the development and utilisation of patient-derived cell lines to
more accurately assess patient responses to novel therapies, particularly in cases where
resistance to currently used therapies is frequently observed (Shafaee & Ellis 2017).

A final consideration in the testing of novel ligand-functionalised liposomes involves the
question of what happens to liposome integrity, ligand attachment, ligand function, and
therefore the biophysical properties of a liposome formulation after intravenous
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administration, which affects in vivo circulation time and clearance properties. For
example, the well-documented propensity of biological molecules, especially proteins,
present in the bloodstream to associate non-specifically with the surface of liposomes in
vivo and the subsequent formation of a protein corona around the liposome may affect
numerous biophysical properties of a liposome formulation (Caracciolo et al. 2017). In
the case of ligand-functionalised liposomes, the physical presence of a protein shield
around the surface of the liposome, including association of plasma proteins with
liposome ligands, may act to inhibit binding of the liposome targeting ligand with its
target receptor, which would affect the targeting success in vivo (Shi et al. 2017). These
potential changes to the liposome are usually unaccounted for but could have significant
effects on the anticipated biodistribution, pharmacokinetic and efficacy profiles of a
liposome formulation, and are therefore important factors to consider when testing
liposomes in biological systems (Walkey & Chan 2012).

4.5 Conclusion
The work presented in this chapter reports novel data on the pharmacokinetics and
biodistribution of N-AI and N-AI PAI-2 liposomes, as well as the efficacy of multiple
doses of N-AI PAI-2 liposomes in two mouse models bearing orthotopic uPAR-positive
breast tumour xenografts. While increased tumour uptake of N-AI PAI-2 liposomes over
N-AI liposomes was observed, further research is needed to clarify if and how the potency
of N-AI as a cytotoxin can be translated into an anti-tumour growth effect by targeting
uPAR-positive tumours. The utilisation of more advanced preclinical models and
methods will enable enhanced evaluation of N-AI PAI-2 liposomes in the in vivo context.
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Chapter 5:
Quantification of Ligand Density and
Stoichiometry on the Surface of Liposomes by
Single-Molecule Fluorescence Microscopy

Single-molecule fluorescence imaging of liposomes

Portions of this chapter have been published in the following work:

Belfiore, L, Spenkelink, LM, Ranson, M, van Oijen, AM & Vine, KL 2018,
‘Quantification of ligand density and stoichiometry on the surface of liposomes using
single-molecule fluorescence imaging’, Journal of Controlled Release, vol. 278, pp. 8086.

Author contributions: LB, LMS, MR, AMvO and KLV designed the experiments; LB
and LMS performed the experiments and analysed the data; LB and LMS wrote the
manuscript; MR, AMvO and KLV edited the manuscript for submission.
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5.1 Introduction
The work described in Chapter 2 of this thesis detailed the preparation and
characterisation of novel N-alkylisatin (N-AI)-loaded, plasminogen activator inhibitor-2
(PAI-2)-functionalised liposomes. The confirmation and quantification of PAI-2 ligand
attachment to the surface of liposomes were attempted using biochemical protein assays,
size-exclusion chromatography and Western blotting, but these methods could not
provide direct and robust quantification of the average number of ligands attached to the
surface of each liposome. This characteristic of an actively targeted liposome formulation
is essential to enable the optimisation of ligand density to ensure optimal tumour cell
uptake, as well as for quality control purposes such as accounting for batch-to-batch
variability. Ligand quantification is particularly important for dual-ligand liposomes, for
which the quantification of both the number and ratio of multiple different ligands
attached to the liposome surface is needed to achieve optimal target cell effect. Currently,
there are no methods to comprehensively characterise actively targeted liposomes in
terms of precise surface ligand quantification. Therefore, there is a need to develop new
methods to quantify the density and stoichiometry of ligands on the surface of ligandfunctionalised liposomes to facilitate their preclinical evaluation, pharmaceutical scaleup and manufacture, and ultimately, their utilisation in clinical applications.

5.1.1 Current approaches for liposome ligand quantification
Liposomes have been utilised as delivery systems for drugs and other molecules in vivo
for several decades (Grimaldi et al. 2016). Despite extensive research into the
development of nanoparticle-based therapeutics, all clinically approved liposome
formulations are non-ligand-directed, with efficacies relying solely on passive targeting
and accumulation (Estanqueiro et al. 2014). A comprehensive list can be found in Chapter
1, Table 1.2, and in the published literature (Shi et al. 2017). Active targeting strategies
using liposomes have been extensively explored in the preclinical setting, particularly
liposomes targeting tumour-associated receptors, with many reported formulations
demonstrating improved efficacy over non-ligand-directed liposomes (Lukyanov et al.
2004; Park et al. 2001). Given the general movement in the field towards actively targeted
nanotherapeutics, the lack of translation of ligand-directed liposome formulations into
clinical practice is somewhat surprising (Anchordoquy et al. 2017). Previous reviews
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have identified some of the likely reasons for this phenomenon, ranging from
methodological difficulties involved in the large-scale preparation of ligand-directed
liposomes, to the limitations of evaluating their efficacy in preclinical models that fail to
adequately recapitulate human tumours (Hare et al. 2017). For example, once liposomes
are administered intravenously, non-specific interactions of liposomes with a range of
plasma proteins may result in the formation of a protein ‘corona’ at the liposome surface,
effectively shielding liposome-bound targeting ligands from interacting with their target
receptors and therefore negating their intended tumour cell targeting ability (Caracciolo
et al. 2017).

The absence of molecular tools for the robust characterisation of complex liposomes may
also be contributing to the lack of clinically approved ligand-directed liposomes.
Specifically, no methodology exists to quantify the number of ligands covalently bound
to the surface of liposomes. Estimation of ligand conjugation is possible based on
preparation parameters, but direct measurement of total surface-bound protein using
standard biochemical assays has inherent limitations. For example, measurement of
surface-bound protein in an actively targeted liposome formulation using colourimetric
biochemical methods is challenging due to phospholipid interference in the measurement
of very low protein concentrations (Klegerman et al. 2002). Flow cytometric methods that
detect the insertion of fluorescently labelled micelles into liposomes as a proxy for
successful liposome functionalisation (Chapter 2, Section 2.3.9) have been reported but
are indirect and semi-quantitative (Mack et al. 2012). While current methods could
potentially be used to quantify the total amount of protein in a sample, they cannot provide
information about the average number of ligands bound to each liposome in a
formulation. Thus, there is a need for fine-scale, single nanoparticle resolution.

The lack of quantitative methodology poses a particular challenge for the development of
liposomes with more than one surface-bound ligand, since the determination of ligand
stoichiometry is important to control for batch-to-batch variability in the laboratory and
for clinical production (Belfiore, L. et al. 2018). The absence of rigorous quantification
protocols hinders high-quality large-scale manufacturing of ligand-directed liposome
formulations, which may introduce regulatory barriers and slow down their introduction
to the clinic. This is because without quantification methods, it is difficult to ascertain the
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effects of different liposome preparation or purification methods on the resultant ligand
density of the liposome formulation. For example, in the laboratory setting, size-exclusion
chromatography (SEC) is commonly used to remove unconjugated ligands from
liposomes but is not high-throughput. Alternative methods more amenable to scaling up,
such as high-speed centrifugation, are more favourable, but it remains unknown whether
centrifugation changes the ligand density of the final preparation. Such questions may be
answered using a robust quantitative methodology.

5.1.2 Single-molecule fluorescence microscopy
Single-molecule fluorescence microscopy is a high-resolution imaging technique that
removes ensemble averaging, allowing the direct visualisation of population distributions
and the precise characterisation of subpopulations (Monachino et al. 2017). The singlemolecule fluorescence microscope removes out-of-focus background fluorescence of the
imaged sample by utilising total internal reflection fluorescence (TIRF), enabling the
detection of individual fluorescently labelled molecules. Laser light of a specific
wavelength is coupled into the microscope objective, and the fluorescent signal from the
sample is detected with an electron-multiplying charge-coupled device (EMCCD) camera
(Fig. 5.1). By tracking the photobleaching steps of individual fluorescently labelled
molecules, the number of fluorophores per molecule and the total number of molecules
can be determined.
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Figure 5.1: Schematic overview of the single-molecule fluorescence microscope. Laser light of a
specific wavelength is coupled into the microscope objective. The fluorescent signal from the sample
is detected with an electron-multiplying charge-coupled device (EMCCD) camera.

Single-molecule methods have already proven to be important biophysical tools for
studying a wide variety of biological processes (Shashkova & Leake 2017), including
mechanisms of DNA replication (Ticau et al. 2017), conformational changes of enzymes
(Marchetti et al. 2017) and the composition and assembly of various multiprotein
complexes (Aggarwal & Ha 2016). However, single-molecule microscopy remains an
under-utilised technique in therapeutics development. Based on how the technique has
been previously used to quantify proteins that have been fluorescently labelled with
fluorophores (Choi et al. 2012; Tessler & Mitra 2011), it should be possible to use the
technique to count protein ligands bound to liposomes. Liposomes can be labelled with
fluorescent dyes, such as octadecyl rhodamine B chloride (R18), which only fluoresce
when bound to lipid membranes (Nunes-Correia et al. 2002). Lipid vesicles have
previously been imaged using single-molecule fluorescence microscopy in the context of
studying protein-membrane interactions (Chadda & Robertson 2016; Liu et al. 2010). In
a similar way, liposomes and other nanoparticles that have surface-attached protein (or
other) ligands can be studied using this high-resolution imaging technique.
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5.1.3 Experimental rationale
Despite the longstanding existence of liposome technology in drug delivery applications,
there have been no ligand-directed liposome formulations approved for clinical use to
date. This lack of translation is due in part to the absence of molecular tools available for
the robust quantification of ligands on the surface of liposomes, which is necessary for
optimising liposome preparation in the preclinical context, and eventually, to
comprehensively characterise an actively targeted liposome formulation as required for
clinical application. The successful development of a new and accurate method to
quantify liposome ligands should help facilitate the production of actively targeted
liposomes and their improved preclinical characterisation.

5.1.4 Aims
This chapter tested the hypothesis that single-molecule fluorescence microscopy can be
used to determine the number of protein ligands bound to functionalised liposomes.
Therefore, the overarching aim of this chapter was to develop single-molecule
fluorescence microscopy as a tool for the quantification of ligands bound to the surface
of liposomes. Specifically, the aims of this chapter were to:
1. Quantify the ligand density and stoichiometry of both single-ligand and dualligand liposomes using single-molecule fluorescence microscopy;
2. Determine the effect of size-exclusion chromatography and centrifugation on the
resultant ligand density of actively targeted liposome formulations; and
3. Determine the effect of conventional and post-insertion functionalisation
methods on the resultant ligand density of actively targeted liposome
formulations.

5.2 Methods
5.2.1 Labelling proteins with fluorophores
Human recombinant plasminogen activator inhibitor-2 (PAI-2), produced in-house by
previously published methods (Cochran et al. 2009), and trastuzumab (TZ, Herceptin®;
Genentech, CA, USA) were labelled with CF488 or CF647 succinimidyl ester fluorescent
dyes (Sigma-Aldrich, MO, USA) as per the manufacturer’s instructions. Absorbance at
280 nm (protein) and 488 nm or 647 nm (dye) was used to calculate the protein
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concentration and degree of labelling (DOL). DOL was further confirmed by electrospray
ionisation mass spectrometry (ESI-MS).

5.2.2 Electrospray ionisation mass spectrometry
Positive ion mass spectra of unlabelled and labelled proteins were acquired on a
quadrupole time of flight mass spectrometer (Micromass Q-TOF Ultima; Waters, MA,
USA) fitted with a Z-spray ionisation source. Samples in phosphate-buffered saline (PBS;
pH 7.4) were exchanged into deionised water containing 0.1% formic acid and made up
to a final concentration of approximately 10 μM. The mass spectra were acquired with a
capillary voltage of 2.6 kV, a cone voltage of 50 V, a source block temperature of 40 °C,
and a resolution power of 5000 Hz. Caesium iodide was used for external calibration.
Mass was calculated using MassLynx MS V4.1 (Waters, MA, USA).

5.2.3 Liposome preparation
Liposomes were prepared using the thin film hydration method as described previously
(Uster et al. 1996). Dipalmitoylphosphatidylcholine (DPPC), cholesterol, 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[(polyethylene glycol)-2000] (mPEG2000-DSPE)
and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene

glycol)-2000] (mal-PEG2000-DSPE) (Avanti Polar Lipids, AL, USA) in a 20:10:0.8:0.2
molar ratio (conventional (CO) method), or DPPC, cholesterol and mPEG2000-DSPE in a
20:10:0.6

molar

ratio

(post-insertion

(PI)

method),

were

dissolved

in

chloroform/methanol (2:1 v/v). For colocalisation experiments, liposomes were labelled
with octadecyl rhodamine B chloride (R18; Invitrogen, CA, USA) by adding R18 to the
chloroform/methanol solution in a 160:1 molar ratio (liposome phospholipid:R18).
Organic solvents were removed by rotary evaporation and subsequent freeze-drying to
form a lipid film.

Phospholipids were reconstituted in degassed HEPES buffer (115 mM NaCl, 20 mM
HEPES, 2.4 mM K2PO4, 1.2 mM CaCl2, 1.2 mM MgCl2; pH 7.4) at a concentration of 20
mM. Once reconstituted, liposomes were passed once through a 0.22 µm polyvinylidene
fluoride (PVDF) membrane (Merck Millipore, MA, USA) and then serially extruded 11
times through a 0.1 µm PVDF membrane using a syringe-driven extruding apparatus
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(Avanti Polar Lipids, AL, USA) at a temperature of 50°C (above the phase-transition
temperature of DPPC). Liposomes were analysed by dynamic light scattering (DLS) to
determine particle diameter using a Zetasizer APS (Malvern Instruments, Malvern, UK).
Liposomes were surface-functionalised with CF647 labelled PAI-2 and CF488 labelled
PAI-2 or TZ using either the CO method or the PI method (Fig. 5.2) (Iden & Allen 2001).

For the CO method, preformed liposomes were incubated with thiolated CF dye labelled
PAI-2 or TZ (at a molar ratio of 3333:1 liposome phospholipid:protein) for 2 h at room
temperature. For the PI method, micelles composed of 0.8 mM mal-PEG2000-DSPE and
0.2 mM mPEG2000-DSPE were prepared as per previously reported methods (Moreira et
al. 2002), and CF dye labelled PAI-2 or TZ was added to the micelles (at a molar ratio of
10:1, mal-PEG2000-DSPE:protein) to form functionalised micelles. Functionalised
micelles were added to preformed liposomes and heated to 60°C for 1 h to facilitate the
post-insertion of micelle lipids into the outer leaflet of the liposomes. Following the
liposome functionalisation steps, unbound protein was removed from liposomes via either
size exclusion chromatography (SEC) using Sepharose CL-4B (Sigma-Aldrich, MO,
USA) or repeated centrifugation at 20,000 x g for 1.5 h at 4°C. Liposomes were
resuspended in HEPES buffer (pH 7.4) for single-molecule fluorescence imaging.

Figure 5.2: Conventional and post-insertion methods for ligand conjugation. The conventional
method involves incubation of preformed liposomes with thiolated proteins (represented by green and
magenta stars), which attach covalently to the liposome surface via terminal maleimide functional
groups. The post-insertion method involves attaching thiolated proteins to maleimide-functionalised
micelles, which are then incubated with preformed liposomes at 60°C to facilitate the transfer of
micelle phospholipids with covalently attached proteins into the outer leaflet of the liposome bilayer.
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5.2.4 Intensity measurements for labelled proteins
Microscope coverslips were thoroughly cleaned to remove any hydrophobic and
hydrophilic contaminants that could cause background fluorescence from the glass. They
were first sonicated for 30 min in ethanol (Chem-Supply, SA, AUS) and then rinsed with
deionised water. Subsequently, they were sonicated for 30 min in 1 M potassium
hydroxide (KOH; Sigma-Aldrich, MO, USA) and rinsed with deionised water again.
After these sonication steps were repeated, the coverslips were dried with N2 (Tanner &
van Oijen 2010). CF dye-labelled proteins were diluted to a concentration of
approximately 10 pM and immobilised on the surface of the cleaned microscope coverslip
for visualisation on an inverted microscope (Nikon Eclipse Ti-E) with a CFI Apo Total
Internal Reflection Fluorescence (TIRF) 100X oil-immersion TIRF objective (NA 1.49,
Nikon). The green- and red-labelled proteins were excited at 1.5 W cm–2 with 488 nm
(Coherent, Sapphire 488-200 CW) and 647 nm (Coherent, Obis 647-100 CW) lasers,
respectively (Fig. 5.1). The signals were separated via dichroic mirrors (Photometrics,
DVΛ Multichannel Imaging System) and appropriate filter sets (Chroma). The imaging
was performed with an EMCCD camera (Photometics, Evolve 512 Delta).

For each measurement, at least two coverslips were used. For each coverslip, multiple (510) fields of view were imaged. Using ImageJ (National Institutes of Health, USA) with
in-house built plugins, the integrated intensity for single CF dyes over time was calculated
after applying a local background subtraction. Using a change-point step-fitting
algorithm, the intensity distributions for a single CF fluorophore were calculated (Fig.
5.3B) (Duderstadt et al. 2016; Watkins & Yang 2005). The histograms obtained were fit
with either a Gaussian or Poisson distribution function using MATLAB 2014b to give a
mean intensity of 3 ± 0.1 x 103 for CF647 (Fig. 5.3C) and 1.2 ± 0.6 x 104 for CF488. To
measure the number of fluorophores per protein, the initial fluorescence intensity per
protein was divided by the intensity of a single fluorophore.

5.2.5 Measurement of protein density on liposomes
To determine the average number of proteins per liposome, liposomes were imaged under
the same conditions as the proteins, and the fluorescence intensity per liposome was
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calculated analogously. The number of proteins per liposome was obtained by dividing
the liposome intensities by the intensity of a single protein.

5.2.6 Data analysis
All data analysis, including the generation of graphs and statistical tests, was performed
using GraphPad Prism software (version 7), unless stated otherwise. Data are presented
as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) as stated.
Pairwise comparisons were made using Student’s t-test, and multiple comparisons were
made using one-way ANOVA with Tukey’s post-test.

5.3 Results
5.3.1 Imaging CF647-labelled PAI-2
To first visualise PAI-2 using single-molecule fluorescence microscopy, the 45 kDa
protein was labelled with a small red fluorophore (CF647) and imaged using TIRF
microscopy, which allowed for the selective excitation of only the fluorescent species on
the coverslip surface and imaging of fluorescence from surface-immobilised proteins with
high contrast and low background (Fig. 5.3A). The intensity of the signal of every
individual protein was measured over time (Fig. 5.3B, black line). The fluorescence
intensity trajectories showed a stepwise decay towards zero due to photobleaching of the
fluorophores attached to the protein. As the height of a single step corresponds to the
intensity of a single fluorophore, the number of fluorophores per protein was determined
by counting the number of steps. Analysis of numerous spots enabled a distribution to be
fitted for the number of fluorophores per protein and for the fluorescence intensity per
fluorophore. The intensity of a single fluorophore was determined using an unbiased
change-point step-fitting algorithm (Fig. 5.3B, red line) (Duderstadt et al. 2016). The
mean intensity of a single CF647 fluorophore was 3 ± 0.1 x 103 (mean ± s.e.m., n = 962)
(Fig. 5.3C). By dividing the total intensity per protein by the intensity of a single
fluorophore, it was calculated that there are 1.5 ± 0.4 (mean ± s.d., n = 291) CF647
fluorophores per protein (Fig. 5.3D), with the width of the distribution in line with that
expected for a Poisson distribution. The measurements were repeated using the same
batch of protein measured in subsequent experiments, which found 2.0 ± 0.6 fluorophores
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per protein (data not shown). ESI-MS analysis found an average of 3 fluorophores per
protein for CF647-labelled PAI-2 (Appendix F).

Figure 5.3: Single-molecule imaging of CF647-labelled PAI-2. (A) Representative field of view of
CF647-labelled plasminogen activator inhibitor-2 (PAI-2) proteins immobilised on a cleaned
coverslip. (B) Example fluorescence intensity trajectories of individual proteins (black line) and
individual steps identified using a change-point algorithm (magenta line). (C) Histogram of the
intensity of a single CF647 fluorophore (fitted with a Gaussian distribution): 3 ± 0.1 x 103 (mean ±
s.e.m., n = 962). (D) Histogram of the number of CF647 fluorophores per protein (fitted with a Poisson
distribution): 1.5 ± 0.4 (mean ± s.d., n = 291).

5.3.2 Imaging CF647-labelled PAI-2-functionalised liposomes
To quantify the number of PAI-2 proteins attached to liposomes using single-molecule
fluorescence microscopy, liposomes were functionalised with CF647-labelled PAI-2 via
the PI method and visualised using TIRF microscopy under the same conditions that were
used to image the CF647-labelled PAI-2. To confirm that the fluorescence signal
observed in the imaging experiments originated from proteins bound to single liposomes,
liposomes were pre-labelled with the fluorophore R18 so that the encapsulated R18 acted
as a marker for liposomes that had an intact lipid bilayer (Serro et al. 2012). Using optics
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that split the image into a yellow and a red channel, the R18-labelled liposomes and
attached CF647-labelled PAI-2 proteins were visualised simultaneously but each on
different areas of the camera sensor to visualise the R18 fluorescence and the signal from
the red-labelled proteins, with a merge of the two signals revealing colocalisation as
indicated by white spots (Fig. 5.4A, top panel). Analysis of these images revealed that
88% of R18-labelled liposomes had at least one CF647-labelled PAI-2 protein attached.
The number of proteins per liposome was determined by dividing the average CF647
fluorescence intensity per liposome by the intensity of a single CF647-labelled PAI-2
protein, obtained previously (Section 5.3.1). The protein density was calculated to be 11
± 4 (mean ± s.d.) proteins per liposome (Fig. 5.4B). DLS analysis of the liposomes
indicated a liposome diameter of 153 ± 56 nm (mean ± s.d.) and a polydispersity index
of 0.041 ± 0.017 (mean ± s.d.) (Fig. 5.4C). R18-labelled liposomes prepared in parallel
using non-maleimide-functionalised micelles did not show colocalisation with CF647labelled PAI-2 when imaged by single-molecule fluorescence microscopy (Fig. 5.4A,
bottom panel).
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Figure 5.4: Imaging CF647-labelled PAI-2-functionalised liposomes. (A) Liposomes labelled with
octadecyl rhodamine B chloride (R18) (left) and CF647-labelled plasminogen activator inhibitor-2
(PAI-2) (middle) were imaged simultaneously (n = 14 fields of view, ~30 liposomes per field of view).
A merge of the two channels (right) showed a high degree of colocalisation (white spots). Liposomes
prepared in parallel using non-maleimide-micelles showed no colocalisation with protein signal (n =
14 fields of view, with ~10 liposomes per field of view). (B) Histogram of the number of proteins per
liposome, fitted with a Poisson distribution (black line): 11 ± 4 (mean ± s.d.). (C) Histogram of
liposome diameter measured by dynamic light scattering, fitted with a Gaussian distribution (black
line): 153 ± 56 (mean ± s.d.). Bars represent the mean ± s.d. (n = 3).

5.3.3 Inhibitory activity of CF647-labelled PAI-2 liposomes
A fluorogenic urokinase plasminogen activator (uPA) activity assay was performed to
determine whether quantification of PAI-2 by single-molecule imaging would enable
appropriate liposome sample dilution in the assay to achieve inhibition of uPA activity
by the PAI-2-functionalised liposomes. The assay was performed for the CF647-labelled
PAI-2-functionalised liposome sample before and after single-molecule quantification at
a molar ratio of 2:1 PAI-2:uPA. PAI-2 concentration of the liposome sample was
informed by either estimation based on preparation parameters (1.78 µM) or by single133

molecule data (45 nM). The single-molecule quantification (proteins per particle)
combined with liposome concentration (particles per mL) as determined by nanoparticle
tracking analysis (NTA; Chapter 2, Section 2.2.3.2) enabled calculation of the average
PAI-2 protein concentration of the liposome sample.

The result of the assay performed before single-molecule quantification indicated no
significant difference between the PAI-2 liposome treatment and positive control
(uninhibited uPA), indicating no measurable inhibitory effect of the PAI-2 liposomes
(Fig. 5.5A). When single-molecule quantification was performed on the sample to guide
the concentration of sample to be used in the assay, the PAI-2 liposome sample showed
significant (P < 0.01) inhibitory activity relative to the positive control (Fig. 5.5B),
indicating that PAI-2 bound to liposomes retained inhibitory activity against uPA when
combined with uPA at a true molar ratio of 2:1, as informed by single-molecule
fluorescence imaging.

Figure 5.5: Activity-based profiling of PAI-2-functionalised liposomes. The inhibitory activity of
plasminogen activator inhibitor-2 (PAI-2)-functionalised liposomes was determined using a
fluorogenic urokinase plasminogen activator (uPA) assay. (A) Prior to determination of PAI-2 ligand
density via single-molecule imaging, estimation of PAI-2 concentration was 1.78 µM. This estimate
was used to dilute the liposome sample to give a 2:1 PAI-2:uPA (inhibitor:enzyme) molar ratio. (B)
After single-molecule imaging was performed, a PAI-2 concentration of 45 nM was indicated for the
liposome preparation, which was used to dilute the liposome sample to yield a 2:1 molar ratio of PAI2:uPA. Data are the mean ± s.d. (n = 3). ** = P < 0.01, ns = not significant.

5.3.4 Ligand stoichiometry of dual-functionalised liposomes
To explore the ability of single-molecule fluorescence imaging to quantify small
differences in protein density, the stoichiometry of two fluorescently-labelled proteins
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was varied during the preparation of a series of dual-functionalised liposomes and their
ratio quantified. To negate potential confounding effects that could arise from using two
different proteins, such as protein size and reactivity, PAI-2 was labelled with either
CF647 or CF488 (0.9 kDa; intensity of a single CF488 fluorophore 1.2 ± 0.6 x 104 (mean
± s.e.m., n = 796); 4.5 ± 2.2 (mean ± s.d., n = 104) fluorophores per protein) to enable
imaging of the two differently labelled (i.e. red and green) proteins. Liposomes were
functionalised via the PI method using red-labelled (CF647) and green-labelled (CF488)
PAI-2 at molar ratios of 1:1, 2:1, 5:1 and 10:1 (red:green) while keeping the total amount
of protein constant for each liposome preparation. The two proteins were visualised
simultaneously using dual-colour imaging and the protein density was determined as
above. At a 1:1 molar ratio, 51 ± 2 % of the total number of proteins per liposome had a
red label and 49 ± 2 % had a green label. Analysis of the other preparations revealed that
changing the ratios of the two labelled proteins during preparation similarly altered the
ratios of proteins incorporated into the liposome, as quantified by single-molecule
fluorescence microscopy (Fig. 5.6A). This relationship was linear, with an R2 value of
0.9655 (Fig. 5.6B). Imaging of the 1:1 dual-functionalised liposomes showed high levels
of colocalisation of red and green spots (white spots), indicating that a high proportion of
liposomes were indeed dual-functionalised (Fig. 5.6C).
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Figure 5.6: Ligand stoichiometry of dual-functionalised liposomes. (A) Histograms of the
measured fraction of red-labelled (magenta) and green-labelled (green) proteins per liposome, where
1:1 (n = 146), 2:1 (n = 111), 5:1 (n = 232) and 10:1 (n = 137) molar ratios of red to green proteins
were used during liposome preparation. Black lines represent Gaussian fits to the data. (B) Measured
ratio of the fraction of red-labelled proteins over the fraction of green-labelled proteins as a function
of the molar ratio used during preparation (mean ± s.e.m.). The errors in the molar ratio are pipetting
errors calculated from the manufacturer-published imprecision ranges of the pipettes used to add the
micelle volumes to the liposomes during preparation. (C) Representative field of view showing merge
of red and green channels of the 1:1 liposome sample, with colocalisation indicated by white spots.

5.3.5 Centrifugation of liposomes to remove unbound ligands
Size-exclusion chromatography (SEC) is a commonly used but low-throughput method
for functionalised liposome preparation, whereas alternative methods, such as high-speed
centrifugation, may be an option to streamline the production process of functionalised
liposomes for preclinical testing. In Chapter 2, high-speed centrifugation was tested as a
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method to efficiently remove unconjugated PAI-2 protein from PAI-2-functionalised
liposome samples. The results indicated that free PAI-2 protein could be removed from
liposomes, with a high recovery of liposomes in the sample following repeated
centrifugation. However, the effect of repeated high-speed centrifugation on PAI-2
protein attachment to the liposome in the final formulation remained unknown. To test
the effect of this method on the final degree of PAI-2 attachment to liposomes, dualfunctionalised PAI-2 liposomes were prepared and functionalised via the PI method as
per Section 5.3.4 using a 1:1 molar ratio of CF647-labelled PAI-2 and CF488-labelled
PAI-2. Following the functionalisation step, any unconjugated PAI-2 was removed from
the liposomes using either SEC or repeated high-speed centrifugation (5 cycles for 90
min at 20,000 x g). Single-molecule imaging of the two final liposome samples revealed
similar numbers of red and green proteins attached to the liposomes (Fig. 5.7). The total
number of attached PAI-2 proteins per liposome was 10.8 and 14.8 for SEC and
centrifugation liposomes, respectively.

Figure 5.7: Size-exclusion chromatography and centrifugation of liposomes. Liposomes
functionalised with both CF647-PAI-2 and CF488-PAI-2 in a 1:1 molar ratio were purified using
either size-exclusion chromatography (left) or repeated centrifugation at 20,000 x g (right) to remove
any unbound PAI-2. Single-molecule fluorescence microscopy of the liposomes was performed to
quantify the number of CF647-labelled PAI-2 proteins and CF488-labelled PAI-2 proteins attached to
the purified liposomes. The black lines represent Gaussian fits to the data. Values are means ± s.e.m.
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5.3.6 Characterisation of PAI-2-TZ dual-functionalised liposomes
Quantification of ligand density and stoichiometry on the surface of dual-functionalised
liposomes is important to optimise preparation parameters and select the most appropriate
method of ligand conjugation to the liposome surface, to enable the production of a dualligand targeted liposome that is optimally effective in its intended application. In the
context of tumour targeting, liposomes bearing two different targeting ligands need to be
able to bind successfully to their respective target cell receptors to enable liposome
internalisation into the target cell. However, the current lack of methodology to determine
the number and ratio of two different ligands on the surface of liposomes means that the
development and optimisation of dual-functionalised liposome formulations is limited.
To explore the utility of single-molecule quantification in the characterisation of novel
clinically relevant ligand-directed liposomes, dual-ligand liposomes were prepared via
both the CO and the PI methods of liposome functionalisation (Fig. 5.1). PAI-2 and
trastuzumab (TZ, Herceptin®; 145 kDa) were labelled with red and green CF
fluorophores, respectively, and conjugated to preformed liposomes using a 1:1 molar ratio
of PAI-2:TZ. DLS showed a small but significant increase in liposome diameter
following functionalisation for PI, but not CO, liposomes (Appendix G). Single-molecule
fluorescence imaging and data analysis of the dual-functionalised liposomes were
performed as outlined in Section 5.3.4. Using single-molecule imaging, the ratio of PAI2 to TZ of the dual-functionalised liposomes was 17 ± 18 (n = 115) for liposomes prepared
via the CO method and 2.1 ± 2.5 (n = 167) for liposomes prepared via the PI method (Fig.
5.8). Imaging of the samples indicated that liposomes prepared via the PI method showed
higher levels of colocalisation than the CO method.
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Figure 5.8: Imaging of PAI-2-TZ dual-functionalised liposomes. (A) Representative field of view
during single-molecule imaging of plasminogen activator inhibitor-2 (PAI-2)/trastuzumab (TZ)
liposomes prepared via the conventional (left) and post-insertion (right) methods. (B) Histograms of
the number of proteins per liposome. The black lines represent Poisson distribution fits to the
histograms. Due to the large number of PAI-2 proteins in the conventional sample, heterogeneities
within the sample broadened the histogram and obscured the Poisson distribution. Therefore, this
histogram was fitted with a Gaussian distribution.
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5.4 Discussion
The quantification of ligands attached to the surface of liposomes is important for the
comprehensive characterisation, production optimisation and quality control of ligandfunctionalised liposome formulations. The overarching aim of this chapter was to use
single-molecule fluorescence microscopy as a tool for the quantification of ligands bound
to the surface of liposomes, which was ultimately successful. In this chapter, the
quantification of proteins attached to the surface of liposomes was achieved for the first
time using single-molecule fluorescence imaging to count the photobleaching steps of
fluorescently labelled proteins bound to liposomes. Liposome and protein signals showed
a high degree of colocalisation, indicating that proteins were bound to intact liposomes
and that proteins could be visualised successfully using the single-molecule fluorescence
microscope. The average number of attached proteins per liposome was determined to be
11 ± 4, and imaging of dual-functionalised liposomes revealed stoichiometries of two
attached proteins in accordance with the molar ratios of protein added during preparation.
Single-molecule quantification indicated that centrifugation of liposomes slightly
increased the final ligand density of liposomes relative to SEC due to the selection of a
highly monodisperse population of liposomes in a particular size range, as expected.
Single-molecule imaging revealed that the PI method generated dual-functionalised
liposomes with a more equal representation of two differently sized protein ligands than
the CO method, demonstrating the ability of the former method to enable superior control
of the final liposome protein densities (Allen & Cullis 2013). Overall, this chapter has
demonstrated the utility of single-molecule fluorescence imaging in the quantification of
the density and stoichiometry of ligands attached to the surface of liposomes, which
enables superior characterisation of functionalised liposomes in the preclinical testing
context.

The lipophilic dye R18 has been previously used in single-molecule fluorescence imaging
experiments (Otterstrom et al. 2014) and was used in this work to visualise intact
liposomes and image proteins conjugated to liposomes, rather than imaging free proteins
in the sample. Liposomes prepared without maleimide-PEG were used to confirm that
only covalently attached proteins colocalised with liposomes in imaging experiments.
The lack of observed colocalisation (Fig. 5.4) demonstrates that non-specific binding of
PAI-2 proteins to liposomes is minimal, as would be expected given the mechanism of
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covalent conjugation of ligands to the liposome surface (Iden & Allen 2001) and given
that the methods used for purification were suitable. The fluorescence intensity of the
R18-labelled liposomes was variable during imaging and this coincided with a mix of
larger and smaller spots observed in the field of view (Fig. 5.4). Given that the R18
molecule partitions in lipid membranes and more R18 molecules can associate with the
bilayers of larger liposomes, this correlation is expected. Similarly, the calculated average
number of attached PAI-2 proteins per liposome was variable, ranging from 3 to 17
proteins. When the same batch of liposomes was analysed by DLS to determine the
average liposome diameter of the sample, the relative width of the liposome size
distribution (0.36) was found to correlate with the relative width of the distribution of the
number of proteins per liposome (0.37) as determined by single-molecule imaging (Fig.
5.4). This suggests that the width of the distribution for the number of proteins per
liposome is a result of the heterogeneity in liposome size, as larger liposomes have a
greater number of attached proteins than smaller liposomes due to the greater number of
mal-PEG moieties available for ligand conjugation to the liposome surface (Allen et al.
1995).

The addition of a 1:1 molar ratio of red-labelled and green-labelled PAI-2 to the
liposomes during the liposome preparation step resulted in a 1:1 measured ratio via singlemolecule imaging in the liposome formulation (Fig. 5.6). This observation indicated that
the two different fluorophores did not affect protein attachment to the liposome surface,
and that the two proteins were incorporated into the liposome in the same 1:1 ratio as their
input stoichiometry in the formulation process. In contrast to preliminary experiments in
which a 1:4 ratio of maleimide-PEG:methoxy-PEG was used in the liposome formulation,
resulting in an average of 2-3 attached proteins per liposome (data not shown), the
maleimide-PEG:methoxy-PEG ratio was changed to 4:1 for the ratiometric experiment in
order to increase the total available sites for protein conjugation. Increasing the number
of total proteins bound to the liposome surface enabled better detection of the variation
between the different protein ratios used and a more robust calculation of ratios. This
change resulted in the attachment of 8-12 proteins per liposome, corresponding to an
approximate 4-fold increase in attached protein when the maleimide concentration was
also increased 4-fold. The increased total protein of the liposomes was particularly
important for the 10:1 liposome sample due to the fact that only dual-functionalised
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liposomes were analysed (i.e. only liposomes that had at least one red-labelled and one
green-labelled protein attached), resulting in a much lower number of dual-functionalised
liposomes available in the sample for analysis than for the 1:1 sample. This explains the
larger calculated error in the measured ratio of the 10:1 sample (Fig. 5.6). Nonetheless,
the ratiometric experiment showed a linear correlation between input and measured ratio
as determined by single-molecule fluorescence imaging, highlighting the ability of the
single-molecule method to quantify small changes in protein attachment in dualfunctionalised liposomes.

In Chapter 2, high-speed centrifugation was explored as an alternative to the
conventionally used but low-throughput SEC to remove unconjugated PAI-2 from PAI2-functionalised liposomes. Centrifugation is commonly used to remove unencapsulated
soluble drug and other small molecules from liposomes (Yalcin et al. 2018), as liposomes
and other nanoparticles pellet under conditions of high speed centrifugation, while soluble
small molecules remain in solution for removal. Following centrifugation of dual-ligand
liposomes to remove unconjugated red- and green-labelled PAI-2, single-molecule
quantification determined that the total number of attached proteins was higher for
centrifuged liposomes relative to size-exclusion purified liposomes (14.8 and 10.8
proteins, respectively) (Fig. 5.7). However, the ratio of the two attached proteins was
similar to liposomes purified using SEC. While it is encouraging that repeated high-speed
centrifugation did not remove the proteins from the liposome surface, the small difference
in protein attachment observed between the two methods is likely due to the fact that
centrifugation selects for larger liposomes. As larger liposomes pellet before smaller
liposomes when centrifuged, the distribution of the liposome population is narrowed with
each centrifugation step as the larger pelleted liposomes are recovered and the smallest
liposomes that remain in solution are removed in the wash steps. Indeed, in Chapter 2 it
was noted that the average diameter of a liposome sample increased from 148.0 nm to
153.9 nm following repeated centrifugation, with 77.1% retention of particles following
centrifugation (Chapter 2, Table 2.3).

In the case of ligand-functionalised liposomes, larger liposomes containing more
phospholipid groups and liposome constituents have a greater number of maleimide-PEG
functional groups in the liposome bilayer and therefore have a greater number of proteins
142

attached to the liposome surface. Since centrifugation selects for larger liposomes with
greater numbers of attached proteins, the centrifuged sample of liposomes had a higher
average number of proteins per liposome. This observation is also supported by the R18
liposome experiment (Section 5.3.2), which found a direct correlation between average
liposome size and total number of attached PAI-2 proteins. Therefore, centrifugation did
not appear to remove conjugated PAI-2 from the surface of liposomes, although the final
liposome population obtained was slightly altered for this reason. While the
centrifugation method is high-throughput, allows for the production of multiple different
liposome preparations in series and results in a high recovery of liposomes (Chapter 2,
Section 2.3.7), the inherent selection towards larger liposomes and resultant narrowing of
the final liposome distribution should be considered as a factor in the production process.

Single-molecule fluorescence microscopy was used to compare the effect of the
conventional and post-insertion functionalisation methods on the resultant ligand density
of actively targeted liposome formulations. Previous research has indicated that there are
no significant differences between single-functionalised liposomes produced via the two
methods in terms of uptake or cytotoxic effect in vitro and in vivo (Iden & Allen 2001).
However, the effect of these functionalisation methods on dual-functionalised liposomes
has not been determined due to the lack of methodology to quantify the density and
stoichiometry of two different proteins attached to the surface of liposomes. In this
chapter, PAI-2/TZ dual-functionalised liposomes prepared using two different
functionalisation methods revealed notable differences in the final composition of the
liposomes as measured by single-molecule fluorescent imaging (Fig. 5.8). When a 1:1
molar ratio of PAI-2 and TZ was used in the conventional preparation method, the
calculated number of attached PAI-2 proteins per liposome was 17 times higher than the
number of TZ antibodies. In contrast, the incorporation of PAI-2 and TZ was more
balanced (~2:1 PAI-2:TZ) when the post-insertion method was used to prepare the
liposomes.

The differences between the two liposomes are unsurprising when the differences
between the two functionalisation methods are considered (Fig. 5.2). The conventional
method involves incubation of a small protein (45 kDa) and a large antibody (150 kDa)
with preformed liposomes, where differences in protein size (i.e. steric hindrance on rates
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of reaction) and reactivity (i.e. the number of available sites for conjugation) may affect
their equal incorporation into the liposomes. The incorporation of these two proteins of
different sizes introduces a degree of competition between them for binding to the
maleimide-PEG at the liposome surface. For conventional liposomes, it was observed that
the degree of colocalisation of the two proteins (indicating dual-functionalised liposomes)
was lower than that of post-insertion liposomes, which may indicate that the presence of
the larger TZ antibody at the liposome surface caused a degree of steric hindrance to PAI2 attachment, resulting in fewer dual-functionalised liposomes and a larger proportion of
liposomes with only TZ attached (i.e. TZ-functionalised liposomes).

In contrast, the post-insertion method showed a high degree of colocalisation between
PAI-2 and TZ, indicating that a greater number of dual-functionalised liposomes were
successfully produced using this method. The post-insertion method negates the effects
of protein differences through the simultaneous insertion of two separate preformed
protein-functionalised micelles into the liposomes (Iden & Allen 2001). This means that
each protein is given the opportunity to covalently attach to all available micelle
maleimide-PEG groups without competition from the other protein before all groups are
then transferred into the liposome outer leaflet. Theoretically, this would result in
liposomes with a more even distribution of the two proteins at the liposome surface, and
this is corroborated by the single-molecule quantification method used in this chapter.
The quantification of PAI-2 and TZ at the surface of liposomes as outlined in this chapter
provides a rationale for the use of the post-insertion method in the production of dualfunctionalised liposomes, in particular for those that have two (or more) very disparate
proteins attached in terms of their size and/or reactivity. This aspect is relevant to the
clinical setting, where liposomes used to target heterogeneous tumour cell populations
would likely bear two different targeting ligands (Chapter 1, Sections 1.4 and 1.6.3).
Therefore, the application of single-molecule quantification enables optimisation of the
preparation protocol in order to allow for a better control of the stoichiometry of the two
ligands at the liposome surface.

Single-molecule fluorescence imaging enabled, for the first time, quantification of the
average number of PAI-2 proteins per liposome for PAI-2-functionalised liposomes,
which enabled a more accurate determination of the PAI-2 concentration of liposome
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samples. The analysis of liposomes by nanoparticle tracking analysis (Chapter 2, Section
2.2.3.2) allowed the determination of liposome concentration (number of particles per
mL), and this value combined with the single-molecule quantification (number of PAI-2
proteins per particle) enabled the calculation of the average PAI-2 protein concentration
of the liposome sample, which was 45 nM. Prior estimation of the average PAI-2 protein
concentration of the liposome sample without the single-molecule data and based only on
preparation parameters, including estimated sample loss and dilution factors, indicated a
PAI-2 concentration of 1.78 µM. The fluorogenic uPA activity assay was performed for
the CF647-labelled PAI-2-functionalised liposome sample both before and after singlemolecule quantification at a molar ratio of 2:1 PAI-2:uPA, with the PAI-2 concentration
of the sample informed by either estimation or single-molecule data. Prior to singlemolecule quantification, the assay indicated no significant difference between the PAI-2
liposome treatment and positive control (uninhibited uPA), indicating no measurable
inhibitory effect of the PAI-2 liposomes (Fig. 5.5). When single-molecule quantification
was performed on the sample to guide the concentration of sample to be used in the assay,
the PAI-2 liposome sample showed significant (P < 0.01) inhibitory activity relative to
the positive control, indicating that PAI-2 bound to liposomes retained inhibitory activity
against uPA when combined with uPA at a true molar ratio of 2:1, as informed by singlemolecule fluorescence imaging. This highlights the ability of single-molecule
quantification to enable more accurate determination of the effect of liposome ligand
density on liposome ligand function, as reflected in a sensitive functional assay.

To further demonstrate the applicability of single-molecule fluorescence microscopy as a
quantification tool for ligand-targeted nanomedicine development, future work could
utilise the methods reported here to demonstrate correlations between the number of
targeting ligands at the liposome surface and functional cellular effects. For example,
single-molecule quantification of liposome ligand density could help determine the
optimal number of ligands for maximum receptor binding, target cellular uptake and
therapeutic effect, or could determine the functional effects of targeted liposomes
produced by different methods. Previous studies have demonstrated that the modulation
of liposome ligand density, achieved by changing the starting maleimide-PEG
concentration of the formulation, affects cellular binding and uptake (Chu et al. 2016;
Gayong et al. 2016; Li, H et al. 2016). The single-molecule method described here could
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be used in future work to further confirm such findings, and also to elucidate additional
characteristics of ligand-directed liposomes. For example, the method could be used to
determine inner and outer leaflet labelling of liposomes produced by the post-insertion
method where heat is used, since it is possible that proteins may insert into the inner
leaflet of the liposomes and therefore not be available for cell targeting. The
quantification of inner and outer leaflet labelling of liposomes could be elucidated by
single-molecule imaging using dyes (e.g. pH-sensitive dyes) as per previously reported
methods (Otterstrom et al. 2014).

The single-molecule quantification technique reported in this chapter appears to be an
accurate and high-throughput method, with the ratiometric experiment demonstrating the
reproducibility of the method across different batches of liposomes. The number of
fluorophores attached per protein (degree of labelling) using the same protein sample was
measured in independent experiments, which found no variation between the calculated
values. PAI-2 protein labelled with CF647 dye was determined to have 1.5 ± 0.4
fluorophores per protein, and when this measurement was repeated several months later
with the same labelled protein, the single-molecule method found 2.0 ± 0.6 fluorophores
per protein (data not shown). In addition, single-molecule measurements from two
different coverslips for the same batch of liposomes found 11.0 ± 2.2 and 13.0 ± 2.1 PAI2 proteins per liposome (data not shown). As described in Section 5.2.5, the singlemolecule method requires determination of the degree of fluorescent labelling of the
protein via single-molecule imaging in addition to imaging of the functionalised
liposomes. This procedure is straightforward, only needs to be done once for a newly
labelled ligand, and can be done at the same time as imaging of the liposome samples.
Once determined, multiple liposome samples that have been functionalised with that
ligand can then be imaged and the data analysed using established protocols. Data
acquisition can easily be further scaled up and automated, and the analysis pipeline can
readily be converted to an automated process to improve the throughput of the method
(Monachino et al. 2017).

While the work presented in this chapter explored the quantification of a small protein
ligand and a whole antibody on the surface of liposomes, in principle, the single-molecule
approach reported in this thesis could also be applied to other surface ligand types and
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nanoparticle systems. Quantification of other commonly used nanoparticle ligand types,
such as antibody fragments, small peptides and aptamers, is possible, provided that the
ligands can be fluorescently labelled for single-molecule imaging. Indeed, previous
studies have utilised single-molecule imaging for quantifying fluorescently labelled
peptides (Liu et al. 2010). Single-molecule fluorescence imaging techniques have been
used to quantitatively characterise peptide-binding to lipid bilayers in order to understand
the structure and function of membrane-bound proteins (Fox et al. 2009). More recently,
single-molecule imaging was used to visualise the three-dimensional motions of
membrane peptides in supported lipid bilayers by taking advantage of the surface-induced
fluorescence attenuation of single emitting fluorophores (Li, Y et al. 2016). In addition to
liposomes, single-molecule imaging could also be utilised in the quantification of ligands
attached to the surface of other types of nanoparticles (Shashkova & Leake 2017), as
previous research has shown successful application of single-molecule fluorescence
microscopy analysis with various nanoparticle types, such as solid lipid nanoparticles
(Zoubari et al. 2017), polymeric nanoparticles (Langdon et al. 2015), micelles (Cheng et
al. 2013) and dendrimers (Younghoon et al. 2013). Such studies further support the
suitability of single-molecule fluorescence microscopy for the characterisation of a wide
variety of ligand types for ligand-functionalised nanoparticle development.

The single-molecule quantification method reported in this chapter is not without
limitations. For example, the formation of a protein corona around the surface of
systemically administered nanoparticles represents a potential problem for the ability of
functionalised liposomes to successfully bind to their target cells in vivo. Quantifying
non-specific protein adsorption to the surface of nanoparticles to determine the effect of
this on nanoparticle functionality cannot be achieved using the single-molecule approach
as this method simply counts the number of fluorescently labelled ligands covalently
attached to the liposome surface. Proteins in biological media that may adsorb to the
liposome surface and ‘shield’ ligands by forming a protein corona would not change the
number of ligands covalently bound to the liposome, only (potentially) the functional
activity of the ligands, which the single-molecule imaging method does not measure. How
the liposome ligand density changes after exposure to biological media is a question that
cannot be answered by single-molecule imaging, but it is an important question for the
nanomedicine field more broadly. Therefore, the development of additional
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characterisation methods for ligand-functionalised liposomes within the biological
context is necessary to facilitate successful preclinical evaluation and clinical translation.

5.5 Conclusion
The work presented in this chapter demonstrates the practical utility of single-molecule
fluorescence microscopy to quantify the number of protein ligands bound to the surface
of liposomes, which represents a key step forward in the characterisation and evaluation
of actively targeted nanotherapies. Using this technique, ligand quantification was
achieved for single-ligand and dual-ligand liposomes, and the methods used to prepare
and functionalise actively targeted liposomes were successfully characterised for their
effect on resultant liposome ligand attachment. By enabling the quantification of surfacebound ligands, this single-molecule imaging technique can be used to optimise liposome
preparation protocols, assist with the scale up of liposome preparation processes, and
allow for batch-to-batch quality control in a preclinical or commercial production setting.
Therefore, the comprehensive characterisation of preclinical ligand-functionalised
liposomes using single-molecule fluorescence imaging may help improve the preclinical
development of novel actively targeted liposomal drug delivery systems for cancer
therapy and facilitate the translation of such nanotherapies from the laboratory through to
clinical use.
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Chapter 6:
Conclusions and Future Directions

Dual-targeted drug-loaded liposomes
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6.1 Introduction
The development of more effective treatments for metastatic breast cancer remains an
important area of research since it is a global health problem and there is currently no
cure for metastatic disease. The urokinase plasminogen activator system has been
recognised to play an important role in the ability of cancer cells to escape the primary
site of the tumour and colonise other parts of the body. This system is particularly relevant
in breast cancer metastasis, including in the human epidermal growth factor receptor 2
(HER2)-positive subtype and the triple-negative breast cancer (TNBC) subtype, both of
which have an aggressive disease profile and poor prognosis. Hence, targeting this system
using novel approaches may be effective in the treatment of metastatic breast cancer.
Plasminogen activator inhibitor-2 (PAI-2) has previously been used to target the
urokinase plasminogen activator receptor (uPAR) and deliver cytotoxins to breast cancer
cells. The work described in this thesis aimed to build upon this concept by attaching
PAI-2 to the surface of PEGylated liposomes containing the potent cytotoxin Nalkylisatin (N-AI), for increased and selective drug delivery to uPAR-positive breast
cancer cells. Therefore, the work presented in this thesis explored the preparation,
characterisation, in vitro evaluation and in vivo evaluation of novel N-AI-loaded PAI-2functionalised liposomes for targeting uPAR in breast cancer.

6.2 N-AI PAI-2 liposomes can be prepared by conventional methods
In order to facilitate the uPAR-mediated uptake of N-AI-loaded liposomes into breast
cancer cells, previously reported methods were optimised to create novel N-AI-loaded
liposomes that were surface-functionalised with PAI-2. Novel N-AI-loaded PAI-2functionalised (N-AI PAI-2) liposomes were successfully prepared and characterised. NAI PAI-2 liposomes were 141.1 ± 5.0 nm in diameter, were monodisperse (polydispersity
index of 0.086 ± 0.030) and had a zeta potential of –4.66 ± 0.52 mV. The liposomes
contained N-AI at a concentration of 2.2 mM, significantly enhancing the aqueous
solubility of N-AI for drug delivery applications. PAI-2 conjugation to the surface of NAI-loaded liposomes was confirmed using size-exclusion chromatography and Western
blotting. A PAI-2 inhibitory activity assay confirmed that PAI-2 attached to the surface
of liposomes remained active against urokinase plasminogen activator (uPA) after
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conjugation, making N-AI PAI-2 liposomes suitable for further in vitro and in vivo
evaluation against breast cancer cells.

The methods used to prepare N-AI PAI-2 liposomes could be further improved to
facilitate high-throughput production for subsequent testing and analysis. The continual
development of new methods and technologies to prepare liposomes is expected to help
facilitate their clinical development. In order to meet the demands for the large-scale
preparation of liposomes as required for clinical use, microfluidic approaches have
recently emerged as a way to produce large quantities of liposomes of a uniform size and
consistent physicochemical properties, which may be a way forward for efficient and
cost-effective liposome preparation (Jahn et al. 2004).

Recent technological developments have contributed to a shift away from conventional
covalent coupling methods of attaching ligands to the surface of liposomes and towards
the specific engineering of antibodies and aptamers for cellular targeting applications.
The use of short-chain antibody fragments as targeting ligands, as opposed to whole
antibodies, is a promising strategy for creating actively targeted liposomes, as the ligands
can be engineered to optimise binding affinity and other physical properties for improved
tumour cell targeting and uptake. As antibody fragments are smaller than whole
antibodies, the immunogenicity may be lower and the in vivo circulation time of the
resultant targeted liposomes more appropriate (i.e. more prolonged) for tumour targeting
(Cheng & Allen 2010). Protocols to develop bispecific immunoliposome formulations
using two different single-chain FV fragments on the liposome surface to target two
different tumour cell populations have been reported, where each ligand shows a retention
of binding activity for its target receptor (Mack et al. 2012). Multivalent liposomal
therapeutic antibody constructs that bind to more than one antigen have been reported
(Chiu et al. 2007), as well as PEGylated hyper-branched polymers bearing two different
targeting ligands (Pearce et al. 2016).

The use of bispecific antibodies bound to the surface of liposomes may facilitate the
recognition of multiple antigens to achieve the same effect attained with conventionally
prepared dual-ligand liposomes (Howard et al. 2016). The successful development of a
liposome with a single surface-attached bispecific antibody that can recognise and bind
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to both endoglin and fibroblast activation protein demonstrates the feasibility of this
approach in dual-targeting (Rabenhold et al. 2015). These approaches allow for more
control in the stoichiometry of the two targeting ligands (i.e. always 1:1) compared to the
traditional conjugation of two separate ligands, and for this reason may aid the production
and regulatory processes required for clinical use of actively targeted liposomes. Such
developments in antibody engineering mean that future nanoparticle-based drug delivery
strategies can more easily permit targeting of multiple cell types, including genetically
distinct tumour cells, but also key cells of the tumour microenvironment that are known
to play a role in supporting tumour growth and spread, including immune cells and cancer
stem cells (Angelova et al. 2017).

6.3 N-AI PAI-2 liposomes are cytotoxic to breast cancer cells
The cellular uptake, localisation and cytotoxicity of N-AI PAI-2 liposomes were
successfully evaluated in vitro using breast cancer cells grown in monolayers and as
multicellular tumour spheroids. As the binding of extracellular PAI-2 to uPAR-bound
uPA results in the receptor-mediated endocytosis of the PAI-2/uPA/uPAR complex, PAI2 can be used as a targeting ligand for the intracellular delivery of covalently attached
cytotoxin to uPAR-positive tumour cells (Cochran et al. 2011). The cellular uptake of
fluorescently labelled PAI-2 liposomes into MDA-MB-231 breast cancer cells (uPARpositive) was significantly increased (P < 0.01) relative to MCF-7 breast cancer cells
(uPAR-negative), as measured by flow cytometry. Confocal microscopy confirmed the
uptake of PAI-2 liposomes and localisation within the cytoplasm and lysosomes of cells.
N-AI PAI-2 liposomes showed a potent cytotoxic effect against both MCF-7 and MDAMB-231 cells grown in 2D (IC50 values of 31.84 ± 8.20 µM and 5.40 ± 1.14 µM,
respectively) and in 3D as multicellular tumour spheroids (IC50 values of 40.2 ± 4.0 µM
and 60.4 ± 7.1 µM, respectively), which supports the use of uPAR as a therapeutic target
and warranted further evaluation of N-AI PAI-2 liposomes in vivo.

The gradual movement away from simplistic monolayer and monoculture cell models and
towards the utilisation of models that better recapitulate in vivo tumours, including
computer simulated models (Dionysiou et al. 2006), ex vivo multicellular tumour spheroid
models (Jiang et al. 2017), co-culture models (Lee et al. 2014), biomimetic microfluidic
tumour microenvironment models (Tang et al. 2017) and patient-derived xenografts
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(Shafaee & Ellis 2017), will allow for the inclusion of some aspects of tumoural
heterogeneity and factor in the contribution of the tumour microenvironment in the
evaluation of novel nanotherapies. As current in vitro models do not reproduce the
complex vascular network, hypoxia, interstitial fluid pressure and fluid shear observed in
the in vivo tumour microenvironment (Li & Lu 2011), a key limitation of multicellular
tumour spheroid models for testing new drug-loaded nanotherapies is that these static
models do not account for transport across the vascular endothelium (Maeda 2015). The
development and validation of in vitro models that recapitulate aspects of the enhanced
permeability and retention (EPR) effect is an emerging field of research. Static 3D coculture models comprised of vascular network structures and tumour spheroids can be
used for incorporating the effect of vascularisation in drug testing experiments
(Swaminathan et al. 2017). Microfluidic-based platforms can be used for monitoring
nanoparticle delivery in a 3D environment that recapitulates circulation, extravasation
and delivery to the tumour across the interstitial space (Li et al. 2018). These models also
enable the examination of tumour cell and vascular cell interactions and how these
interactions affect drug delivery, which is an important aspect of evaluating novel
liposome formulations (Tang et al. 2017). These approaches are expected to help guide
nanotherapy research in its early stages and provide a more accurate understanding of the
expected efficacy should the formulation progress to in vivo studies or clinical trials.

6.4 PAI-2 enhances the tumour accumulation of liposomes in vivo
Following the in vitro evaluation of N-AI PAI-2 liposomes, the biodistribution,
pharmacokinetic profile and anti-tumour efficacy of the liposomes were explored in vivo
using mouse models of breast cancer. N-AI PAI-2 liposomes were found to have a plasma
circulation half-life of 5.82 hours, with clearance predominately via the spleen, yet
significantly increased tumour uptake of N-AI PAI-2 liposomes relative to N-AI
liposomes was observed. No significant differences were noted in primary or metastastic
anti-tumour growth in two mouse models of TNBC. Further research is needed to clarify
if and how the potency of N-AI as a cytotoxin can be translated into an anti-tumour growth
effect by targeting uPAR-positive tumour cells in vivo using PAI-2-functionalised
liposomes.
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Tumour targeting by liposomes is primarily mediated by the enhanced permeability and
retention (EPR) effect, which is dependent on a number of factors, including interstitial
fluid pressure and vascularity of the tumour, as well as the physical properties of the
liposome formulation (Nichols & Bae 2014). It is well established that liposomes need to
be relatively small and have a long circulation time to take advantage of the EPR effect
for tumour targeting (Perche & Torchilin 2013). While Doxil® is comprised of liposomes
of approximately 80-100 nm in diameter (Soundararajan et al. 2009), other clinically used
liposome formulations for cancer therapy are slightly larger in size, including Onivyde™
with a mean diameter of 110 nm, and Myocet® with a diameter of 150-250 nm (Bulbake
et al. 2017). Endosomes, which are 50-150 nm in diameter, show promise in drug delivery
applications, but their utility faces the same challenges as liposomes with regards to
clearance from the plasma and poor tumour targeting specificity (Si et al. 2019). Notably,
the high tumour accumulation of Doxil® in humans is due in large part to the very long
circulation half-life (up to 45 hours) of the formulation, which is comprised of PEGylated
liposomes to reduce the rate of plasma clearance (Gabizon et al. 1994). Neutral or
negatively charged liposomes (as in the case of Doxil®) have been shown to be better
suited for drug delivery to solid tumours as they associate less with angiogenic blood
vessels than positively charged liposomes, and are therefore more likely to extravasate
(Krasnici et al. 2003). To increase the specificity of tumour targeting, ligand-targeted
liposomes can be combined with the application of pH, temperature or magnetic field
triggers to enable the controlled release of drug cargo at the tumour site and reduce offtarget effects (Han et al. 2016). While there are general optimal liposome properties for
tumour targeting, liposomes should be designed for the specific tumour type to be
targeted, with consideration of the tumour microenvironment and the EPR effect
(Rosenblum et al. 2018).

The development of animal models that recapitulate the EPR effect at a level more
analogous to the human condition would be of benefit in the initial evaluation of novel
targeted nanotherapies. Further research is required to better understand the EPR effect
and elucidate the differences in this phenomenon between animal and human tumours,
and between different tumour types, in order to increase translation of nanoparticle-based
therapeutics into the clinic (Lammers et al. 2016). This could be achieved via imaging
methods, such as the radionuclide imaging of liposomes to determine their fate in vivo
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(van der Geest et al. 2016). Intravital imaging techniques can be used to assess the depth
of nanoparticle (and drug cargo) penetration into the tumour and the movement of
nanoparticles away from the major blood vessels that vascularise the tumour (Puttick et
al. 2015; Zhao, Y et al. 2017). Single photon emission computed tomography (SPECT)
and positron emission tomography (PET) can also be used to quantify the in vivo
distribution of nanoparticles, including the accumulation of nanoparticles at the tumour
site, in a non-invasive manner (Harrington et al. 2001).

The use of models that recapitulate intratumoural heterogeneity is important in the
evaluation of dual-ligand liposomes designed to target multiple tumour cell receptors.
Patient-derived xenografts are more representative of the clinical situation as they capture
some elements of intratumoural heterogeneity, as well as the diversity observed between
patients with cancer (Gomez-Cuadrado et al. 2017). In addition to intratumoural
heterogeneity, the interpatient heterogeneity observed in cancer also warrants the
development and utilisation of patient-derived xenografts and patient-derived cell lines
to more accurately assess patient responses to novel therapies, particularly in cases where
resistance to currently used therapies is frequently observed (Shafaee & Ellis 2017).
Additionally, the use of tumour models in immunocompetent animals is important given
the known effect of the adaptive immune system on tumour growth and metastasis
(Kitamura et al. 2015). The increasing use of such models lends itself to the improved
assessment of targeted therapies in the context of cancer treatment (Budhu et al. 2014).

6.5 Single-molecule imaging can be used to quantify liposome ligands
Due to the lack of robust methods to quantify liposome ligands, single-molecule
fluorescence microscopy techniques were successfully developed to quantify the density
and stoichiometry of protein ligands attached to the surface of targeted liposomes. As
reported in Chapter 5, single-molecule imaging confirmed that PAI-2 molecules were
attached to the liposome surface, with an average of 11 ± 4 PAI-2 molecules per liposome.
This was the first direct confirmation and quantification of PAI-2 attached to the surface
of liposomes and marks an important first step in utilising these high resolution
technologies in nanomedicine-based therapeutics development (Pujals et al. 2019). The
method enabled the quantification of ligands after liposomes had been purified using two
alternative methods and revealed the effects of these methods on the resultant liposome
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ligand density. It was also demonstrated that the post-insertion method is more favourable
for creating dual-ligand liposomes than the conventional method, as single-molecule
imaging was able to quantify the density and ratio of PAI-2 and trastuzumab ligands
attached to clinically relevant dual-functionalised liposomes. Therefore, this work has
demonstrated the utility of single-molecule fluorescence imaging in the quantification of
the density and stoichiometry of ligands attached to the surface of liposomes, which
enables superior characterisation of functionalised liposomes in the preclinical testing
context.

Future work using single-molecule fluorescence imaging could help to elucidate
additional characteristics of ligand-directed liposomes. For example, the quantification of
ligands by single-molecule imaging could determine inner and outer leaflet labelling of
liposomes produced by the post-insertion method, since it is possible that ligands may
insert into the inner leaflet of the liposomes and not be available for cell targeting. The
quantification of inner and outer leaflet labelling of liposomes could be elucidated by
single-molecule imaging using pH-sensitive dyes as per previously reported methods
(Otterstrom et al. 2014). The work described in this thesis explored differences in the
ligand density of liposomes produced specifically by the conventional and post-insertion
methods, but the single-molecule imaging method could also be used to explore the
functionalisation of liposomes produced by a range of methods, in addition to controlling
for batch-to-batch variability in liposome production.

Single-molecule quantification can be used to help address the issues surrounding the
standardisation of liposome characterisation in the broader field of nanomedicine research
(Faria et al. 2018). There are currently no FDA guidelines or associated documentation
outlining the requirements for the determination of target ligand density on liposomes or
other nanoparticle-based formulations. Approximations for ligand density and the number
of ligands per nanoparticle have been determined by making assumptions, such as that
the nanoparticle is spherical, contains a certain number of functional groups and that the
bioconjugation reaction is 100% efficient. Notably, the ligand density of single-chain
anti-HER2 antibodies conjugated to the surface of doxorubicin-loaded liposomes (MM302) has never been quantified, as traditional methods for characterisation were not

156

applicable to functionalised liposomes (Hendriks et al. 2013; Nellis, Ekstrom, et al. 2005;
Nellis, Giardina, et al. 2005).

To further demonstrate the applicability of single-molecule fluorescence microscopy as a
quantification tool for ligand-targeted nanomedicine development, future work could
utilise the methods reported here to demonstrate correlations between the number of
targeting ligands at the liposome surface and functional cellular effects. For example, the
single-molecule quantification of liposome ligand density could help determine the
optimal number of ligands for maximum receptor binding, target cellular uptake or
therapeutic effect, or could determine the functional effects of targeted liposomes
produced by different methods. Previous studies have demonstrated that the modulation
of liposome ligand density, achieved by changing the starting maleimide-PEG
concentration of the formulation, affects cellular binding and uptake (Chu et al. 2016;
Gayong et al. 2016; Li, H et al. 2016). The single-molecule method described here could
be used in future work to further confirm such findings.

Given the utility of single-molecule imaging in the characterisation of ligand-directed
liposomes, the method reported in this thesis could be further developed to make the
quantification process more high-throughput. Data acquisition could be further scaled up
and automated, and the analysis pipeline could readily be converted into an automated
process (Monachino et al. 2017). To further improve the method, a fluorescent antibody
detection system could be used to bypass the need to pre-label ligands with fluorescent
dyes. This would allow characterisation and analysis of liposomes at any point during or
after their production. The recent development of a high-resolution optical nanoscopy
technique to determine the number and distribution of functional moieties on the surface
of nanoparticles without the need for fluorescent labelling is another promising method
for characterising actively targeted liposomes in the preclinical setting (Delcanale et al.
2018).

6.6 Conclusion
The first clinically approved liposome, Doxil®, has been in use for over 20 years and is
still used as an effective treatment for several cancers. However, the liposome field has
not yet evolved into translating effective targeted liposomes. Ligand-directed liposomes
157

have the potential to increase the selectivity of therapy, and dual-ligand liposomes may
additionally address intratumoural heterogeneity to overcome patient resistance to
targeted therapies. The work described in this thesis demonstrated the successful
development and characterisation of a novel ligand-directed uPAR-targeted liposome
containing the potent anti-mitotic cytotoxin N-AI for the treatment of metastatic breast
cancer. Cellular uptake and cytotoxicity of the liposomes were demonstrated in vitro
against breast cancer cell lines varying in uPAR expression. In vivo, increased tumour
uptake was demonstrated for ligand-directed liposomes relative to non-ligand directed
liposomes, although no obvious anti-tumour benefit was observed in the models
described. A single-molecule fluorescence microscopy method was successfully
developed to enable future characterisation of ligand-directed liposomes to help guide
their production and evaluation in the preclinical setting.

Together, the findings in this thesis support the rationale for targeting uPAR-positive
breast cancer cells using N-AI-loaded PAI-2-functionalised liposomes. The results also
provide a basis for the further development of dual-ligand liposomes that can target
heterogeneous tumour cells within the HER2-positive and TNBC subtypes, in which
uPAR has been shown to play a key role in driving metastasis. Despite the hurdles left to
overcome in the production, evaluation and translation of ligand-directed liposomes
towards clinical use in the context of cancer therapy, the utility of liposome technologies
is promising. The continued development of better methodologies and models to
comprehensively characterise novel ligand-directed liposomes and assess the likelihood
of their performance in humans, including the recapitulation of intratumoural
heterogeneity, will likely improve the translation of novel targeted nanotherapies from
preclinical models through to the clinic.
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Appendix A: Absorption spectra of N-AI and liposome phospholipid

The concentration of N-alkylisatin (N-AI) encapsulated in liposomes could not be
determined by UV-vis spectrophotometry and interpolation from a N-AI standard curve
as the liposome phospholipid interfered with the peak absorbance of N-AI at 310 nm and
435 nm (Fig. A1).

Figure A1: Liposome phospholipid interference with N-AI absorption spectrum. The
phospholipid of empty liposomes interferes at 310 nm and 435 nm, the two peak absorption
wavelengths for N-AI.
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Appendix B: HPLC standard curve for N-AI quantification

The concentration of N-alkylisatin (N-AI) loaded into liposomes was determined by high
performance liquid chromatography (HPLC), which showed an N-AI concentration of 2.2
mM, equating to 43.1% drug loading (% w/w) based on the starting amount of N-AI used
in the liposome preparation. Concentration was determined by interpolation from an NAI standard curve (Fig. B1).

Figure B1: HPLC standard curve for quantifying N-AI encapsulated in liposomes.
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Appendix C: Quantification of PAI-2 by Western blotting

A plasminogen activator inhibitor-2 (PAI-2) standard curve was successfully constructed
using Western blotting and densitometry, which showed a linear relationship (Fig. C1).

Figure C1: Western blot standard curve for quantification of PAI-2. (A) Various amounts of PAI2 were run on a SDS-PAGE gel and then transferred to a nitrocellulose membrane for detection by
Western blotting. (B) Quantification of PAI-2 bands using densitometry shows a linear relationship.
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Appendix D: Toxicology of N-AI-loaded liposomes in mice

Toxicology studies performed by the Targeted Cancer Therapeutics Laboratory
(University of Wollongong) have shown that N-alkylisatin (N-AI)-loaded liposomes are
non-toxic in mice, with up to 100 mg/kg total dose of liposomal N-AI showing no adverse
effects (Fig. D1).

Figure D1: Toxicology testing of empty and N-AI-loaded liposomes in mice. Mice were treated
with either a single bolus dose or multiple doses (indicated by arrows) of N-AI-loaded liposomes or
empty (EMP) liposomes at an equivalent phospholipid concentration and weight change was
monitored over time.

190

Appendix E: Final cohort organ weights in PK/BD study

To determine the pharmacokinetic and biodistribution (PK/BD) profiles of N-AI-loaded
non-functionalised liposomes (N-AI) and N-AI-loaded PAI-2-functionalised liposomes
(N-AI PAI-2) in tumour-bearing mice, liposomes were labelled with tritiated cholesteryl
hexadecyl ether (3H-CHE) to enable the detection of liposomes in plasma and tissues by
liquid scintillation counting. Mice treated with N-AI and N-AI PAI-2 liposomes showed
no significant differences in the average final weight of the kidneys, liver, spleen and
lungs (Fig. E1).

Figure E1: Final organ weights at experimental endpoint. At the end of each experimental time
point, mice were euthanised by CO2 inhalation, and the (A) kidneys, (B) liver, (C) spleen and (D)
lungs were removed in whole and weighed. Values are the mean ± s.d. (n = 24). n.s., not significant
(P > 0.05).
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Appendix F: ESI-MS of CF647-labelled PAI-2

To visualise PAI-2 using single-molecule fluorescence microscopy, PAI-2 was labelled
with a small red fluorophore (CF647, ~836 g/mol). Electrospray ionisation-mass
spectrometry (ESI-MS) revealed up to 6 fluorophores per protein (average of 3) for
CF647-labelled PAI-2 (Fig. F1).

Figure F1: ESI-MS of CF647-labelled PAI-2. (A) Unlabelled PAI-2 and (B) CF647-labelled PAI2. Masses refer to the molecular weight of unlabelled PAI-2 (~45 kDa) with varying numbers of
attached CF647 (~0.836 kDa) molecules. Masses were generated using MassLynx V4.1 (Waters, MA,
USA).
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Appendix G: Diameter of CO and PI dual-functionalised liposomes

Liposomes functionalised with CF647-labelled PAI-2 and CF488-labelled trastuzumab
(TZ) were prepared via the conventional (CO) or post-insertion (PI) method. Liposomes
were analysed by dynamic light scattering before and after the functionalisation step to
determine average liposome diameter. When the PI method was used, a significant
increase in diameter (P < 0.05) was observed following functionalisation (Fig. G1). There
was no significant increase in liposome diameter following functionalisation via the CO
method.

Figure G1: Diameter of liposomes before and after dual-functionalisation. A diameter increase
was observed for liposomes prepared via the post-insertion (PI) method, but not for the conventional
(CO) method, after functionalisation (funct). * = P < 0.05, n.s. = not significant (P > 0.05).

193

